Document:

EX-10.7

 Exhibit 10.7 

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information
is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
 Execution Copy 

8-6-2019 

CONFIDENTIAL 
 COLLABORATION AND
LICENSE AGREEMENT 
 BY AND BETWEEN 

4D MOLECULAR THERAPEUTICS, INC 

AND 
 UNIQURE BIOPHARMA
B.V. 
 August 6, 2019 
  

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 

COLLABORATION AND LICENSE AGREEMENT 

This Collaboration and License Agreement (this “Agreement” or “New CLA”) is entered into and made effective
on August 6, 2019 (the “New CLA Effective Date”), by and between 4D Molecular Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware and having a principal office located at 5858 Horton
St, Emerystation North, Suite 460, Emeryville, CA 94608 (“4DMT”), and uniQure biopharma B.V., a corporation organized and existing under the laws of The Netherlands and having a principal office located at Paasheuvelweg 25a, 1105 BP
Amsterdam, The Netherlands (“uniQure”). 
 INTRODUCTION 

1. 4DMT is a biopharmaceutical company focused on research, development, manufacturing and marketing of novel adeno-associated viral vectors
for delivery of nucleic acids to target cells and gene therapy biopharmaceutical products based thereon. 
 2. uniQure is a
biopharmaceutical company focused on the research, development, manufacturing and marketing of gene therapy based biopharmaceutical products. 

3. 4DMT and uniQure desire for 4DMT to conduct a new research program to identify improved AAV Capsid Variants (as defined below) for delivery
to liver (in the case of some such AAV Capsid Variants) or the central nervous system (in the case of others). 
 4. 4DMT and uniQure have
previously entered into a Collaboration and License Agreement effective on January 17th, 2014, (the “Original CLA”) pursuant to which, 4DMT and uniQure had a collaboration for the identification of novel AAV Capsid Variants for development
and commercialization as therapeutic products in the Field (defined below), and the Parties are, concurrent with the execution of this Agreement, amending and restating the Original CLA in its entirety by entering into an Amended and Restated
Collaboration and License Agreement, effective of even date herewith (the “Amended and Restated CLA”), and, through the execution of this Agreement and the Amended and Restated CLA, the Parties have resolved the matters that were referred
to and described in correspondence between the Parties dated February 28, 2019 with respect to the Original CLA. 
 5. uniQure desires
to receive from 4DMT exclusive rights under 4DMT’s intellectual property rights to research (subject to 4DMT’s retained rights to conduct research), develop, manufacture and commercialize certain gene therapy Products based on use of New
Capsid Variants (defined below) to deliver Transgenes (defined below) based on Restricted Targets (defined below) in the Field pursuant to this Agreement, and subject to 4DMT’s Step-In Rights (defined
below). 
 6. 4DMT desires to retain non-exclusive rights to, exclude from the exclusive grant
described above the non-exclusive rights to, and/or receive from uniQure non-exclusive rights under uniQure’s intellectual property rights to, research, develop,
manufacture and commercialize certain gene therapy products based on use of New Capsid Variants to deliver Transgenes based on Restricted Targets within and outside of the Field, in accordance with 4DMT’s
Step-In Rights pursuant to this Agreement. 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 7. uniQure also desires to receive from 4DMT
non-exclusive rights under 4DMT’s intellectual property rights to research, develop, manufacture and commercialize certain gene therapy products based on use of New Capsid Variants to deliver Transgenes
based on targets other than Restricted Targets (Non-Restricted Targets, more particularly defined below), in accordance with uniQure’s Step-In Rights pursuant to
this Agreement. 
 8. 4DMT would retain all other rights to New Capsid Variants (e.g., rights to New Capsid Variants outside the Field and
related to Non-Restricted Targets), subject to uniQure’s Step-In Rights for Non-Restricted Targets and information rights as
described herein. 
 NOW, THEREFORE, in consideration of the mutual covenants contained herein, and other good and valuable consideration,
the receipt of which is hereby acknowledged, 4DMT and uniQure agree as follows effective as of the Effective Date: 
 ARTICLE I 

DEFINITIONS 
 Unless
specifically set forth to the contrary herein, the following terms, whether used in the singular or plural, shall have the respective meanings set forth below: 

1.1 “4DMT AAV Capsid Variant”. 4DMT AAV Capsid Variant means any AAV Capsid Variant that does not carry a Gene Therapy
Construct contained in a Royalty Bearing Construct or Royalty Bearing Product. 
 1.2 “4DMT AAV Capsid Variant Library”.
4DMT AAV Capsid Variant Library means any AAV Capsid Variant Library constructed by or licensed to 4DMT, including all AAV Capsid Variant Libraries provided to 4DMT pursuant to the UCB Agreements. 

1.3 “4DMT Intellectual Property”. 4DMT Intellectual Property means the 4DMT Know-How
and the 4DMT Patent Rights. 
 1.4 “4DMT Know-How”. 4DMT Know-How means Know-How that is (a) Controlled by 4DMT or its Affiliates as of the Effective Date or during the Research Term, and (b) necessary or useful to conduct
the Research Program or to research, Develop, make and have made, use or Commercialize any New Capsid Variant, or a Royalty Bearing Construct or Royalty Bearing Product due to the presence of such New Capsid Variant therein. 4DMT Know-How includes Core 4DMT Know-How but does not include Joint Know-How. 

1.5 “4DMT Patent Right”. 4DMT Patent Right means any Patent Right Controlled by 4DMT or its Affiliates as of the Effective
Date or during the Term that Covers 4DMT Know-How. 4DMT Patent Rights include Core 4DMT Patent Rights but do not include Joint Patent Rights. 

  
 - 2 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 1.6 “4DMT Product”. 4DMT Product means a Royalty Bearing Product that
(a) delivers a Transgene that Affects a Non-Restricted Target (or variant of a Non-Restricted Target), or (b) that delivers a Transgene that Affects a
Restricted Target (or variant of a Restricted Target), and, in the case of (b) (but to avoid doubt, this is not required for (a)), 4DMT has obtained non-exclusive rights to Develop and Commercialize such
Royalty-Bearing Product pursuant to the exercise of its Step-In Rights in Section 4.4. Notwithstanding anything express or implied, no 4DMT Product shall deliver a Transgene that relates to any Restricted
Target for which 4DMT has not obtained rights to deliver as part of a Royalty-Bearing Product pursuant to the exercise of its Step-In Rights under Section 4.4. 

1.7 “4D Product Patent”. 4D Product Patent means any Product Patent upon which 4DMT’s or its Affiliates’ personnel
are properly named inventors (as determined under U.S. patent law) and uniQure’s and its Affiliates’ are not. 
 1.8
“AAV”. AAV means adeno-associated virus. 
 1.9 “AAV Capsid Variant”. AAV Capsid Variant means an AAV
capsid that is modified as compared to the wild type sequence. 
 1.10 “AAV Capsid Variant Library”. AAV Capsid Variant
Library means a collection of variant AAV capsid open reading frames inserted into an AAV genome in a manner that renders such variants genome replication-competent with the appropriate helper virus functions and capable of being selected and
evolved to optimize their ability to deliver nucleic acid sequences to human or animal cells. 
 1.11 “Accounting
Standards”. Accounting Standards means, with respect to uniQure and its Affiliates, International Financial Reporting Standards (“IFRS”) or, to the extent applicable, generally accepted accounting principles as practiced in
the United States (“GAAP”), and with respect to 4DMT and its Affiliates, GAAP, in each case as they exist from time to time, consistently applied. 

1.12 “Affects”. Affects, with respect to a Transgene and a Target, means that the Transgene (a) encodes such Target or a
variant of such Target, (b) knocks down the mRNA corresponding to such Target or a variant of such Target, (c) encodes an antibody or other protein that specifically binds the protein encoded by such Target, or (d) otherwise directly
affects such Target (e.g., via gene editing) or the protein that such Target encodes. 
 1.13 “Affiliate”. Affiliate means,
with respect to a Party, any entity that directly or indirectly controls, is controlled by, or is under common control with such Party. As used in this definition, the term “control” means the possession, directly or indirectly, of
the power to direct or cause the direction of the management and policies of an entity, whether through ownership of voting securities, by contract or otherwise. For purposes of this definition, “control” shall be presumed to exist if one
of the following conditions are met: (a) in the case of corporate entities, direct or indirect ownership of more than fifty percent (50%) of the stock or shares having the right to vote for the election of directors, and (b) in the case of
non-corporate entities, direct or indirect ownership of more than fifty percent (50%) of the equity interest with the power to direct the management and policies of such
non-corporate entities. 
 1.14 “Animal POC”. Animal POC means demonstration of gene
expression and/or gene function of a Transgene cassette for a Target, in an animal model or patient-derived cells; provided that such demonstration shall be in an established, relevant animal model of a disease, if available. 

  
 - 3 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 1.15 “Business Day”. Business Day means a day that is not a Saturday, Sunday
or a day on which banking institutions in New York, New York, USA or Amsterdam, The Netherlands are authorized by Law to remain closed. 

1.16 “Calendar Quarter”. Calendar Quarter means the respective periods of three (3) consecutive calendar months
ending on March 31, June 30, September 30 and December 31; provided, however, that the first Calendar Quarter hereunder shall commence on the Effective Date and the final Calendar Quarter hereunder shall end on the
effective date of termination or expiration of this Agreement. 
 1.17 “Calendar Year”. Calendar Year means each
successive period of twelve (12) months commencing on January 1 and ending on December 31; provided, however, that the first Calendar Year hereunder shall commence on the Effective Date and the final Calendar Quarter
hereunder shall end on the effective date of termination or expiration of this Agreement 
 1.18 “CEO”. CEO means the Chief
Executive Officer of a Party or, if there is no Chief Executive Officer of a Party, the Board Chairperson or senior-most executive officer or equivalent of such Party. 

1.19 “CNS”. CNS means the central nervous system. [***] 

1.20 “CNS Term”. The CNS Term means the period beginning on the New CLA Effective Date and ending on the later of (a) [***]
([***]) years from the date of initiation of work under the Research Plan for CNS, and (b) the date on which 4DMT delivers [***] ([***]) (i.e., when it has delivered [***]) New CNS Variants to uniQure with the Vector Characterization Data with
respect to each of such [***] ([***]) New CNS Variants that the Research Plan for CNS requires 4DMT to provide. It is understood that the Selection Processes giving rise to such New CNS Variants shall be the Selection Processes directed at
identifying CNS-targeted variants as defined and called for in the Research Plan, or, if such Selection Processes do not yield [***] ([***]) New CNS Variants meeting the Delivery Success Criteria (that can
then proceed into the studies that generate Vector Characterization Data in accordance with the Research Plan for CNS), then Selection Processes for CNS-targeted AAV Capsid Variants that 4DMT conducts in
addition or as follow-ups to (but in each case not in replacement or in lieu of) such CNS-directed Selection Processes called for in the Research Plan, and in any event
meeting the requirements of Section 3.1. If 4DMT conducts such in-addition-to and/or follow-up CNS-directed Selection Processes, then the Vector Characterization Data that 4DMT would have to report to uniQure in order for the applicable New CNS Variants to count as one of the [***] ([***]) New CNS Variants of
clause (b) of the first sentence of this definition, shall be equivalent to the Vector Characterization Data that 4DMT is required to report to uniQure under the Research Plan with respect to the New CNS Variants that it delivers thereunder.
uniQure’s information and input rights as to any such additional Selection Processes that 4DMT may choose to conduct are as provided for in Section 3.1. 

  
 - 4 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 1.21 “Commercially Reasonable Efforts”. Commercially Reasonable Efforts
means, with respect to a Party, the efforts required in order to carry out a task in a diligent and sustained manner without undue interruption or delay, which level is at least commensurate with the level of effort that a similarly situated Third
Party would devote to a product of similar market potential and having similar commercial and scientific advantages and disadvantages resulting from its own research efforts or to which it has rights, taking into account its safety and efficacy,
regulatory status, the competitiveness of the marketplace, its proprietary position, pricing, reimbursement, launching strategy and other market-specific factors, and all other relevant factors. 

1.22 “Commercialization” or “Commercialize”. Commercialization or Commercialize means any activity directed
to obtaining pricing or reimbursement approvals, marketing, promoting, distributing, importing, exporting, offering to sell or selling a product, or to have any such activity performed. When used as a verb, “Commercialize” means to engage
in Commercialization. 
 1.23 “Construct”. Construct means an AAV Capsid Variant carrying and comprising a Gene Therapy
Construct. 
 1.24 “Confidential Information”. Confidential Information means any and all information and data,
including all uniQure Know-How, 4DMT Know-How and Joint Know-How, and all other scientific,
pre-clinical, clinical, regulatory, manufacturing, marketing, financial and commercial information or data, whether communicated in writing or orally or by any other method, which is provided by one Party to
the other Party in connection with this Agreement or the Prior Confidentiality Agreement. All Core uniQure Know-How shall be considered the Confidential Information of uniQure, with respect to which:
(a) uniQure shall be considered the disclosing Party, (b) 4DMT shall be considered the receiving Party, and (c) clauses (b) and (e) of Section 8.2 shall not apply. All Core 4DMT Know-How
shall be considered the Confidential Information of 4DMT, with respect to which: (i) 4DMT shall be considered the disclosing Party, (ii) uniQure shall be considered the receiving Party, and (iii) clauses (b) and (e) of
Section 8.2 shall not apply. 
 1.25 “Control”. Control means, with respect to any item of or right under Patent Rights
or Know-How, the possession (whether by ownership or license, other than a license pursuant to this Agreement) of the ability of a Party or, as applicable, its Affiliate (subject to Section 12.7), to
grant access to, or a license or sublicense of, such items or right as provided for herein without violating the terms of any agreement or other arrangement with any Third Party existing at the time such Party would be required hereunder to grant
the other Party such access or license or sublicense. 
 1.26 “Core 4DMT Intellectual Property”. Core 4DMT Intellectual
Property means Core 4DMT Know-How and Core 4DMT Patent Rights. 
 1.27 “Core 4DMT Know-How”. Core 4DMT Know-How means [***]. 
 1.28
“Core 4DMT Patent Right”. Core 4DMT Patent Right means any Patent Right that Covers the Core 4DMT Know-How, including New Variant Patents. 

  
 - 5 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 1.29 “Core uniQure Intellectual Property”. Core uniQure Intellectual
Property means Core uniQure Know-How and Core uniQure Patent Rights. 
 1.30 “Core uniQure Know-How”. Core uniQure Know-How means [***]. 
 1.31
“Core uniQure Patent Right”. Core uniQure Patent Right means any Patent Right that Covers the Core uniQure Know-How. For clarity, Core uniQure Patent Rights excludes New Variant Patents. 

1.32 “Cover”, “Covering” or “Covered”. Cover, Covering or Covered means, with respect to a
product, technology, process or method that, in the absence of ownership of or a license granted under a Valid Claim, the manufacture, use, offer for sale, sale or importation of such product or the practice of such technology, process or method
would infringe such Valid Claim (or, in the case of a Valid Claim that has not yet issued, would infringe such Valid Claim if it were to issue). With respect to a composition, “Coverage” exists if the applicable Valid Claim claims such
composition, its method of manufacture, or its methods of use. 
 1.33 “Default”. Default means with respect to a Party that
(a) any representation or warranty of such Party set forth herein shall have been untrue in any material respect when made or (b) such Party shall have failed to perform any material obligation set forth in this Agreement. 

1.34 “Delivery Success Criteria”. Delivery Success Criteria means the following criteria that determines whether a given AAV
Capsid Variant demonstrates superior delivery to the CNS or liver for introduction into those additional validation and characterization studies that are defined in the applicable Research Plan: [***]. 

1.35 “Development” or “Develop”. Development or Develop means
pre-clinical and clinical drug development activities, including: test method development and stability testing, toxicology, formulation, process development, manufacturing
scale-up, development-stage manufacturing, quality assurance/quality control procedure development and performance with respect to clinical materials, statistical analysis and report writing and clinical
studies, regulatory affairs, and all other pre-Regulatory Approval activities. When used as a verb, “Develop” means to engage in Development. 

1.36 “EMA”. EMA means the European Medicines Agency, or any successor agency. 

1.37 “European Union” or “EU”. European Union or EU means the countries that are members of the European
Union, as redefined from time to time. 
 1.38 “FDA” or “Food and Drug Administration”. FDA or Food and
Drug Administration means the United States Food and Drug Administration, or any successor agency. 

  
 - 6 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 1.39 “Field”. Field means the delivery of Gene Therapy Constructs to
cells in (a) the CNS or (b) the liver, in each case where such delivery is for the purpose of effecting expression of the applicable RNA or amino acid sequence in the targeted cells and is potentially useful for the diagnosis, treatment,
cure, palliation or prevention of a disease or medical condition in humans or animals, irrespective of the administration site or mode of administration (e.g., intravenous, direct injection, subcutaneous or intrathecal) of the Construct used
to effect delivery. For clarity, intravenous or intrathecal administration of any Construct targeted to cells in other organs (i.e., not specifically targeted to liver or CNS tissues), including for treatment of neoplastic and eye disorders,
are excluded from the Field. 
 1.40 “First Commercial Sale”. First Commercial Sale means, with respect to any Royalty
Bearing Product and a country, the first sale for end use or consumption of such Royalty Bearing Product in such country after all required approvals, including Regulatory Approval, have been granted by the Regulatory Authority of such country. For
clarity, sales for test marketing, sampling and promotional uses, clinical trials purposes or compassionate use shall not constitute a First Commercial Sale. 

1.41 “Gene Therapy Construct”. Gene Therapy Construct means any Transgene that is packaged into an AAV Capsid Variant to form
a Construct, and is intended to be delivered to a targeted tissue to treat, cure, prevent or ameliorate a disease or condition of the CNS or liver by any gene therapy application or modality. 

1.42 “Good Laboratory Practices”. Good Laboratory Practices means the then-current good laboratory practice standards
promulgated or endorsed by the FDA, as defined in 21 C.F.R. Part 58 (or such other comparable regulatory standards in jurisdictions outside the U.S. to the extent applicable to the relevant study, as they may be updated from time to time). 

1.43 “Governmental Authority”. Governmental Authority means any United States federal, state or local or any foreign
government, or political subdivision thereof, or any multinational organization or authority or any authority, agency or commission entitled to exercise any administrative, executive, judicial, legislative, police, regulatory or taxing authority or
power, any court or tribunal (or any department, bureau or division thereof), or any governmental arbitrator or arbitral body. 
 1.44
“IGT”. IGT means Integrative Gene Therapeutics, Inc., a California corporation, which jointly owns with UC certain of the UC Patent Rights. 

1.45 “Indication”. Indication means any disease, condition or syndrome. 

1.46 “Invention”. Invention means any new and useful process, article of manufacture, Construct, composition of matter,
formulation or apparatus, or any improvement thereof, discovery or finding, which is patentable. 
 1.47 “Invoice”. Invoice
means an original invoice sent by 4DMT to uniQure with respect to any payment due hereunder substantially in the form attached hereto as Schedule 1. 

  
 - 7 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 1.48 “Know-How”. Know-How means (a) any scientific or technical information, results and data of any type whatsoever, in any tangible or intangible form whatsoever, that is not in the public domain, including databases,
practices, methods, techniques, specifications, formulations, formulae, protein sequences, nucleic acid sequences, AAV Capsid Variants, AAV Capsid Variant Libraries, Gene Therapy Constructs, Constructs, knowledge,
know-how, trade secrets, skill, experience, test data including pharmacological, medicinal chemistry, biological, chemical, biochemical, toxicological and clinical test data, analytical and quality control
data, stability data, studies and procedures, and manufacturing process and development information, results and data, and (b) any biological, chemical, or physical material or composition of matter that is not in the public domain or otherwise
generally available to the public. 
 1.49 “Law”. Law means all laws, statutes, rules, codes, regulations, orders, judgments
or ordinances applicable to a Party, this Agreement or the activities contemplated hereunder. 
 1.50 “Licensed IP”.
Licensed IP means the 4DMT Intellectual Property, the Joint Intellectual Property, and the Intellectual Property licensed by uniQure to 4DMT pursuant to Section 5.2. 

1.51 “Liver Term”. The Liver Term means the period beginning on the New CLA Effective Date and ending on the later of (a)
[***] ([***]) years from the date of initiation of work under the Research Plan for Liver, and (b) the date on which 4DMT delivers [***] ([***]) (i.e., when it has delivered [***]) New Liver Variants to uniQure with the Vector Characterization
Data with respect to each of such [***] ([***]) New Liver Variants that the Research Plan for Liver requires 4DMT to provide. It is understood that the Selection Processes giving rise to such New Liver Variants shall be the Selection Processes
directed at identifying liver -targeted variants as defined and called for in the Research Plan, or, if such Selection Processes do not yield [***] ([***]) New Liver Variants meeting the Delivery Success Criteria (that can then proceed into the
studies that generate Vector Characterization Data in accordance with the Research Plan for Liver), then Selection Processes for liver-targeted AAV Capsid Variants that 4DMT conducts in addition or as
follow-ups to (but in each case not in replacement or in lieu of) such liver-directed Selection Processes called for in the Research Plan, and in any event meeting the requirements of Section 3.1. If 4DMT
conducts such in-addition-to and/or follow-up liver -directed Selection Processes, then the Vector Characterization Data that
4DMT would have to report to uniQure in order for the applicable New Liver Variants to count as one of the [***] ([***]) New Liver Variants of clause (b) of the first sentence of this definition, shall be equivalent to the Vector
Characterization Data that 4DMT is required to report to uniQure under the Research Plan with respect to the New Liver Variants that it delivers thereunder. uniQure’s information and input rights as to any such additional Selection Processes
that 4DMT may choose to conduct are as provided for in Section 3.1. 
 1.52 “Materials”. Materials means any tangible
chemical or biological research materials that are provided or otherwise made available by one Party to the other Party under the terms of Section 3.3 for use in performance of the Research Program; provided, however, that
Materials will not include any AAV Capsid Variant Libraries. 
 1.53 “NDA”. NDA means a New Drug Application or Biologics
License Application filed with the FDA or any other application required for the purpose of marketing or selling or commercially using a therapeutic or prophylactic product to be filed with a Regulatory Authority in a
non-U.S. country or group of countries, including a Product License Application or Marketing Authorization Application (“MAA”) in the European Union or Japan. 

  
 - 8 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 1.54 “Net Sales”. Net Sales means, with respect to a Royalty Bearing Product
(either a uniQure Product or a 4DMT Product, as applicable), the gross amount of sales of such Royalty Bearing Product invoiced by a Party or its Affiliates to Third Parties, less the following to the extent related to such Royalty Bearing Product
and incurred by such Party or its Affiliates and invoiced to the Third Party: 
 (a) sales returns and allowances actually paid, granted or
accrued, including trade, quantity and cash discounts and any other adjustments, including those granted on account of price adjustments or billing errors; 

(b) rejected goods, damaged or defective goods, recalls, returns; 

(c) rebates, chargeback rebates, compulsory rebates, reimbursements or similar payments granted or given to wholesalers or other distributors,
buying groups or health care insurance carriers; 
 (d) non-collectable receivables; 

(e) customs or excise duties, sales tax, consumption tax, value added tax, and other taxes (except income taxes); or 

(f) charges for packing, freight, shipping and insurance. 

Each of the foregoing deductions shall be determined as incurred in the ordinary course of business in type and amount consistent with good industry practice
and in accordance with Accounting Standards on a basis consistent with such Party’s audited consolidated financial statements. For clarity, sales by uniQure or its Affiliates of a Royalty Bearing Product to a Third Party Distributor of such
Royalty Bearing Product in a given country shall be considered a sale to a Third Party customer. All such discounts, allowances, credits, rebates, and other deductions shall be fairly and equitably allocated to the Royalty Bearing Products and other
products of uniQure and its Affiliates such that the Royalty Bearing Product does not bear a disproportionate portion of such deductions. 

In the event any Royalty Bearing Product is sold for consideration other than cash, Net Sales for such sale shall be the average price of such
Royalty Bearing Product sold for cash during the relevant period in the relevant country. 
 In the event that any discount, reduction,
payment or rebate is offered for a Royalty Bearing Product where such Royalty Bearing Product is sold to a Third Party customer as part of a grouped set of products, the applicable discount, reduction, payment or rebate for such Royalty Bearing
Product in such arrangement shall be based on the weighted average discount, reduction, payment or rebate of such grouped set of products. 

  
 - 9 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 Any Royalty Bearing Products used for promotional or advertising purposes (in reasonable and
customary amounts) or used for Clinical Trials or other research purposes shall not be included in Net Sales. Donations for charity reasons or compassionate use shall also not be included in Net Sales. 

1.55 “New Capsid Variant(s)”. New Capsid Variant means any New CNS Variant or New Liver Variant. 

1.56 “New CNS Variant(s)”. New CNS Variant means any AAV Capsid Variant identified by 4DMT or its Affiliate, or any Third
Party pursuant to rights granted by 4DMT or its Affiliate, during the CNS Term in a Selection Process designed to identify AAV Capsid Variants specifically targeting cells of the CNS, but excluding any such AAV Capsid Variants that are Selected
Capsid Variants. An AAV Capsid Variant is “identified” in a Selection Process when it is sequenced. An AAV Capsid Variant does not need to satisfy (or necessarily have been tested against) the applicable Delivery Success Criteria to
qualify as a New CNS Variant. 
 If data of the types listed in the definition of Vector Characterization Data that is generated by, for or under right from
4DMT demonstrate that an AAV Capsid Variant from any other Selection Process (i.e., one not under the Research Plan of this Agreement or one that was not designed to identify AAV Capsid Variants specifically targeting cells of the CNS) conducted by,
for or under right from 4DMT during the CNS Term is improved or superior to the top [***] ([***]) New CNS Variants arising under the Research Program in the following ways, then 4DMT will share the Vector Characterization Data with
uniQure:[***] 
 In that case, any such AAV Capsid Variant with respect to which 4DMT is required to share such data of the types listed in Vector
Characterization Data demonstrating such improvement or superiority ((a) or (b) or (c)) shall be deemed a New CNS Variant, and such data shall be deemed Vector Characterization Data. It is understood that 4DMT is not under any obligation to
generate such data (nor to have it generated for or under right from 4DMT), nor to perform any research or other activities not set forth in the Research Plan, but that, pursuant to the terms of this Agreement, uniQure may further investigate any
such deemed New CNS Variants. 
 1.57 “New Liver Variant(s)”. New Liver Variant means any AAV Capsid Variant identified by
4DMT or its Affiliate, or any Third Party pursuant to rights granted by 4DMT or its Affiliate, during the Liver Term in a Selection Process designed to identify AAV Capsid Variants specifically targeting cells of the liver, but excluding any such
AAV Capsid Variants that are Selected Capsid Variants. An AAV Capsid Variant is “identified” in a Selection Process when it is sequenced. An AAV Capsid Variant does not need to satisfy (or necessarily have been tested against) the
applicable Delivery Success Criteria to qualify as a New Liver Variant. 
 If data of the types listed in the definition of Vector Characterization Data
that is generated by, for or under right from 4DMT demonstrate that an AAV Capsid Variant from any other Selection Process (i.e., one not under the Research Plan of this Agreement or one that was not designed to identify AAV Capsid Variants
specifically targeting cells of the liver) conducted by, for or under right from 4DMT during the Liver Term is improved or superior to the top [***] ([***]) New Liver Variants arising under the Research Program in the following ways, then
4DMT will share the Vector Characterization Data with uniQure:[***] 

  
 - 10 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 In that case, any such AAV Capsid Variant with respect to which 4DMT is required to share such data of the
types listed in Vector Characterization Data demonstrating such improvement or superiority ((a) or (b) or (c)) shall be deemed a New Liver Variant, and such data shall be deemed Vector Characterization Data. It is understood that 4DMT is not
under any obligation to generate such data (nor to have it generated for or under right from 4DMT), nor to perform any research or other activities not set forth in the Research Plan, but that, pursuant to the terms of this Agreement, uniQure may
further investigate any such deemed New Liver Variants. 
 1.58 “New Variant Patent”. New Variant Patent means any Patent
Right Covering one or more New Capsid Variants (for clarity, whether by their composition, method of use, or method of manufacture). It is understood that New Variant Patents (1) may include dependent claims directed to the combination
of a New Capsid Variant and a Transgene and (2) do not include any Patent Rights claiming inventions that are conceived and reduced to practice solely by employees, agents and/or consultants of uniQure or its Affiliate independently and outside
of the Research Program, without the use of information pertaining to a Selected Capsid Variant or New Capsid Variant sequence disclosed to uniQure under this Agreement or the Amended and Restated CLA. 

1.59 “Non-Restricted Targets” means all Targets within the Field that are not
Restricted Targets. 
 1.60 “Party” and “Parties”. Party means uniQure or 4DMT individually, and Parties
means uniQure and 4DMT collectively. 
 1.61 “Patent Rights”. Patent Rights means patents, patent applications or
provisional patent applications, utility models and utility model applications, petty patents, innovation patents, patents of addition, divisionals, continuations,
continuation-in-part applications, continued prosecution applications, requests for continued examinations, reissues, renewals, reexaminations and extensions and
supplementary protection certificates granted in relation thereto, in any country of the world. For clarity, Patent Rights shall include any Patent Right that claims priority to or common priority with such Patent Rights. 

1.62 “Product”. Product means any preparation in final form, either for sale by prescription, over-the-counter or any other method, or for administration to human patients in clinical trials, for any and all uses, and in any and all formulations and combinations, which
preparation contains a Construct. 
 1.63 “Product Patent”. Any Patent Right Covering an invention invented pursuant to the
activities conducted under this Agreement, the independent claims of which Patent Right are specifically drawn to a Construct combining (i) a New Capsid Variant and (ii) the Gene Therapy Construct of a given Product, and that does not
claim priority to any New Variant Patent. 
 1.64 “Prosecution and Maintenance”. Prosecution and Maintenance means, with
respect to a Patent Right, the preparation, filing, prosecution and maintenance of such Patent Right, as well as reexaminations, reissues and the like with respect to such Patent Right, together with the conduct of interferences, the defense of
oppositions and other similar proceedings with respect to the particular Patent Right; and “Prosecute and Maintain” shall have the correlative meaning. 

  
 - 11 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 1.65 “Regulatory Authority”. Regulatory Authority means any
applicable Governmental Authority involved in granting approvals for the manufacturing, marketing, reimbursement or pricing of a Royalty Bearing Product in the Territory or any portion thereof, including the FDA and EMA (as applicable), and any
successor Governmental Authority having substantially the same function. 
 1.66 “Research Plan for CNS”. Research Plan for
CNS means the research plan providing for one (1) or more Selection Processes intended to identify AAV Capsid Variants for delivery to the CNS, that is attached as Schedule 2. 

1.67 “Research Plan for Liver”. Research Plan for Liver means the research plan providing for one (1) or more Selection
Processes intended to identify AAV Capsid Variants for delivery to the liver, that is attached as Schedule 2. 
 1.68
“Research Program”. Research Program means, collectively, the program of research to be undertaken by 4DMT as described in the Research Plan for CNS and the Research Plan for Liver. 

1.69 “Research Term”. Research Term means the period commencing on the New CLA Effective Date and ending on the date of
expiration of the Liver Term or the CNS Term, whichever expires later. 
 1.70 “Research Year”. Research Year means a twelve
(12) month period during the Research Term beginning on the Effective Date or on any anniversary thereof. 
 1.71 “Restricted
Target(s)”, Restricted Target(s) means, the [***] ([***]) Targets to be selected by uniQure from within the Field, each of such [***] ([***]) Targets is to be selected by uniQure within the [***] ([***]) day period commencing on the New CLA
Effective Date, and each of which must relate to a disease or condition of the CNS or the liver. 
 1.72 “Royalty Bearing
Construct”. Royalty Bearing Construct means a Construct containing a New Capsid Variant and a Gene Therapy Construct that Affects a Restricted Target or a Non-Restricted Target (but not any Target
that is not a Restricted Target or a Non-Restricted Target). 
 1.73 “Royalty Bearing
Product”. Royalty Bearing Product means a Product containing a Royalty Bearing Construct. 
 1.74 “Royalty Term”.
Royalty Term means, with respect to a Royalty Bearing Product, on a Royalty Bearing Product-by-Royalty Bearing Product and a country-by-country basis, the period beginning on the First Commercial Sale of such Royalty Bearing Product in such country by a Party or any of its Affiliates or Sublicensees, and ending on latest of:
(a) the 

  
 - 12 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 
expiration of the last Valid Claim within the Licensed IP Covering such Royalty Bearing Product in such country, (b) the expiration of any applicable exclusivity, including orphan drug
status or data exclusivity, and any extension thereto, granted by a Regulatory Authority in such country with respect to such Royalty Bearing Product, or (c) the tenth (10th) anniversary of
the date of the First Commercial Sale by a Party or any of its Affiliates or Sublicensees of such Royalty Bearing Product in such country. 

1.75 “Selected Capsid Variant”. Selected Capsid Variant means the AAV Capsid Variants listed in Schedule 3 to this Agreement.

 1.76 “Selection Process”. Selection Process means the iterative evolution or isolation of lead AAV Capsid Variants from
one or more AAV Capsid Variant Libraries in cells (cultured or primary) in vitro or in animals in vivo intended to result in the identification of AAV Capsid Variants demonstrating properties suitable to a specified target tissue. For
clarity, a Selection Process can be one that is performed by 4DMT or its Affiliate either for itself or for, with or by any Third Party under rights granted by 4DMT to such Third Party, and need not be one that is conducted under the Research
Program of this Agreement or designed for the same type of tissue in order to qualify under this definition. . 
 1.77 “Step-In Rights”. Step-In Rights means, on a AAV Capsid Variant-by-AAV Capsid Variant
and Target-by-Target basis, the rights of uniQure or of 4DMT, respectively, to step-in and obtain
non-exclusive license rights with respect to a New Capsid Variant for delivery of a Transgene that Affects a Non-Restricted Target (in the case of uniQure) or a
Restricted Target (in the case of 4DMT), in each case pursuant to the provisions of Section 4.4. 
 1.78 “Sublicensee”.
Sublicensee means, with respect to a Party, a Third Party to whom such Party (or its Affiliate or another of its Sublicensees) has granted a license or sublicense under the Licensed IP to Develop, make and have made, use or Commercialize a Royalty
Bearing Product; provided, however, that a Sublicensee shall not include any Third Party Distributor. 
 1.79
“Target”. Target means the biological gene or genetic material of interest to affect a disease or condition of the CNS or liver. 

1.80 “Territory”. Territory means all countries and territories in the world. 

1.81 “Third Party”. Third Party means an entity other than uniQure, 4DMT and their respective Affiliates. 

1.82 “Third Party Distributor”. Third Party Distributor means any Third Party that provides (but does not Develop) Royalty
Bearing Products directly to customers under agreement with uniQure, its Affiliates or Sublicensees. 
 1.83 “Transgene”.
Transgene means (a) a given nucleic acid sequence that encodes an RNA sequence, and (b) any functionally equivalent sequence variants of such given nucleic acid sequence, [***]. 

  
 - 13 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 1.84 “UC AAV Capsid Variant”. UC AAV Capsid Variant means any AAV Capsid
Variant provided to 4DMT pursuant to the UCB Agreements. 
 1.85 “UC Patent Right”. UC Patent Right means any Patent Right
licensed to 4DMT pursuant to the UCB Agreements. 
 1.86 “UC Product”. UC Product means a Royalty Bearing Product that is
Covered by a UC Patent Right. 
 1.87 “UCB Agreements”. UCB Agreements means (a) the Exclusive License and Bailment
Agreement between 4DMT and the Regents of the University of California (“UC”), Agreement Control No. 2014-03-0089, dated December 19, 2013;
(b) the Exclusive License and Bailment Agreement between 4DMT and UC, Agreement Control No. 2014-03-0090, dated December 19, 2013; and (c) the Agreement
for Use of Certain Biological Materials between 4DMT and UC, Agreement Control No. 2014-30-0088, dated December 19, 2013, in each case in the form provided to
uniQure by 4DMT as of the Effective Date. 
 1.88 “uniQure Intellectual Property”. uniQure Intellectual Property means
uniQure Know-How and uniQure Patent Rights. 
 1.89 “uniQure
Know-How”. uniQure Know-How means Know-How that is (a) Controlled by uniQure or its Affiliates as of the Effective
Date or during the Research Term, and (b) necessary or useful to conduct the Research Program or to research, Develop, make and have made, use or Commercialize the relevant New Capsid Variant, or a Royalty Bearing Compound or Royalty Bearing
Product due to the presence of such New Capsid Variant therein. uniQure Know-How includes Core uniQure Know-How but does not include Joint
Know-How. 
 1.90 “uniQure Patent Right”. uniQure Patent Right means any
Patent Right Controlled by uniQure or its Affiliates as of the Effective Date or during the Term that Covers uniQure Know-How. uniQure Patent Rights include Core uniQure Patent Rights but do not include Joint
Patent Rights. 
 1.91 “uniQure Product”. uniQure Product means a Royalty Bearing Product that (a) delivers a Transgene
that Affects a Restricted Target (or variant of a Restricted Target), or (b) that delivers a Transgene that Affects a Non-Restricted Target (or variant of a
Non-Restricted Target), and in the case of (b) uniQure has obtained non-exclusive rights to Develop and Commercialize such Royalty-Bearing Product pursuant to the
exercise of its Step-In Rights in Section 4.4. Notwithstanding anything express or implied, no uniQure Product shall deliver any Transgene that relates to any
Non-Restricted Target for which uniQure has not obtained rights to deliver as part of a Royalty-Bearing Product pursuant to the exercise of its Step-In Rights
under Section 4.4. 
 1.92 “uniQure Product Patent”. uniQure Product Patent means any Product Patent upon which
uniQure’s or its Affiliates’ personnel are properly named inventors (as determined under U.S. patent law) and 4DMT and its Affiliates’ are not. 

  
 - 14 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 1.93 “Valid Claim”. Valid Claim means (a) a claim of an issued patent
that has not expired or been abandoned, or been revoked, held invalid or unenforceable by a patent office, court or other governmental agency of competent jurisdiction in a final and non-appealable judgment
(or judgment from which no appeal was taken within the allowable time period), or (b) a claim within a patent application which application has not been pending for more than [***] ([***]) years from the date of its priority filing date and
which claim has not been irretrievably revoked, irretrievably cancelled, irretrievably withdrawn, held invalid or abandoned by a patent office, court or other governmental agency of competent jurisdiction in a final and non-appealable judgment (or judgment from which no appeal was taken within the allowable time period), or finally determined to be unallowable in a decision from which an appeal cannot or can no longer be taken;
provided, however, that with respect to the UC Patent Rights licensed under the Exclusive License and Bailment Agreement between 4DMT and UC, Agreement Control
No. 2014-03-0089, the foregoing [***] ([***]) year limitation shall be extended to [***] ([***]) years. 

“Vector Characterization Data” means any and all data, results and other Know-How
that is generated either by or on behalf of a Party or its Affiliate, whether alone or together with, by or for any of its Third Party licensees, contractors or collaborators, with respect to any New Capsid Variant, in regards to any of the
following with respect to such New Capsid Variant:[***] 
 1.94 Additional Definitions. Each of the following definitions is set forth
in the section of this Agreement indicated below: 
  

			
	 Definition:
	  	Section:
	 4DMT
	  	Preamble
	 4DMT Indemnitees
	  	9.5
	 Additional Cure Period
	  	10.2(a)
	 Agreement
	  	Preamble
	 Audited Party
	  	6.5
	 Auditing Party
	  	6.5
	 Bankruptcy Code
	  	5.4
	 CREATE Act
	  	7.10
	 Damages
	  	9.5
	 Defaulting Party
	  	10.2(a)
	 Dispute
	  	11.1
	 Effective Date
	  	Preamble
	 Excluded Claim
	  	11.2
	 Executives
	  	2.3(b)
	 Fair Market Value
	  	6.3(b)(iii)
	 GAAP
	  	1.11
	 IFRS
	  	1.11
	 Initiating Party
	  	7.6(d)
	 Joint Counsel
	  	7.5
	 Joint Intellectual Property
	  	7.2(a)

  
 - 15 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

			
	 Definition:
	  	Section:
	 Joint Know-How
	  	7.2(a)
	 Joint Patent Rights
	  	7.2(a)
	 JRSC
	  	2.1(a)
	 M&A Event
	  	12.7
	 MAA
	  	1.53
	 Non-Defaulting Party
	  	10.2(a)
	 Orange Book
	  	7.9(a)
	 Paragraph IV Certification
	  	7.9(b)
	 Paragraph IV Proceeding
	  	7.9(b)(ii)
	 Records
	  	3.5(a)(i)
	 SEC Filing
	  	8.5(c)
	 Sublicense Consideration
	  	6.3(b)
	 Sublicense Income Sharing Percentages
	  	6.3(a)
	 Term
	  	10.1
	 Third Party Claim
	  	9.5
	 Trade Secret Election
	  	7.3(b)
	 USPTO
	  	7.10
	 UC
	  	1.87
	 uniQure
	  	Preamble
	 uniQure Indemnitees
	  	9.6

 ARTICLE II 

GOVERNANCE 
 2.1
Joint Research Steering Committee. 
 (a) Composition. Promptly after the Effective Date, the Parties shall establish a joint
research steering committee (the “JRSC”). The JRSC shall be comprised of at least [***] ([***]) named representatives of uniQure and at least [***] ([***]) named representatives of 4DMT, one of whom shall be David Schaffer (unless
due to his death, illness or disability), or such other numbers as the Parties may agree in writing. As soon as practicable after the Effective Date (but in no event more than [***] ([***]) Business Days after the Effective Date), each Party shall
designate by written notice to the other Party its initial representatives on the JRSC. Each Party may replace one or more of its non-mandatory representatives, in its sole discretion, effective upon written
notice to the other Party of such change. These representatives shall have appropriate technical credentials, experience and knowledge, and ongoing familiarity with the Research Program. The JRSC shall be disbanded upon expiration of the Research
Term. 
 (b) Function and Powers of the JRSC. During the Research Term, the JRSC’s responsibilities shall include:
(i) providing a forum for discussion of the Research Plan for Liver and the Research Plan for CNS, the status of the Research Program, and relevant data (but not making any decisions with respect thereto, other than as provided in clause
(iii) of this sentence 

  
 - 16 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 
or as provided in Section 2.6); (ii) serving as a forum for informal resolution of disagreements that may arise in the relation to the Parties’ activities under the Research Program
(but not deciding any such disagreement); and (iii) amending the Research Plan for Liver and/or the Research Plan for CNS, solely in the circumstances described in and under the terms and conditions of Section 2.6. 

2.2 Meetings. The JRSC shall each hold at least [***] per Calendar Quarter during the Research Term. Upon necessity, either Party shall
be entitled to request additional meetings of the JRSC. Meetings of the JRSC shall be effective only if at least [***] ([***]) representatives of each Party are present or participating. The location of meetings shall be as agreed by the Parties,
and may be held in person, alternating locations between the Parties, or by telephone conference call or by videoconference; provided, however, that at least [***] ([***]) meetings of the JRSC each Calendar Year are held in person.
4DMT’s costs and expenses incurred in connection with preparing for and participating in all such meetings shall be paid for by uniQure in accordance with the budget for the Research Plan for Liver or Research Plan for CNS, as applicable.
Either Party may, from time to time, invite additional representatives or consultants to attend JRSC meetings; provided that at least [***] ([***]) Business Days’ prior written notice is given of a Party’s intention to invite such
other representatives or consultants and providing full details about the name, employer and professional background of such other representatives or consultants. Each representative and consultant participating in or attending a JRSC meeting shall
be bound by a written agreement with confidentiality obligations substantially the same as those set forth in ARTICLE VIII. The JRSC shall be co-chaired by a representative from each Party. The chairpersons
shall set the agendas for the JRSC meeting in advance. Within ten (10) Business Days prior to each scheduled meeting, each Party shall, in accordance with Section 3.5(b), provide a report to the JRSC detailing its progress with respect to
the Research Program. The Parties will rotate the responsibility for recording, preparing and issuing minutes for each JRSC meeting, to be circulated within [***] ([***]) Business Days after each meeting. 

2.3 Decision-making. 

(a) Initial Dispute Resolution Procedures. Subject to the provisions of this Section 2.3, actions to be taken by the JRSC shall
be taken only following a unanimous vote, with each Party, through its representatives, having one (1) vote. Notwithstanding the foregoing, and subject to Section 2.6, in the circumstances described in such Section, [***] shall have the
final say and final decision-making authority on any and all disputes pertaining to any amendments to the Research Plan for CNS or amendments to the Research Plan for Liver, and any such final decision by [***] on such matters shall not be subject
to further review by referral to Executives or otherwise under this Section 2.3 or under any of the dispute resolution provisions of this Agreement. 

(b) Referral of Unresolved Matters to Executives. If, in accordance with Section 2.3(a), the JRSC does not resolve any matter
considered by it within [***] ([***]) Business Days after the matter is first considered by it, the matter may be referred by either Party to the CEO of 4DMT and CEO of uniQure (the “Executives”) to be resolved by negotiation in
good faith as soon as practicable, but in no event later than [***] ([***]) Business Days after referral. Such resolution, if any, of a referred issue by the Executives shall be final and binding on the Parties. Any decision made by the Executives
under this Section 2.3(b) shall be deemed a decision of the JRSC for purposes of this Agreement. 

  
 - 17 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 (c) Final Decision-Making. If a dispute referred to the Executives pursuant to
Section 2.3(b) has not been resolved in accordance with Section 2.3(b), then, subject to Section 2.3(d), [***] shall have the final decision-making authority. Any decision made by [***] pursuant to this Section 2.3(c) shall be
deemed a decision of the JRSC for purposes of this Agreement. 
 (d) Exceptions. Notwithstanding Section 2.3(c), [***] shall not
have the right to exercise such decision-making authority (i) in a manner that excuses [***] from any of its obligations specifically enumerated under this Agreement; (ii) in a manner that negates any consent rights or other rights
specifically allocated to [***] under this Agreement; (iii) in a manner that would require [***] to perform activities (A) for which [***] (except as expressly set forth in this Agreement), (B) that [***], or (C) that [***]; (iv) in a
manner that would take away [***]’s right to perform activities that [***] has previously agreed to perform as set forth in the Research Plan; (v) in a manner that would require [***] to perform any act that it reasonably believes to be
inconsistent with any Law or any approval, order, policy, guidelines of a Regulatory Authority or ethical requirements or ethical guidelines; (vi) to determine that [***] has fulfilled any obligation under this Agreement or that [***] has
breached any obligation under this Agreement; or (vii) to amend the relevant Delivery Success Criteria. 
 (e) This Section 2.3
(and each of its subsections) shall not be used to imply any greater decision-making authority on the part of the JRSC than is set forth in Section 2.1(b) (i.e., the JRSC’s sole decision-making authority is to decide upon amendments to the
Research Plan for CNS and the Research Plan For Liver, subject always and solely in the circumstance and manner stated in Section 2.6). 

2.4 Limitations on JRSC Authority. The JRSC shall have only the powers assigned expressly to it in this ARTICLE II and elsewhere in this
Agreement, and shall not have any power to amend, modify or waive compliance with this Agreement. In furtherance thereof, each Party shall retain the rights, powers and discretion granted to it under this Agreement and no such rights, powers or
discretion shall be delegated or vested in the JRSC unless such delegation or vesting of rights is expressly provided for in this Agreement or the Parties expressly so agree in writing. 

2.5 Sharing of Vector Characterization and Other Data at the JRSC. Each Party shall share with and disclose to the other Party the
Vector Characterization Data obtained by such Party with respect to New Capsid Variants, pursuant to the requirements of Section 4.3. Each Party shall do so during the Research Term and thereafter, and whether such Vector Characterization Data
is generated within or outside of the Research Program. During the Research Term, 4DMT will keep the JRSC informed of: (a) any and all reasonably relevant data and information generated under the Research Program (including Vector
Characterization Data; and (b) all New CNS Variants and New Liver Variants that have been identified by 4DMT, [***], in connection with the next JRSC meeting after their identification. 

  
 - 18 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 2.6 Amendments to Research Plans. Notwithstanding anything express or implied in this
Agreement, the JRSC shall only have the power to amend the Research Plan for CNS and the Research Plan for Liver in the following circumstances: (a) the then-current version of the applicable research plan (i.e., the Research Plan for CNS or
the Research Plan for Liver) cannot be carried out as written; or (b) the JRSC achieves unanimous consensus (with no exercise of any final say) that a change needs to be made and as to the change. 

ARTICLE III 

RESEARCH PROGRAM 

3.1 Objectives of the Research Program. The Research Program under this Agreement shall be defined, collectively, by the activities as
described in the Research Plan for CNS and the Research Plan for Liver, each as appended to this Agreement as of the Effective Date (or as they may be amended in accordance with this Agreement). The objective of the Research Plan for CNS is for 4DMT
to identify [***] ([***]) New CNS Variants that meet the applicable Delivery Success Criteria for entry into validation studies, the Vector Characterization Data from which validation studies will be the package of data that 4DMT is required to
provide to uniQure in order to satisfy its obligation to present [***] ([***]) New CNS Variants with the required Vector Characterization Data. The objective for the Research Plan for Liver is to identify the New Liver Variants that meet the
applicable Delivery Success Criteria, the Vector Characterization Data from which validation studies will be the package of data that 4DMT is required to provide to uniQure in order to satisfy its obligation to present [***] ([***]) New Liver
Variants with the required Vector Characterization Data. As and to the extent provided for in the Research Plan, 4DMT would provide quantities of such New Capsid Variants to uniQure for testing. If the CNS Selection Processes or the liver Selection
Processes of the Research Program do not yield at least [***] ([***]) New Capsid Variants meeting the applicable Delivery Success Criteria for entry into validation studies to generate the required Vector Characterization Data packages, then
(a) if requested by 4DMT, uniQure may (but is not required to) [***]; and/or (b) [***]. 
 3.2 Conduct of the Research Program.

 (a) 4DMT shall initiate work on the Research Plan for Liver and the Research Plan for CNS within [***] ([***]) weeks after the New CLA
Effective Date. Any amendments to the Research Plan for CNS or the Research Plan for Liver will be only as agreed by the JRSC. 
 (b) 4DMT
shall use Commercially Reasonable Efforts to conduct the Research Program in accordance with the Research Plan for CNS and the Research Plan for Liver. 4DMT shall have an affirmative obligation during the term the Research Program and thereafter
during the term of this Agreement to disclose all data and other information related to the Research Plan on a timely basis, including, without limitation, all Vector Characterization Data created pursuant to the Research Program, the Research Plan
for Liver, and the Research Plan for CNS, as well as the existence and status of all New Capsid Variants generated outside the Research Program during the applicable CNS Term or Liver Term (as applicable based on whether the

  
 - 19 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 
variant at issue is a New CNS Variant or a New Liver Variant), and all Vector Characterization Data associated with such New Capsid Variants. For clarity, New CNS Variants only arise during the
CNS Term, and New Liver Variants only arise during the Liver Term, even though they, or the Vector Characterization Data with respect thereto, may be later reported between the Parties. 

(c) Either Party shall have the right to utilize the services of any Third Party to perform its obligations under the Research Plan to the
extent that such Third Party is specifically approved in the Research Plan or otherwise approved by the JRSC, provided that any permitted Third Party must have entered into a written agreement with such Party that includes terms and
conditions (i) protecting and limiting use and disclosure of Confidential Information at least to the same extent as under ARTICLE VIII, and (ii) requiring the Third Party and its personnel to assign to such Party all right, title and
interest in and to any intellectual property (and intellectual property rights) created or conceived in connection with performance of subcontracted activities. Each Party shall remain at all times fully liable for its responsibilities under this
Agreement. 
 (d) 4DMT and uniQure shall conduct the Research Program in accordance with all applicable Laws, including, if and as
applicable, Good Laboratory Practices. Each Party hereby certifies that it will not employ or otherwise use in any capacity in performing any activity hereunder the services of any person or entity known to it to be debarred under 21 USC
§335a. For clarity, each of the New CNS Variants and each of the New Liver Variants to be entered into validation studies under the Research Program shall meet the applicable Delivery Success Criteria as defined in the Research Plans unless the
Parties in their discretions agree otherwise in writing. 
 3.3 Materials and Know-How
Transfer/Use of Constructs. 
 (a) In order to facilitate the Research Program, each Party shall, to the extent set forth in the
Research Plan, provide to the other Party certain Materials and, subject to Section 3.4, Know-How Controlled by the supplying Party for use by the other Party in furtherance of the Research Program. All
Materials and Know-How provided by one Party to the other Party remain the sole property of the supplying Party. 

(b) All Materials transferred pursuant to the Research Program shall be used (i) only for the specific purpose provided for in the
Research Plan, and (ii) solely under the control of the receiving Party. The Materials may not be used or delivered to or for the benefit of any Third Party without the prior written consent of the supplying Party, and shall not be used in
research or testing involving human subjects, except as expressly contemplated in the Research Plan or in accordance with this Agreement. All Materials shall be returned to the supplying Party or destroyed (at the election of the supplying Party)
promptly after completion of the use permitted under this Agreement. 
 (c) THE MATERIALS ARE PROVIDED “AS IS” AND WITHOUT ANY
REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR OF FITNESS FOR ANY PARTICULAR PURPOSE OR ANY WARRANTY THAT THE USE OF THE MATERIALS WILL NOT INFRINGE OR VIOLATE ANY PATENT OR OTHER PROPRIETARY
RIGHT OF ANY THIRD PARTY. 

  
 - 20 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 (d) At the end of the Research Term, to the extent that samples have not already been
provided to uniQure under the Research Program, 4DMT shall promptly provide to uniQure samples of New Capsid Variants that are at that time in 4DMT’s possession. For clarity, this means the quantities specified in the Research Plan, not all
quantities of New Capsid Variants at that time in 4DMT’s possession. Other than as may be provided in the Research Plan, 4DMT shall not be required to transfer any Royalty Bearing Constructs to uniQure, unless the Parties mutually otherwise
agree in writing in their discretions at a later date. 
 3.4 Third Party Intellectual Property. The conduct of activities under the
Research Plan may use Patent Rights or Know-How licensed by 4DMT pursuant to the UCB Agreements, subject to the terms and conditions of the UCB Agreements. 4DMT shall be solely responsible for all obligations
under the UCB Agreements, including any and all payments and royalties due thereunder. In developing the Research Plan, the Parties shall discuss whether any Third Party Patent Rights or Know-How, other than
Patent Rights or Know-How licensed by 4DMT pursuant to the UCB Agreements, will be utilized in the conduct of activities under the Research Plan. 4DMT shall disclose to uniQure the details of any restrictions
on use or payment obligations of which it is aware that would be triggered by such use of Third Party Patent Rights or Know-How in the Research Program. If the Parties mutually agree to use any inventions
claimed in any Patent Right or use any Know-How that is licensed to or has been acquired by 4DMT other than pursuant to the UCB Agreements, and if such use would require the payment of additional consideration
to the Third Party from which the Patent Rights or Know-How was licensed or acquired, then such Patent Right or Know-How shall be deemed under the Control of 4DMT,
provided that uniQure expressly agrees in writing to bear any such additional consideration actually to be paid by 4DMT to the Third Party (which amounts uniQure may offset pursuant to Section 6.2(c)(ii)) with respect to the Development,
manufacture or Commercialization of Royalty Bearing Constructs or Royalty Bearing Products. For clarity, nothing in this Section 3.4 shall limit uniQure’s rights to obtain from a Third Party, independent of 4DMT, a license or other right
with respect to such Third Party’s Patent Rights or Know-How. 
 3.5 Records and Reports.

 (a) Records. 
 (i)
4DMT shall maintain records, in sufficient detail and in good scientific manner appropriate for patent and regulatory purposes, which shall fully and properly reflect all work done and results achieved in the performance of the Research Program by
or on behalf of 4DMT (the “Records”), including the procedures, techniques and methodologies used, the progress made, and any Invention conceived or reduced to practice or otherwise made within the scope of or in connection with the
Research Program. As part of keeping the Records, 4DMT shall ensure that all of its personnel, and all of its agents that are involved in the Research Program, will keep accurate laboratory notebooks, which laboratory notebooks: (A) shall be
duly signed, dated and witnessed; and (B) shall be created and maintained in accordance with its standard operating procedures that would be sufficient to allow for said laboratory notebooks to be used in

  
 - 21 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 
any proceeding before the United States Patent and Trademark Office or United States courts, in order to establish the date of invention for any Invention in accordance with the United States
patent laws. During the Term, 4DMT shall, upon written request by uniQure, which shall not be unreasonably made: (1) make all Records available for inspection and review by uniQure during normal business hours in a timely manner; and
(2) provide copies of the Records or any part thereof to uniQure, as reasonably requested by uniQure. 
 (ii) In connection with
uniQure’s exercise of its back-up right for patent filing as relates to the New Variant Patents (if applicable), uniQure shall have the right to request that a copy of the relevant portions of the
laboratory notebooks relating to all stages of the generation of the applicable New Capsid Variants be provided by 4DMT to uniQure. After such request by uniQure, 4DMT shall provide such copies of the laboratory notebooks promptly to uniQure, which
shall be maintained by uniQure as 4DMT’s Confidential Information. 
 (b) Reports to the JRSC. Between [***] ([***]) and [***]
([***]) Business Days prior to each scheduled JRSC meeting, the Parties shall provide to the JRSC a written report on the progress of the Research Program, summarizing the work performed under the Research Program and evaluating the work performed
in relation to the goals of the Research Program. Each Party shall provide such other information required by the Research Program or reasonably requested by the other Party and reasonably available, relating to the progress of the goals or
performance of the Research Program. 
 ARTICLE IV 

DEVELOPMENT AND COMMERCIALIZATION OF PRODUCTS; DILIGENCE 

4.1 Responsibility. 

(a) uniQure shall have the full right, but not the obligation, at its sole expense, for the worldwide research, Development, manufacturing and
Commercialization of uniQure Products pursuant to the exercise by uniQure of its rights under this Agreement (including its ownership rights and/or its exercise of any of the licenses granted to uniQure under Section 5.1(b)) in accordance with
the terms and conditions and limitations of such license rights, and, subject to the payment obligations under Article VI and all other relevant terms and conditions of this Agreement. For clarity, this does not apply to those 4D Products, if any,
addressing Restricted Targets pursuant to 4DMT’s non-exclusive rights after an exercise of 4DMT’s Step-In Rights that results in 4DMT obtaining non-exclusive rights to such 4DMT Products addressing Restricted Targets. Moreover, it does not apply to any 4DMT Products directed to a Non-Restricted Target, even after an
exercise by uniQure of its Step-In Rights related to a uniQure Product to such Non-Restricted Target. 

(b) 4DMT shall have the full right, but not the obligation, at its sole expense, for the worldwide research, Development, manufacturing and
Commercialization of 4DMT Products pursuant to the exercise by 4DMT of its rights under this Agreement (including its ownership rights and/or its exercise of any of the licenses granted to 4DMT under Section 5.2(c)) in accordance with the terms
and conditions and limitations of such license rights, and 

  
 - 22 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 
subject to the payment obligations under Article VI and all other relevant terms and conditions of this Agreement. For clarity, this does not apply to those uniQure Products, if any, addressing Non-Restricted Targets pursuant to uniQure’s non-exclusive rights after an exercise of uniQure’s Step-In Rights that results
in uniQure obtaining non-exclusive rights to such uniQure Products addressing Non-Restricted Targets. 

4.2 Diligence. No Party will have any diligence obligations with respect to either 4DMT Products or uniQure Products, except as provided
in Section 4.4 with respect to Proposed Products, and the circumstance in which either a not-stepping-in Party chooses to pursue a Proposed Product in lieu of
allowing the other Party to obtain rights thereto pursuant to such other Party’s Step-In Rights, or in the circumstance in which the stepping-in Party obtains non-exclusive rights to such Proposed Product. 
 4.3 Obligation to Share Vector Characterization Data
for AAV Capsid Variants. 
 (a) Commencing on the New CLA Effective Date and continuing throughout the Term, uniQure shall provide,
within [***] ([***]) days after each January 31st and July 31st of each Calendar Year, a written report to 4DMT that summarizes the Vector
Characterization Data generated by or on behalf of uniQure or its Affiliate or Sublicensee with respect to each New Capsid Variant for which any research, Development, Commercialization or other vector characterization activities were conducted by
or on behalf of uniQure or its Affiliate or Sublicensee during the [***]. 
 (b) Commencing on the New CLA Effective Date and continuing
throughout the Term, 4DMT shall provide, within [***] ([***]) days after each January 31st and July 31st of each Calendar Year, a written
report to uniQure that summarizes the Vector Characterization Data generated by or on behalf of uniQure or its Affiliate or Sublicensee with respect to each AAV Capsid Variant or New Capsid Variant for which any research, Development,
Commercialization or other vector characterization activities were conducted by or on behalf of 4DMT or its Affiliate or Sublicensee during the [***]. 

(c) Either Party may terminate its obligation to provide written reports pursuant to this Section 4.3 after the Research Term, if it
ceases all research, development, commercialization or other activities that would result in the generation of any further unreported Vector Characterization Data with respect to New Capsid Variants, and the Party provides written notice to the
other Party so stating and also certifying that all Vector Characterization Data that is required to be reported with respect to New Capsid Variants has been so reported. 

4.4 Step-In Rights of each Party for Proposed Products. 

(a) Step-In Rights of 4DMT. 

(i) At any time after the expiration of the CNS Term (for products based on New CNS Variants) or the Liver Term (for products based on New
Liver Variants), 4DMT may make a bona fide proposal to uniQure for Developing and Commercializing a Product using a New Capsid Variant in the Field to deliver a Transgene that Affects any Restricted Target (each, a “4DMT Proposed
Product”), including a development plan and a plan 

  
 - 23 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 
to finance such activities. Within [***] ([***]) days after receipt of a notice from 4DMT of a 4DMT Proposed Product, uniQure shall notify 4DMT whether uniQure is conducting or is interested in
conducting research or Development of such 4DMT Proposed Product, or a Product that uniQure believes in good faith is or would be competitive with such 4DMT Proposed Product (a “Competitive Product”). 4DMT shall have the right to
select a maximum total of [***] ([***]) Proposed Products as 4DMT Proposed Products per calendar year under this Section 4.4 and under Section 4.4 of the Amended and Restated CLA, such total to be determined in the aggregate under this
Agreement and the Amended and Restated CLA, taken collectively. 
 (ii) If uniQure notifies 4DMT in good faith that uniQure is conducting or
is interested in conducting research or Development of such 4DMT Proposed Product or Competitive Product, uniQure shall within [***] ([***]) months after such notice, deliver to 4DMT a plan (including projected timelines) for the research and
Development thereof and, thereafter, shall use Commercially Reasonable Efforts to research, Develop, manufacture and Commercialize such 4DMT Proposed Product or Competitive Product in accordance with such plan. Each progress report provided to 4DMT
under Section 4.3 from and after the date of uniQure’s notice under this Section shall contain a summary of the activities undertaken and the status of uniQure’s research and Development efforts with respect to such Third Party
Proposed Product, 4DMT Proposed Product, uniQure Proposed Product or Competitive Product during the [***]. 
 (iii) If uniQure notifies 4DMT
that uniQure is not conducting and is not interested in conducting research or Development of such 4DMT Proposed Product, or Competitive Product, then the date of uniQure’s such written notice (or the deadline therefor, if uniQure is required
to provide such notice and fails to provide notice by such date whether clause (ii) above or this clause (iii) would otherwise), then this shall be the “Effective Time” for such 4DMT Proposed Product and the applicable Restricted
Target, and the license to 4DMT in Section 5.2(c) shall become effective as of the Effective Time. 
 (b) Step-In Rights of uniQure. 
 (i) At any time after the expiration of the CNS Term (for products based
on New CNS Variants) or the Liver Term (for products based on New Liver Variants), uniQure may make a bona fide proposal to 4DMT for Developing and Commercializing a Product using a New Capsid Variant in the Field to deliver a Transgene that Affect
any Non-Restricted Target (each, a “uniQure Proposed Product”), including a development plan and a plan to finance such activities. Within [***] ([***]) days after receipt of a notice from
uniQure of a uniQure Proposed Product, 4DMT shall notify uniQure whether 4DMT is conducting or is interested in conducting research or Development of such uniQure Proposed Product, or a Product that 4DMT believes in good faith is or would be
competitive with such uniQure Proposed Product (a “4D Competitive Product”). uniQure shall have the right to select a maximum total of [***] ([***]) Proposed Products as uniQure Proposed Products per year under this
Section 4.4. 

  
 - 24 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 (ii) If 4DMT notifies uniQure in good faith that 4DMT is conducting or is interested in
conducting research or Development of such uniQure Proposed Product or Competitive Product, 4DMT shall within [***] ([***]) months after such notice, deliver to uniQure a plan (including projected timelines) for the research and Development thereof
and, thereafter, shall use Commercially Reasonable Efforts to research, Develop, manufacture and Commercialize such uniQure Proposed Product or Competitive Product in accordance with such plan. Each progress report provided to uniQure under
Section 4.3 from and after the date of 4DMT’s notice under this Section shall contain a summary of the activities undertaken and the status of 4DMT’s research and Development efforts with respect to such Third Party Proposed Product,
uniQure Proposed Product, 4DMT Proposed Product or Competitive Product during the [***]. 
 (iii) If 4DMT notifies uniQure that 4DMT is not
conducting and is not interested in conducting research or Development of such uniQure Proposed Product, or Competitive Product, then the date of 4DMT’s such written notice (or the deadline therefor, if 4DMT is required to provide such notice
and fails to provide notice by such date whether clause (ii) above or this clause (iii) would otherwise apply), then this shall be the “UQ Effective Time” for such uniQure Proposed Product and the applicable Non-Restricted Target, and the license to uniQure in Section 5.1(b)(ii) shall become effective as of the UQ Effective Time. 

(c) General Rights of 4DMT Related to Non-Restricted Targets. For clarity, 4DMT owns the New
Variant Patents and has the right to pursue 4DMT Products delivering Transgenes that Affect Non-Restricted Targets, without the need to obtain any rights under this Section 4.4 (i.e., as a default matter
4DMT has the right to pursue 4DMT Products delivering Transgenes that Affect Non-Restricted Targets, with no need to “step in” to obtain such rights, and for that reason, 4DMT’s Step-In Rights under this Section 4.4 do not apply to 4DMT Products delivering Transgenes that Affect Non-Restricted Targets). 

4.5 Pharmacovigilance. Within [***] ([***]) months after the Effective Date, the Parties shall enter into an agreement governing
the exchange of adverse event safety data (including post-marketing spontaneous reports) received by a Party and its Affiliates, including such data received from, in the case of uniQure, its Sublicensees or, in the case of 4DMT, its licensees,
relating to any AAV Capsid Variant provided to uniQure by 4DMT hereunder in order to monitor the safety of all Constructs and Products and to meet reporting requirements with any applicable Regulatory Authority. Such data sharing agreement shall not
require the sharing of data that would disclose confidential know-how or trade secrets of a Party or its Affiliates, or in the case of uniQure, its Sublicensees or, in the case of 4DMT, its licensees, if such
data may be cross-referenced, such as through a Drug Master File, to satisfy the requirements of Law and any applicable Regulatory Authority. 

4.6 Marking. Prior to the issuance in the United States of Patent Rights included in the UC Patent Rights, uniQure agrees to mark
Royalty Bearing Product(s) Covered by any UC Patent Right (or their containers or labels) sold in the United States under the licenses granted in this Agreement with the words “Patent Pending,” and following the issuance in the United
States of one or more Patent Rights included in the UC Patent Rights, with the patent numbers of the UC Patent Right(s) Covering such Royalty Bearing Product. All Royalty Bearing Products Covered by any UC Patent Right sold in other countries will
be marked in such manner as to conform with the patent Laws and practice of such countries. 

  
 - 25 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 ARTICLE V 

GRANTS OF RIGHTS 

5.1 Licenses to uniQure. 

(a) Research License to uniQure. Subject to the terms and conditions of this Agreement, 4DMT hereby grants to uniQure, and uniQure
hereby accepts, during the Research Term, an exclusive (but not as to 4DMT), worldwide, royalty-free, non-sublicenseable license under the 4DMT Intellectual Property and 4DMT’s interest in the Joint
Intellectual Property, solely to (i) conduct activities assigned to uniQure under the Research Plan for Liver or the Research Plan for CNS, (ii) evaluate Constructs, or (iii) evaluate the data developed in the conduct of activities
under the Research Program or during the Research Term. This license is intended to include the right for uniQure to make sequence modifications to New Capsid Variants solely for the purpose of (1) adapting New Capsid Variants to insect cells
or insect cell expression vectors and systems, and/or (2) modifying any “Selected Capsid Variants” as defined in the Amended and Restated CLA with or to include any motif, mutation, or substitution identified under this New CLA;
provided that (x) uniQure shall promptly disclose to 4DMT all AAV Capsid Variants resulting from such activities, (y) such resulting AAV Capsid Variants shall be deemed New Capsid Variants for all purposes under this Agreement, and
(z) the Patent Rights that may be filed with respect to such resulting deemed New Capsid Variants shall be deemed New Variant Patents for all purposes under this Agreement, and the Know-How with respect
thereto shall be deemed the subject matter of New Variant Patents (whether or not Patent Rights are ever filed with respect to such Know-How) and therefore Core 4DMT
Know-How, for all purposes under this Agreement. For clarity, the obligations of uniQure under the foregoing clauses (x), (y) and (z) with respect to any uniQure-modified New Capsid Variants or any
uniQure-modified Selected Capsid Variants as described in the foregoing sentence shall not apply to any AAV Capsid Variant (or any modification or improvement thereof) that is identified or generated by uniQure or any of its Affiliates or
Sublicensees independently and outside of the Research Program, without the use of any information disclosed to uniQure pursuant to this Agreement or the Amended and Restated CLA as to the sequence of any New Capsid Variant or Selected Capsid
Variant. 
 (b) Development and Commercialization Licenses to uniQure. 

Exclusive License for use of New Capsid Variants in connection with the Restricted Targets. Subject to the terms and conditions of
this Agreement, and on a New Capsid Variant-by-New Capsid Variant basis, 4DMT hereby grants to uniQure, and uniQure hereby accepts, an exclusive (even as to 4DMT, except
solely to the extent that 4DMT obtains non-exclusive rights within the scope of this license pursuant to an exercise of 4DMT’s Step-In Rights), worldwide,
royalty-bearing license, including the right to grant sublicenses in accordance with Section 5.3, under the 4DMT Intellectual Property (including all Vector Characterization Data reported by 4DMT to uniQure under this Agreement) and 4DMT’s
interest in the Joint Intellectual Property, to research (subject to 4DMT’s retained rights to conduct research under the Research Program and to research Constructs related to Restricted Targets for potential exercise of 4DMT’s Step-In Rights in relation thereto), Develop, make and have made, use, import, sell and Commercialize the New Capsid Variants, and any modifications or improvements thereto, as

  
 - 26 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 
and into Royalty Bearing Constructs and Royalty Bearing Products in the Field. For clarity, the license granted to uniQure under this paragraph shall expressly include the right to create
improvements or modifications to the sequence or composition of matter of any New Capsid Variant, provided that such improved or modified sequence or composition of matter is used solely in connection with the applicable Restricted Target in
the Field, and (x) uniQure shall promptly disclose to 4DMT all resulting AAV Capsid Variants made, (y) such resulting AAV Capsid Variants shall be deemed New Capsid Variants for all purposes under this Agreement, and (z) the Patent
Rights that may be filed with respect to such resulting deemed New Capsid Variants shall be deemed New Variant Patents for all purposes under this Agreement, and the Know-How with respect thereto shall be
deemed the subject matter of New Variant Patents (whether or not Patent Rights are ever filed with respect to such Know-How) and therefore Core 4DMT Know-How, for all
purposes under this Agreement. For clarity, the obligations of uniQure under the foregoing clauses (x), (y) and (z) with respect to any uniQure-modified New Capsid Variants described in the foregoing sentence shall not apply to any AAV Capsid
Variant (or any modification or improvement thereof) that is identified or generated by uniQure or any of its Affiliates or Sublicensees independently and outside of the Research Program, without the use of any information disclosed to uniQure
pursuant to this Agreement or the Amended and Restated CLA as to the sequence of any New Capsid Variant or Selected Capsid Variant. 
 (c)
Non-Exclusive License for Proposed Products elected by uniQure pursuant to its Step-In Rights under Section 4.4. 

(i) Subject to the terms and conditions of this Agreement (including 4DMT’s retained rights related to Products delivering Transgenes
related to the applicable Non-Restricted Target), and on a New Capsid Variant by New Capsid Variant basis, effective upon the UQ Effective Time for the applicable
Non-Restricted Target and New Capsid Variant under Section 4.4(b), 4DMT hereby grants to uniQure, and uniQure hereby accepts, a non-exclusive, worldwide,
royalty-bearing license, including the right to grant sublicenses in accordance with Section 5.3, under the 4DMT Intellectual Property (including all Vector Characterization Data reported by 4DMT to uniQure under this Agreement) and 4DMT’s
interest in the Joint Intellectual Property, to research, Develop, make and have made, use and Commercialize the uniQure Proposed Product to the applicable Non-Restricted Target as Royalty Bearing Constructs
and Royalty Bearing Products within the Field. Such license may become effective one (1) or more times, in connection with one (1) or more elections by uniQure under Section 4.4 that result in the UQ Effective Time occurring under
Section 4.4(b) for the applicable uniQure Proposed Product, Non-Restricted Target, and New Capsid Variant. For clarity, the license granted under this paragraph to uniQure shall expressly include the
right to create improvements or modifications to the sequence or composition of matter of any New Capsid Variant, provided that such improved or modified sequence or composition of matter is used solely in connection with the applicable Non-Restricted Target in the Field. 
 (ii) In order to enable uniQure to research Constructs related to Non-Restricted Targets for the potential exercise of uniQure’s Step-In Rights pursuant to Section 4.4, uniQure shall have, and 4DMT hereby grants to uniQure, a non-exclusive research-use-only license to use any and all Vector Characterization Data reported to uniQure by 4DMT and any other
necessary 4DMT Intellectual Property, on a New Capsid Variant by New Capsid Variant basis, regardless of whether such New Capsid Variant was generated or identified under this Agreement or outside of this Agreement, to the extent necessary for
uniQure to evaluate whether to exercise its Step-In Rights pursuant to Section 4.4. 

  
 - 27 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 (d) Recordation. Following the Effective Date or at any time during the Term, 4DMT at
the request and expense of uniQure shall promptly register or record the licenses granted to uniQure under this Agreement with the appropriate patent offices in all applicable countries of the Territory; provided that such registration or
recordation specifies the applicable limitations of such license, and provided further that such registration shall have no effect on the allocation of Prosecution and Maintenance rights and obligations set forth in ARTICLE VII. In the
event any of the licenses granted to uniQure under this Agreement are terminated in accordance with the terms of this Agreement, uniQure shall promptly take such actions and execute such documents as are reasonably requested by 4DMT to cancel such
registration(s) or recordation(s) in the applicable countries with respect to the terminated license grants. 
 (e) Grant-Back License to
uniQure. 4DMT hereby grants to uniQure, and uniQure hereby accepts, a non-exclusive, worldwide, royalty-free license, including the right to grant sublicenses through multiple tiers, under the 4DMT Patent
Rights and 4DMT Know-How that (i) arise from activities that are conducted under this Agreement in connection with Royalty Bearing Constructs and Royalty Bearing Products in the course of making
modifications to New Capsid Variants and (ii) claim or cover compositions of matter or general methods of use of New Capsid Variants (for clarity, including such Patent Rights and Know-How claiming or
covering compositions combining Gene Therapy Constructs in general and AAV Capsid Variants in general or general methods of making or using such combinations of Gene Therapy Constructs and AAV Capsid Variants), to research, Develop, make and have
made, use, import, sell and Commercialize New Capsid Variants, and Products containing New Capsid Variants in connection solely with the Restricted Targets and any Non-Restricted Targets licensed to uniQure
pursuant to the Step-In Rights under Section 4.4. 
 5.2 Licenses to 4DMT. 

(a) Research License to 4DMT. Subject to the terms and conditions of this Agreement, uniQure hereby grants to 4DMT, and 4DMT hereby
accepts, during the Research Term, a non-exclusive, worldwide, royalty-free, non-sublicenseable license under the uniQure Intellectual Property, solely to the extent
necessary to conduct activities assigned to 4DMT under the Research Program during the Research Term. 
 (b) Grant-Back License to
4DMT. uniQure hereby grants to 4DMT, and 4DMT hereby accepts, a non-exclusive, worldwide, royalty-free license, including the right to grant sublicenses through multiple tiers, under the Patent Rights and Know-How Controlled by uniQure pursuant to the licenses granted by 4DMT to uniQure in Section 5.1 (including such Patent Rights and Know-How licensed to uniQure pursuant
to Section 5.1 claiming or covering compositions combining Gene Therapy Constructs in general and AAV Capsid Variants in general or general methods of making or using such combinations of Gene Therapy Constructs and AAV Capsid Variants), and to
use the Vector Characterization Data reported by uniQure to 4DMT under this Agreement, to research, Develop, make and have made, use and Commercialize New Capsid 

  
 - 28 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 
Variants, and Products containing New Capsid Variants, in all cases outside the Field or within 4D Products within the scope of rights within which 4DMT is entitled to research, Develop, and
Commercialize 4D Products under this Agreement. For the avoidance of doubt, 4DMT’s practice of the foregoing license shall be subject to the license rights of uniQure under Section 5.1 and its right to grant sublicenses under
Section 5.3. 
 (c) Non-Exclusive License for Proposed Products elected by 4DMT pursuant to
its Step-In Rights under Section 4.4. Subject to the terms and conditions of this Agreement (including uniQure’s retained rights related to Products delivering Transgenes that
Affect the applicable Restricted Target), and on a New Capsid Variant-by-New Capsid Variant basis, effective upon the Effective Time with respect to the given 4DMT
Proposed Product and Restricted Target pursuant to Section 4.4(a), uniQure hereby grants to 4DMT, and 4DMT hereby accepts, a non-exclusive, worldwide, royalty-bearing license, including the right to grant
sublicenses in accordance with Section 5.3, under the uniQure Intellectual Property that is necessary or useful due to the presence of the applicable New Capsid Variant (including all Vector Characterization Data reported by uniQure to 4DMT
under this Agreement) and uniQure’s interest in the Joint Intellectual Property, to research, Develop, make and have made, use and Commercialize such 4DMT Proposed Products as Royalty Bearing Constructs and Royalty Bearing Products within the
Field. Any licenses granted pursuant to this Section are limited to only uniQure Intellectual Property that specifically relates to New Capsid Variants, including patent claims specifying a New Capsid Variant (if any) or specifically claiming any
methods of use or making any New Capsid Variants (if any), and excluding all other uniQure Intellectual Property, including compositions of matter or methods of making compositions of matter and methods of manufacturing Products (but not the New
Capsid Variants therein) pursuant to this Agreement. Such license may become effective one (1) or more times, in connection with one (1) or more elections by 4DMT under Section 4.4 that result in the Effective Time occurring under
Section 4.4(a)(iii) for the applicable Proposed Product and Restricted Target. 
 5.3 Sublicenses. Each Party shall have the
right to grant sublicenses (through multiple tiers) under the license granted to it under Section 5.1(b) (in the case of uniQure) or Section 5.2(c) (in the case of 4DMT) to its Affiliates and Third Parties; provided that any
sublicense granted to a Third Party under this Agreement shall be pursuant to a written agreement that subjects such Sublicensee to all relevant restrictions and limitations set forth in this Agreement. Each Party granting a sublicense shall provide
the other Party with the name and address of each Sublicensee of its rights under this ARTICLE V, the date of the grant of the sublicense and a description of the rights granted promptly after the execution and delivery of the sublicense agreement.
The Party granting the sublicense shall remain responsible for the performance of its Sublicensees, and shall ensure that each Sublicensee complies with the applicable terms and conditions of this Agreement.  

5.4 Rights Retained by the Parties. Except as expressly set forth in this Agreement, neither Party shall acquire any license or other
intellectual property interest, by implication or otherwise, in any Confidential Information of the other Party or under any Patent Right or Know-How in which such other Party or its Affiliates has rights.
Without limiting the generality of the foregoing, any of 4DMT’s rights to 4DMT Intellectual Property not specifically licensed to uniQure shall be retained by 4DMT, and any of uniQure’s rights to uniQure Intellectual Property not
specifically licensed to 4DMT shall be retained by uniQure. 

  
 - 29 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 5.5 Section 365(n) of the Bankruptcy Code. All rights and licenses granted under or
pursuant to any section of this Agreement are and will otherwise be deemed to be for purposes of Section 365(n) of the United States Bankruptcy Code (Title 11, U.S. Code), as amended or any comparable Law outside the United States (the
“Bankruptcy Code”), licenses of rights to “intellectual property” as defined in Section 101(35A) of the Bankruptcy Code. The Parties will retain and may fully exercise all of their respective rights and elections
under the Bankruptcy Code. Each Party agrees that the other Party, as licensee of such rights under this Agreement, will retain and may fully exercise all of its rights and elections under the Bankruptcy Code or any other provisions of applicable
Law outside the United States that provide similar protection for “intellectual property.” The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against a Party under the Bankruptcy Code or
analogous provisions of applicable Law outside the United States, the other Party will be entitled to a complete duplicate of (or complete access to, as appropriate) the intellectual property licensed to such other Party and all embodiments of such
intellectual property, to the extent necessary for such other Party to practice the licenses granted to it pursuant to this Agreement under such intellectual property, which, if not already in such other Party’s possession, will be promptly
delivered to it upon such other Party’s written request thereof. Any agreement supplemental hereto will be deemed to be “agreements supplementary to” this Agreement for purposes of Section 365(n) of the Bankruptcy Code 

5.6 UCB Agreement Pass-Through Provisions. uniQure acknowledges that 4DMT has provided it with a copy of the executed UCB Agreements,
and agrees that this Agreement is subject in all respects to the terms and conditions of the UCB Agreements. Notwithstanding the generality of the foregoing: 

(a) uniQure acknowledges that UC (and, to the extent applicable, IGT) may publish any and all technical data resulting from any research
performed by UC (and, to the extent applicable, IGT) relating to the inventions disclosed in the UC Patent Rights, and UC (and, to the extent applicable, IGT) expressly reserves the right to use such inventions, UC AAV Capsid Variants and related
technology for its educational and research purposes, to disseminate the UC AAV Capsid Variants and other tangible materials associated with, or required to practice such inventions or the UC Patent Rights to researchers at nonprofit institutions
for their educational and research purposes, and to permit other nonprofit institutions to use the UC AAV Capsid Variants to practice the UC Patent Rights for education and research purposes. 

(b) uniQure shall keep 4DMT informed of its large/small entity status, as defined in 15 U.S.C. 632. 

(c) uniQure acknowledges that certain of the inventions disclosed in the UC Patent Rights were funded in part by the U.S. Government, and
agrees that in accordance with 35 U.S.C. 204, to the extent required by Law, any products covered by the UC Patent Rights and sold in the United States will be substantially manufactured in the United States. 

  
 - 30 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 (d) uniQure acknowledges that 4DMT’s exclusive rights, privileges, and licenses under
the UCB Agreements will expire on the date of the last-to-expire Valid Claim under the UC Patent Rights covered in each agreement, respectively, unless earlier
terminated. 
 (e) For any sublicense under the UC Patent Rights that uniQure grants under Section 5.3, uniQure shall ensure that
(i) such further sublicense is subject to a written sublicense agreement and is bound by all of the applicable terms, conditions, obligations, restrictions and other covenants of the UCB Agreements that protect or benefit UC’s (and, if
applicable, the U.S. Government’s) rights and interests to the same extent that this Agreement does, and (ii) it or the Sublicensee shall, within [***] ([***]) days after executing such sublicense agreement, furnish to 4DMT for delivery to
UC, subject to any confidentiality provisions, all material terms of such sublicense pertaining to UC’s interests, including the Sublicensee’s name and address, and indemnification of UC as provided in this Agreement. 

(f) The Parties acknowledge and agree that upon termination of the UCB Agreements for any reason, uniQure’s sublicenses under the UC
Patent Rights under this Agreement will remain in effect and will be assigned to UC, except that UC will not be bound to perform any duties or obligations set forth herein that extend beyond the duties and obligations of UC set forth in the UCB
Agreements. 
 (g) uniQure acknowledges that nothing contained in this Agreement will be construed as conferring any right to use in
advertising, publicity or other promotional activities any name, trademark, trade name, or other designation of UC (including any contraction, abbreviation, or simulation of any of the foregoing), and that unless required by Law, regulation, or
rules of a securities exchange, or consented to in writing by UC, the use by uniQure of the name “The Regents of the University of California” or the name of any University of California campus in advertising, publicity or other
promotional activities is expressly prohibited. 
 ARTICLE VI 

PAYMENTS; ROYALTIES AND REPORTS 

6.1 [Intentionally omitted]. 

6.2 Royalties. 
 (I)
Royalties Payable by uniQure for uniQure Products. 
 On a Royalty Bearing
Product-by-Royalty Bearing Product basis, uniQure shall pay to 4DMT royalties on worldwide Net Sales of uniQure Products as provided in this Section 6.2: 

(a) Royalty Rate. uniQure shall pay to 4DMT royalties on Net Sales of each Royalty Bearing Product Commercialized by uniQure and its
Affiliates equal to [***] percent ([***]%) of all such Net Sales of such Royalty Bearing Product achieved during the applicable Calendar Year. 

  
 - 31 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 (b) Royalty Term. uniQure’s royalty obligations to 4DMT under this
Section 6.2 for uniQure Products shall be in effect on a country-by-country and Royalty Bearing
Product-by-Royalty Bearing Product basis during the relevant Royalty Term. Upon expiration of the Royalty Term for a Royalty Bearing Product in a country, the license
under Section 5.1(b) shall be fully paid-up, irrevocable, perpetual and exclusive under the relevant Licensed IP for such Royalty Bearing Product in such country. 

(c) Royalty Adjustments. 

(i) Non-Patented Product. If a Royalty Bearing Product is sold in a country and the composition
of matter, formulation, or method of use of such Royalty Bearing Product is not Covered by a Valid Claim within the Licensed IP in such country at the time of sale, then the royalty rate for such Royalty Bearing Product in such country shall be
reduced by [***] percent ([***]%) of the applicable rate determined pursuant to Section 6.2(I)(a), unless such Royalty Bearing Product embodies an Invention with respect to which uniQure made a Trade Secret Election, in which case no such
reduction shall apply. 
 (ii) Third Party Offset. If uniQure is required, in order to avoid infringement of any Patent Right not
licensed hereunder that Covers the composition of matter, formulation, or method of use of a Royalty Bearing Product, to obtain a license from a Third Party in order to Develop, make, have made, use or Commercialize such Royalty Bearing Product in a
country in the Territory and to pay a royalty or other consideration under such license (including in connection with the settlement of a patent infringement claim), then the royalty payments due under Section 6.2(I)(a) with respect to Net
Sales for such Royalty Bearing Product in such country shall be reduced by [***] percent ([***]%) of the amounts payable by uniQure to such Third Party for such license that are reasonably and appropriately allocable to such Royalty Bearing Product
in such country, provided that in no event shall the foregoing reduce the amount of royalties payable to 4DMT in any [***] by more than [***] percent ([***]%) of the amount determined pursuant to Section 6.2(I)(a), as adjusted by
application of the terms of Section 6.2(I)(c)(i). 
 (iii) Limits on Deductions. Except as expressly provided in this
Section 6.2, there shall not be any offset to or deduction from the royalties payable pursuant to this Section 6.2. Notwithstanding Sections 6.2(c)(i) and (ii) to the contrary, in no event shall the cumulative effect of the deductions
in Sections 6.2(I)(c)6.2(c)(i) and (ii) reduce the royalties to less than [***] percent ([***]%) of the amounts determined pursuant to Section 6.2(I)(a). 

(II) Royalties Payable by 4DMT for 4DMT Products. 

On a Royalty Bearing Product-by-Royalty Bearing Product basis,
for each 4DMT Product Commercialized by 4DMT and its Affiliates, 4DMT shall pay to uniQure royalties on annual worldwide Net Sales of such 4DMT Product as provided in this Section 6.2: 

(a) Royalty Rate. 4DMT shall pay to uniQure royalties on Net Sales of each Royalty Bearing Product Commercialized by 4DMT and its
Affiliates equal to [***] percent ([***]%) of all such Net Sales of such Royalty Bearing Product achieved during the applicable Calendar Year. 

  
 - 32 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 (b) Royalty Term. 4DMT’s royalty obligations to uniQure under this
Section 6.2 shall be in effect on a country-by-country and Royalty Bearing
Product-by-Royalty Bearing Product basis during the relevant Royalty Term. Upon expiration of the Royalty Term for a Royalty Bearing Product in a country, the license
under Section 5.2(c) shall be fully paid-up, irrevocable, perpetual and non-exclusive under the relevant Licensed IP for such Royalty Bearing Product in such
country. 
 (c) Royalty Adjustments. 

(i) Non-Patented Product. If a Royalty Bearing Product is sold in a country and the composition
of matter, formulation, or method of use of such Royalty Bearing Product is not Covered by a Valid Claim within the Licensed IP in such country at the time of sale, then the royalty rate for such Royalty Bearing Product in such country shall be
reduced by [***] percent ([***]%) of the applicable rate determined pursuant to Section 6.2(a), unless such Royalty Bearing Product embodies an Invention with respect to which 4DMT made a Trade Secret Election, in which case no such reduction
shall apply. 
 (ii) Third Party Offset. If 4DMT is required, in order to avoid infringement of any Patent Right not licensed
hereunder that Covers the composition of matter, formulation, or method of use of a Royalty Bearing Product, to obtain a license from a Third Party in order to Develop, make, have made, use or Commercialize such Royalty Bearing Product in a country
in the Territory and to pay a royalty or other consideration under such license (including in connection with the settlement of a patent infringement claim), then the royalty payments due under Section 6.2(a) with respect to Net Sales for such
Royalty Bearing Product in such country shall be reduced by [***] percent ([***]%) of the amounts payable by 4DMT to such Third Party for such license that are reasonably and appropriately allocable to such Royalty Bearing Product in such country,
provided that in no event shall the foregoing reduce the amount of royalties payable to uniQure in any [***] by more than [***] percent ([***]%) of the amount determined pursuant to Section 6.2(a), as adjusted by application of the terms
of Section 6.2(c)(i). 
 (iii) Limits on Deductions. Except as expressly provided in this Section 6.2, there shall not be
any offset to or deduction from the royalties payable pursuant to this Section 6.2. Notwithstanding Sections 6.2(II)(c)(i) and (ii) to the contrary, in no event shall the cumulative effect of the deductions in Sections 6.2(c)(i) and
(ii) reduce the royalties to less than [***] percent ([***]%) of the amounts determined pursuant to Section 6.2(II)(a). 
 6.3
Sublicense Consideration. 
 (a) uniQure shall pay to 4DMT the following percentages (“Sublicense Income Sharing
Percentages”) of Sublicense Consideration received by uniQure for sublicenses under the Licensed IP under this Agreement: 
 (i)
[***] percent ([***]%) for any sublicense that (A) is granted prior to initiating Animal POC for any Construct or Product that is subject of the sublicense and (B) does not require uniQure to manufacture any such Construct or Product for
Clinical Trial or commercial purposes;  

  
 - 33 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 (ii) [***] percent ([***]%) for any sublicense that (A) is granted prior to initiating
Animal POC for any Construct or Product that is subject of the sublicense and (B) requires uniQure to manufacture any such Construct or Product for Clinical Trial or commercial purposes;  

(iii) [***] percent ([***]%) for any sublicense that does not meet the criteria set forth in Section 6.3(a)(i) or
Section 6.3(a)(ii) above; 
 provided, however, that none of subsections (i), (ii) or (iii) shall result in uniQure
paying to 4DMT under this Section 6.3 a percentage of any Sublicense Consideration consisting of royalties from Sublicensees on sales of UC Products during the applicable Royalty Term that is less than [***] percent ([***]%) of Net Sales by
such Sublicensee of such UC Products. 
 (b) The term “Sublicense Consideration” shall mean consideration of any kind
received by uniQure from a Sublicensee for the grant of a sublicense under this Agreement, such as upfront fees, royalties or milestone fees and including any premium paid by the Sublicensee over the Fair Market Value (as defined below) for stock of
uniQure in consideration for such sublicense; provided, however, the following are not included in Sublicense Consideration: 

(i) Support for activities of uniQure relating to the research, Development, manufacturing or Commercialization of Royalty Bearing Products,
which shall not exceed the fully burdened cost (and in the case of manufacturing costs, the Fully Burdened Manufacturing Cost) for undertaking such activities performed by or for uniQure (including Third Parties on uniQure’s behalf) by more
than [***] percent ([***]%); 
 (ii) Proceeds derived from debt financing and any loans to uniQure by the Sublicensee; 

(iii) Consideration received for the purchase of stock in uniQure or its Affiliate to the extent that the price per share for such equity
does not exceed the Fair Market Value of such stock. The term “Fair Market Value” shall mean the average price at which the stock in question is publicly trading at for [***] ([***]) days prior to the earlier of (A) the date of
the announcement of its purchase by the Sublicensee or (B) the date of its purchase by the Sublicensee, or if the stock is not publicly traded, the value of such stock as determined in good faith by the Board of Directors of uniQure or its
applicable Affiliate as of the time of receipt of payment; and 
 (iv) Reimbursement of uniQure’s patent costs related to Patent
Rights. 
 (c) 4DMT shall pay to uniQure the following percentages (“4D Sublicense Income Sharing Percentages”) of 4D
Sublicense Consideration received by 4DMT for sublicenses under the Licensed IP under this Agreement: 

  
 - 34 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 (i) [***] percent ([***]%) for any sublicense that (A) is granted prior to initiating
Animal POC for any Construct or Product that is subject of the sublicense and (B) does not require 4DMT to manufacture any such Construct or Product for Clinical Trial or commercial purposes;  

(ii) [***] percent ([***]%) for any sublicense that (A) is granted prior to initiating Animal POC for any Construct or Product that is
subject of the sublicense and (B) requires 4DMT to manufacture any such Construct or Product for Clinical Trial or commercial purposes;  

(iii) [***] percent ([***]%) for any sublicense that does not meet the criteria set forth in Section 6.3(a)(i) or Section 6.3(a)(ii)
above; 
 provided, however, that none of subsections (i), (ii) or (iii) shall result in 4DMT paying to uniQure under this
Section 6.3 a percentage of any 4D Sublicense Consideration consisting of royalties from Sublicensees on sales of UC Products during the applicable Royalty Term that is less than [***] percent ([***]%) of Net Sales by such Sublicensee of such
UC Products. 
 (d) The term “4D Sublicense Consideration” shall mean consideration of any kind received by 4DMT from a
Sublicensee for the grant of a sublicense under this Agreement, such as upfront fees, royalties or milestone fees and including any premium paid by the Sublicensee over the Fair Market Value (as defined below) for stock of 4DMT in consideration for
such sublicense; provided, however, the following are not included in Sublicense Consideration: 
 (i) Support for activities
of 4DMT relating to the research, Development, manufacturing or Commercialization of Royalty Bearing Products, which shall not exceed the fully burdened cost (and in the case of manufacturing costs, the Fully Burdened Manufacturing Cost) for
undertaking such activities performed by or for 4DMT (including Third Parties on 4DMT’s behalf) by more than [***] percent ([***]%); 

(ii) Proceeds derived from debt financing and any loans to 4DMT by the Sublicensee; 

(iii) Consideration received for the purchase of stock in 4DMT or its Affiliate to the extent that the price per share for such equity does
not exceed the Fair Market Value of such stock. The term “Fair Market Value” shall mean the average price at which the stock in question is publicly trading at for [***] ([***]) days prior to the earlier of (A) the date of the
announcement of its purchase by the Sublicensee or (B) the date of its purchase by the Sublicensee, or if the stock is not publicly traded, the value of such stock as determined in good faith by the Board of Directors of 4DMT or its applicable
Affiliate as of the time of receipt of payment; and 
 (iv) Reimbursement of 4DMT’s patent costs related to Patent Rights. 

  
 - 35 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 (e) For purposes of this Article 6, “Sublicense Consideration received by uniQure”
shall include Sublicense Consideration received by uniQure’s Affiliates (applying the definition of Sublicense Consideration mutatis mutandis to such Affiliates) and “4D Sublicense Consideration received by 4D” shall include 4D
Sublicense Consideration received by 4DMT’s Affiliates (applying the definition of Sublicense Consideration mutatis mutandis to such Affiliates). 

6.4 Reports; Payments. Within [***] ([***]) days after the end of each Calendar Quarter during which there are Net Sales giving rise to
a payment obligation under Section 6.2 or uniQure (or 4DMT, as applicable) received Sublicense Consideration or 4D Sublicense Consideration giving rise to a payment obligation under Section 6.3, (a) uniQure (or 4DMT as applicable) shall
submit to 4DMT (or uniQure as applicable) a report (i) identifying for each Royalty Bearing Product the Net Sales for such Royalty Bearing Product for each country for such Calendar Quarter, the calculation of royalties (including gross sales
and all deductions taken from gross sales and all reductions pursuant to Section 6.2(c)), and the royalties payable to 4DMT (or uniQure as applicable) and (ii) identifying the Sublicense Consideration received by uniQure (or 4DMT as
applicable) in such Calendar Quarter and the one or more Sublicense Income Sharing Percentages applicable to such Sublicense Consideration, or 4D Sublicense Income Sharing Percentages applicable to such 4D Sublicense Consideration and
(b) uniQure (or 4DMT as applicable) shall pay to 4DMT (or uniQure as applicable) all royalties payable under Section 6.2 and portions of Sublicense Consideration or 4D Sublicense Consideration payable under Section 6.3. 

6.5 Books and Records; Audit Rights. Each Party (the “Audited Party”) shall keep (and shall cause its Affiliates and
Sublicensees to keep) complete, true and accurate books and records in accordance with its Accounting Standards in sufficient detail for the other Party (the “Auditing Party”) to determine the payments due under this Agreement. Each
Auditing Party shall have the right, once annually at its own expense, to have an independent, certified public accounting firm of nationally recognized standing, selected by the Auditing Party and reasonably acceptable to the Audited Party, review
any such records of the Audited Party in the location(s) where such records are maintained by the Audited Party upon reasonable notice (which shall be no less than [***] ([***]) days prior notice) and during regular business hours and under
obligations of strict confidence, for the sole purpose of verifying the accuracy of the amounts paid under this Agreement within a [***] period preceding the date of the request for review. The report of such accounting firm shall be limited to a
certificate stating whether any report made or invoice or payment submitted by the Audited Party during such period is accurate or inaccurate, and the amount of any Net Sales, Sublicense Consideration, 4D Sublicense Consideration, royalty or other
payment discrepancy. No other information shall be provided to the Auditing Party. The Audited Party shall receive a copy of each such report concurrently with receipt by the Auditing Party. Should such inspection lead to the discovery of a
discrepancy to the Auditing Party’s detriment, the Audited Party shall pay the amount of the discrepancy within [***] ([***]) days after its receipt from the accounting firm of the certificate showing the amount of the discrepancy. The Auditing
Party shall pay the full cost of the review unless the audit determined an underpayment of royalties by the Audited Party which is greater than [***] percent ([***]%) of the amount due for the applicable period, in which case the Audited Party shall
pay the reasonable costs charged by such accounting firm for such review. Any overpayment of royalties by uniQure (or 4DMT, as applicable) revealed by an inspection shall be fully creditable against future royalty payments by such Audited Party
under Section 6.2. 

  
 - 36 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 6.6 Withholding Taxes. 

(a) Subject to the provisions of Section 12.7, if Laws require withholding by uniQure of taxes imposed upon 4DMT on account of any royalty
or other payment paid under this Agreement, such taxes shall be deducted by uniQure as required by Law from such remittable royalty or other payment and shall be paid by uniQure to the proper tax authorities; provided that before making any
such deduction or withholding, uniQure shall give 4DMT notice of the intention to make such deduction or withholding, which notice shall include the authority, basis and method of calculation for the proposed deduction or withholding, and shall be
provided to the extent practicable at least a reasonable period of time before such deduction or withholding is required, in order for 4DMT to obtain reduction of or relief from such deduction or withholding. Official receipts of payment of
withholding taxes shall be secured and sent to 4DMT as evidence of such payment. The Parties shall exercise their best efforts to ensure that any withholding tax imposed is reduced as far as possible under the provisions of any relevant tax treaty.

 (b) Subject to the provisions of Section 12.7, if Laws require withholding by 4DMT of taxes imposed upon uniQure on account of any
royalty or other payment paid under this Agreement, such taxes shall be deducted by 4DMT as required by Law from such remittable royalty or other payment and shall be paid by 4DMT to the proper tax authorities; provided that before making any
such deduction or withholding, 4DMT shall give uniQure notice of the intention to make such deduction or withholding, which notice shall include the authority, basis and method of calculation for the proposed deduction or withholding, and shall be
provided to the extent practicable at least a reasonable period of time before such deduction or withholding is required, in order for uniQure to obtain reduction of or relief from such deduction or withholding. Official receipts of payment of
withholding taxes shall be secured and sent to uniQure as evidence of such payment. The Parties shall exercise their best efforts to ensure that any withholding tax imposed is reduced as far as possible under the provisions of any relevant tax
treaty. 
 6.7 United States Dollars. All dollar ($) amounts specified in this Agreement are United States dollar amounts. 

6.8 Payment Method and Currency Conversion. Except as otherwise provided herein, all payments due to a Party hereunder shall be due and
payable within [***] ([***]) days after receipt of an invoice from the other Party and shall be paid via a bank wire transfer to such bank account as such Party shall designate. For the purposes of determining the amount of any payment due hereunder
for the relevant Calendar Quarter under Section 6.2 or Section 6.3, amounts received by a Party in any foreign currency shall be converted into United States dollars in accordance with the normal business practice of such Party, as applied
consistently across its business. 

  
 - 37 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 6.9 Blocked Payments. (a) If, by reason of applicable Laws in any country in the
Territory, it becomes impossible or illegal for uniQure or any of its Affiliates or Sublicensees to transfer, or have transferred on its behalf, royalties or other payments to 4DMT, uniQure shall promptly notify 4DMT of the conditions preventing
such transfer and such royalties or other payments shall be deposited in local currency in the relevant country to the credit of 4DMT in a recognized banking institution with a good creditworthiness, such banking institution to be designated by 4DMT
or, if none is designated by 4DMT within [***] ([***]) days, in a recognized banking institution selected by uniQure or its Affiliate or Sublicensee, as the case may be, and identified in a written notice given to 4DMT. If so deposited in a foreign
country, uniQure shall provide, or cause its Affiliate or Sublicensee to provide, reasonable cooperation to 4DMT so as to allow 4DMT to assume control over such deposit as promptly as practicable. 

(b) If, by reason of applicable Laws in any country in the Territory, it becomes impossible or illegal for 4DMT or any of its
Affiliates or Sublicensees to transfer, or have transferred on its behalf, royalties or other payments to uniQure, 4DMT shall promptly notify uniQure of the conditions preventing such transfer and such royalties or other payments shall be deposited
in local currency in the relevant country to the credit of uniQure in a recognized banking institution with a good creditworthiness, such banking institution to be designated by uniQure or, if none is designated by uniQure within [***] ([***]) days,
in a recognized banking institution selected by 4DMT or its Affiliate or Sublicensee, as the case may be, and identified in a written notice given to uniQure. If so deposited in a foreign country, 4DMT shall provide, or cause its Affiliate or
Sublicensee to provide, reasonable cooperation to uniQure so as to allow uniQure to assume control over such deposit as promptly as practicable.  

6.10 Late Payments. Any payment not made within [***] ([***]) Business Days after the due date for such payment pursuant to the terms of
this Agreement shall bear interest at a rate of the thirty-day U.S. dollar LIBOR rate effective for the date that payment was due (as published in The Wall Street Journal, Eastern Edition) plus [***]
per annum. Calculation of interest will be made for the exact number of days the payment was past due based on a year of 360 days (actual days/360). 

ARTICLE VII 
 PATENTS

 7.1 Disclosure. Each Party shall promptly disclose to the other Party any Inventions that it or its Affiliates or
Sublicensees or their employees, independent contractors, or agents solely or jointly make, conceive, reduce to practice, or otherwise discover under this Agreement, and each Party shall maintain and make available to the other Party records
regarding any Inventions that it has an obligation to assign under Section 7.2(a). 
 7.2 Ownership. 

(a) uniQure shall solely own all Core uniQure Intellectual Property, and 4DMT shall solely own all Core 4DMT Intellectual Property. Without
limiting the generality of the foregoing, this means that 4DMT shall own the New Variant Patents, and uniQure shall own the uniQure Product Patents. All other Inventions arising under this Agreement or the Parties’ activities hereunder, shall
be owned by inventorship. Without additional consideration, each Party 

  
 - 38 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 
shall assign and hereby does assign to the other Party such of its right, title, and interest in and to such Inventions, Know-How and Patent Rights (and
shall require its Affiliates and Sublicensees, and all employees, independent contractors and their employees, and agents of such Party and its Affiliates and Sublicensees to so assign to the other Party such of their right, title, and interest) and
agrees to take all necessary actions and execute any documents as is necessary to effectuate the allocation of right, title, and interest as set forth in this Section 7.2(a). 

(b) Except as otherwise expressly set forth in Section 7.2(a), as between the Parties, (i) each Party shall solely own all Know-How and Inventions invented solely by employees, agents and consultants of such Party or its Affiliates, and any Patent Right related thereto, subject to the licenses granted under ARTICLE V, and (ii) Know-How and Inventions invented jointly by employees, agents, or consultants of the Parties or their Affiliates (“Joint Intellectual Property”, which includes any Patent Right Covering
such Know-How and Inventions (“Joint Patent Rights”) and any Know-How included in such Joint Intellectual Property (“Joint Know-How”)) shall be jointly owned, subject to the licenses granted under ARTICLE V. Inventorship shall be determined in accordance with U.S. patent Laws for purposes of determining ownership in accordance
with the foregoing. Except as explicitly provided for herein, the nature of the ownership rights in Joint Patent Rights shall be equivalent to the rights of co-inventors under U.S. patent law in the absence of
a written agreement. 
 (c) Except as expressly provided in this Agreement, and subject to any restriction herein (including the licenses
granted under ARTICLE V), (i) each joint owner may engage in research, Development, manufacturing and Commercialization activities relating to Joint Intellectual Property, and (ii) each may assign, license, sell or otherwise encumber or
transfer any such interest without the prior written approval of the other Party and without obligation to account or provide compensation to the other Party. 

7.3 uniQure Prosecution and Maintenance of Patent Rights. 

(a) uniQure shall be solely responsible for the Prosecution and Maintenance of the uniQure Patent Rights, including the Core uniQure Patent
Rights, at its sole expense and its sole discretion. uniQure shall give 4DMT an opportunity to review the text of each application, office action response or other substantive document for a Core uniQure Patent Right specifically relating to [***]
(but not any other uniQure Patent Right) before filing with any patent office in the Territory, shall consider 4DMT’s reasonable comments with respect thereto, and shall supply 4DMT with a copy of each such application, office action response
or other substantive document as filed, together with notice of its filing date and serial number. 
 (b) uniQure shall have the sole right
to determine whether any patent application is filed with respect to any Core uniQure Know-How and whether to maintain any Invention included in the Core uniQure
Know-How as a trade secret. uniQure shall provide 4DMT with written notice if uniQure elects not to file a patent application claiming any particular Invention included in the Core uniQure Know-How (each, a “Trade Secret Election”). 

  
 - 39 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 (c) Notwithstanding anything express or implied and provided that a Patent Right has not
been filed hereunder with respect to a New Capsid Variant, uniQure shall give reasonable notice to 4DMT (no less than [***] ([***]) days) prior to filing a uniQure Product Patent disclosing a New Capsid Variant, and the Parties shall cooperate
reasonably in the filing of such uniQure Product Patent, including coordinating the timely filing of a Patent Right with respect to a New Capsid Variant and, where appropriate, the simultaneous filing of such patents by each Party. 

7.4 4DMT Prosecution and Maintenance of Patent Rights. 

(a) 4DMT shall be solely responsible for the Prosecution and Maintenance of the 4DMT Patent Rights, including the Core 4DMT Patent Rights, at
its sole expense and its sole discretion. 4DMT will reasonably inform uniQure regarding the Prosecution and Maintenance of 4DMT Patent Rights ([***]). Notwithstanding the foregoing, the Parties acknowledge that UC will handle the Prosecution and
Maintenance of the UC Patent Rights in accordance with the terms of the UCB Agreements. 
 (b) 4DMT shall have the sole right to determine
whether any patent application is filed with respect to any Core 4DMT Know-How and whether to maintain any Invention included in the Core 4DMT Know-How as a trade
secret. 4DMT shall provide uniQure with written notice if 4DMT elects not to file a patent application claiming any particular Invention included in the Core 4DMT Know-How specifically relating to compositions
of matter of, methods of use of, or methods of making any New Capsid Variant because 4DMT prefers to maintain such Invention as a trade secret (each, a “Trade Secret Election”). 

(c) 4DMT shall notify uniQure at least [***] ([***]) days in advance of any applicable deadline if (i) 4DMT decides that it does not wish to
continue the Prosecution and Maintenance of a published Core 4DMT Patent Right specifically relating to [***] for which no substitute has been filed, or (ii) 4DMT decides that it intends to abandon claim scope in a [***], which claim scope is
intended to be maintained by uniQure, in which case, with respect to this clause (ii), uniQure may assume responsibility for such claim scope by filing a divisional application restricted to such claim scope. In such cases (i) or (ii), 4DMT
shall allow uniQure to assume responsibility for Prosecution and Maintenance of such Core 4DMT Patent Right or divisional application [***]. If uniQure assumes such responsibility, then uniQure may designate any counsel of its choice reasonably
acceptable to 4DMT to handle the Prosecution and Maintenance of such Core 4DMT Patent Right or divisional application (which shall otherwise continue to be part of the Core 4DMT Patent Rights). 

7.5 Prosecution and Maintenance of Joint Patent Rights. The Prosecution and Maintenance of any Joint Patent Right shall be
through a mutually selected patent counsel. Within [***] ([***]) days following the Effective Date, the Parties shall agree on a patent counsel (“Joint Counsel”) who shall be engaged by both Parties for the Prosecution and
Maintenance of all such Joint Patent Rights. The following terms shall apply to each Joint Patent Right: 
 (a) The Parties shall instruct
Joint Counsel to conduct its activities as follows: The Joint Counsel shall give uniQure and 4DMT (or each Party’s designee) an opportunity to review the text of each application, office action response or other substantive document for a Joint
Patent Right before filing with any patent office in the Territory, shall 

  
 - 40 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 
incorporate uniQure’s and 4DMT’s (or each Party’s designee) reasonable comments with respect thereto, and shall supply uniQure and 4DMT (or each Party’s designee) with a copy
of each such application, office action response or other substantive document as filed, together with notice of its filing date and serial number. In the event that 4DMT and uniQure provide Joint Counsel with conflicting instructions regarding the
Prosecution and Maintenance of a Joint Patent Right, Joint Counsel shall make the Parties aware of such conflicting instructions and, if the Parties are not able to resolve such conflict within a reasonable time prior to the applicable filing
deadline, the Joint Counsel shall take such action as would reasonably be expected to maximize the scope, extent and coverage of such Joint Patent Right. 

(b) Both Parties shall cooperate with Joint Counsel in Prosecution and Maintenance of patent applications for Joint Patent Rights, including
providing Joint Counsel with data and other information as appropriate with respect thereto. 
 (c) Joint Counsel shall keep uniQure and
4DMT advised of the status of the Prosecution and Maintenance of Joint Patent Rights, including actual and prospective patent filings for Joint Patent Rights, and shall provide each Party with advance copies of any and all papers related thereto.
Joint Counsel shall promptly give notice to uniQure and 4DMT of the grant, lapse, revocation, surrender, invalidation or abandonment of any Joint Patent Right. 

(d) The Parties shall equally share all fees and costs charged by Joint Counsel with respect to the Prosecution and Maintenance of Joint
Patent Rights and all other mutually agreed and approved out-of-pocket costs and expenses incurred by either Party in connection with such Prosecution and Maintenance of
Joint Patent Rights. 
 (e) uniQure shall notify 4DMT and Joint Counsel at least [***] ([***]) days in advance of the next deadline if
(A) uniQure decides that it does not wish to continue paying for the Prosecution and Maintenance of a particular Joint Patent Right for which no substitute has been filed, or (B) uniQure decides that it intends to abandon claim scope in a
Joint Patent Right which claim scope is intended to be maintained by 4DMT, in which case, with respect to this clause (B), 4DMT may assume responsibility for such claim scope by filing a divisional application restricted to such claim scope. In such
cases (A) or (B), uniQure shall allow 4DMT to assume responsibility for Prosecution and Maintenance of the respective Patent Rights, including [***]. If 4DMT assumes such responsibility, then: (i) 4DMT may designate any counsel of its choice to
handle the Prosecution and Maintenance of such Joint Patent Right or of the divisional application and it shall cease to be a part of the Joint Patent Rights; (ii) uniQure shall lose its licenses to such former Joint Patent Right or divisional
application under ARTICLE V and such former Joint Patent Right or divisional application shall be deemed a 4DMT Patent Right; and (iii) uniQure shall and hereby does transfer and assign all right, title and interest in said former Joint Patent
Right or of the divisional application to 4DMT as the sole owner. If 4DMT decides not to assume such responsibility, then it shall instruct Joint Counsel to abandon the Prosecution and Maintenance of such Joint Patent Right or not to file such
divisional application. 

  
 - 41 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 (f) 4DMT shall notify uniQure and Joint Counsel at least [***] ([***]) days in advance of
the next deadline if (A) 4DMT decides that it does not wish to continue paying for the Prosecution and Maintenance of a particular Joint Patent Right for which no substitute has been filed, or (B) 4DMT decides that it intends to abandon claim scope
in a Joint Patent Right which claim scope is intended to be maintained by uniQure, in which case, with respect to this clause (B), uniQure may assume responsibility for such claim scope by filing a divisional application restricted to such claim
scope. In such cases (A) or (B), 4DMT shall allow uniQure to assume responsibility for Prosecution and Maintenance of the respective Patent Rights, including [***]. If uniQure assumes such responsibility, then: (i) uniQure may designate
any counsel of its choice to handle the Prosecution and Maintenance of such Joint Patent Right or of the divisional application and it shall cease to be a part of the Joint Patent Rights and no further uniQure royalty obligations shall exist under
this Agreement with respect thereto; (ii) 4DMT shall lose its licenses to such former Joint Patent Right or divisional application under ARTICLE V and such former Joint Patent Right or divisional application shall be deemed a uniQure Patent Right;
and (iii) 4DMT shall and hereby does transfer and assign all right, title and interest in said former Joint Patent Right or of the divisional application to uniQure as the sole owner. If uniQure decides not to assume such responsibility, then it
shall instruct Joint Counsel to abandon the Prosecution and Maintenance of such Joint Patent Right or not to file such divisional application. 

7.6 Third Party Infringement. 

(a) Notice. Each Party shall promptly report in writing to the other Party any known or suspected (i) infringement of any of the
4DMT Patent Rights, uniQure Patent Rights or Joint Patent Rights, or (ii) unauthorized use or misappropriation of any of the 4DMT Know-How, uniQure Know-How or
Joint Know-How, of which such Party becomes aware and shall provide the other Party with all available evidence regarding such known or suspected infringement or unauthorized use. 

(b) Enforcement of Solely Owned Patent Rights. uniQure shall have the sole right to enforce the uniQure Patent Rights, including the
Core uniQure Patent Rights. Subject to UC’s rights under the UCB Agreements with respect to any UC Patent Right included in the 4DMT Patent Rights, 4DMT shall have the sole right to enforce any 4DMT Patent Right, including the Core 4DMT Patent
Rights. Each Party shall cooperate in the prosecution of any such suit brought by the enforcing Party as may be reasonably requested by the enforcing Party; provided that the enforcing Party shall promptly reimburse all out-of-pocket expenses (including reasonable counsel fees and expenses) actually incurred by the non-enforcing Party in connection with
such cooperation. 
 (c) Enforcement of Joint Patent Rights. 

(i) Restricted Target Products. uniQure shall have the first right, but not the obligation, to initiate a lawsuit or take other
reasonable action to enforce the Joint Patent Rights against any infringement in the Field by a Product that delivers a Transgene related to a Restricted Target. 4DMT shall cooperate in the prosecution of any such suit as may be reasonably requested
by uniQure, including joining any action as party-plaintiff at uniQure’s sole discretion; provided that uniQure shall promptly reimburse all out-of-pocket
expenses (including reasonable counsel fees and expenses) actually incurred by 4DMT in connection with such cooperation. 

  
 - 42 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 (ii) Non-Restricted Target Products. 4DMT
shall retain any and all rights to initiate a lawsuit or take other reasonable action to enforce the Joint Patent Rights against any infringement that is (A) outside the Field, and/or (B) by Products related to Non-Restricted Targets. uniQure shall cooperate in the prosecution of any such suit as may be reasonably requested by 4DMT, including joining any action as party-plaintiff at 4DMT’s sole discretion; provided
that 4DMT shall promptly reimburse all out-of-pocket expenses (including reasonable counsel fees and expenses) actually incurred by uniQure in connection with such
cooperation. 
 (iii) Step-In Right of 4D. If uniQure does not initiate a lawsuit or take
other reasonable action pursuant to this Section 7.6(c) regarding infringement or alleged infringement of a New Variant Patent, then 4DMT shall have the right, but not the obligation, to initiate such lawsuit or take such other action, after
providing [***] ([***]) days’ notice to uniQure and giving good faith consideration to uniQure’s reason(s) for not initiating a lawsuit or taking other action. For this purpose, uniQure shall cooperate in the prosecution of any such suit
as may be reasonably requested by 4DMT, including joining any action as party-plaintiff if needed for standing purposes; provided, that 4DMT shall promptly reimburse all
out-of-pocket expenses (including reasonable counsel fees and expenses) actually incurred by uniQure in connection with such cooperation. 

(d) Conduct of Certain Actions; Costs. The Party initiating legal action shall have the sole and exclusive right to select counsel for
any suit initiated by it pursuant to Section 7.6(b) or 7.6(c) (the “Initiating Party”). The Initiating Party shall bear its own out-of-pocket costs
incurred in any such legal action, including the fees and expenses of the counsel selected by it. The other Party shall have the right to participate and be represented in any such legal action (in cases where such other Party has standing) by its
own counsel at its own expense. The Initiating Party shall have the final say about the strategy and decisions in the suit and any settlement. 

(e) Recoveries. Any amount recovered in any action or settlement of any such action shall be allocated first to equally reimburse each
Party’s actual out-of-pocket costs (including reasonable attorneys’ fees and expenses) incurred in such action and any amount remaining shall be allocated to
the Initiating Party; provided that for recoveries for infringement within the Field, the amount of remaining recovery received by the Initiating Party or its Affiliate will be [***]. 

7.7 Patent Invalidity Claim. Each Party shall promptly notify the other in the event of any legal or administrative action by any Third
Party against a 4DMT Patent Right, uniQure Patent Right or Joint Patent Right of which it becomes aware, including any nullity, revocation, reexamination or compulsory license proceeding. To the extent such action is in connection with an
enforcement of such Patent Right under Section 7.6, the Parties’ rights with respect to defending any such Patent Right in any such proceeding shall correspond to those set forth in Section 7.6. 

  
 - 43 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 7.8 Patent Term Extensions. 

(a) uniQure shall have full and exclusive right to determine and control all filings of requests for any patent term extension or supplemental
patent certificate or their equivalents in any country in the Territory for any uniQure Patent Right, including any Core uniQure Patent Right, and all costs and expenses relating thereto shall be paid by uniQure. 

(b) 4DMT shall have full and exclusive right to determine and control all filings of requests for any patent term extension or supplemental
patent certificate or their equivalents in any country in the Territory for any 4DMT Patent Right, including any Core 4DMT Patent Right, and all costs and expenses relating thereto shall be paid by 4DMT. 

(c) The Parties shall jointly determine how to defend any such action relating to any Joint Patent Right. 

(d) The Parties shall reasonably cooperate with each other in obtaining patent term extensions or supplemental protection certificates or
their equivalents in any country in the Territory. 
 7.9 Orange Book; Paragraph IV Certification. 

(a) uniQure shall have the right, but not the obligation, to list any uniQure Patent Rights in the then-current edition of the FDA
publication “Approved Drug Products With Therapeutic Equivalence Evaluations” (the “Orange Book”), or equivalent patent listings in other countries. 4DMT shall have the right, but not the obligation, to list any 4DMT
Patent Rights in the then-current edition of the Orange Book, or equivalent patent listings in other countries. 
 (b) With respect to any
notification provided by a Third Party to uniQure or 4DMT under 21 U.S.C. § 355(j)(2)(B) making a certification described in 21 U.S.C. § 355(j)(2)(A)(vii)(IV) with respect to any uniQure Patent Right that is listed for a
Royalty Bearing Product in the Orange Book, or equivalent actions in other countries, (each a “Paragraph IV Certification”), the following shall apply notwithstanding Sections 7.6 and 7.7: 

(i) Without any avoidable delay, however at the latest within [***] ([***]) Business Days after receipt of any notification of a Paragraph IV
Certification, such Party shall notify the other Party in writing and attach of copy of such notification. uniQure and 4DMT shall thereafter consult and cooperate fully to determine a course of action with respect to any such proceeding, including
the negotiation of the offer of confidential access. 
 (ii) With respect to any uniQure Patent Right, uniQure shall have the sole right to
initiate any infringement proceeding as a result of such Paragraph IV Certification (a “Paragraph IV Proceeding”) with respect to a Royalty Bearing Product, including by commencing a patent infringement action under 35 U.S.C.
§ 271(e)(2)(A), and shall bear the expense of any such Paragraph IV Proceeding and, if legally required, may commence such action in 4DMT’s or the relevant 4DMT Affiliate’s name and on 4DMT’s or the relevant 4DMT
Affiliate’s behalf. 

  
 - 44 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 (iii) Section 7.6(e) shall apply if any amount is recovered in any Paragraph IV Proceeding
or settlement of any Paragraph IV Proceeding under this Section 7.9(b). 
 7.10 CREATE Act. Each Party acknowledges and agrees
that this Agreement is a “joint research agreement” as contemplated by 35 U.S.C. § 102(c), and that all Inventions are intended to have the benefit of the rights and protections conferred by the Cooperative Research and Enhancement
Act of 2004 (the “CREATE Act”). In the event that a Party seeks to rely on the foregoing and to invoke the CREATE Act with respect to any Invention, such Party will give prior written notice to the other Party of its intent to
invoke the CREATE Act and of each submission or disclosure such Party intends to make to the United States Patent and Trademark Office (the “USPTO”) pursuant to the CREATE Act, including: (a) any disclosure of the existence or
contents of this Agreement to the USPTO, (b) the disclosure of any “subject matter developed by the other Party” (as such term is used in the CREATE Act) in an information disclosure statement or otherwise, or (c) the filing of
any terminal disclaimer over the intellectual property of the other Party, it being agreed that no such submission, disclosure or filing shall be made by such Party without the prior written consent of the other Party, such consent not to be
unreasonably withheld, conditioned or delayed, except that no such consent shall be required to disclose to the USPTO, through an information disclosure statement or otherwise, any “subject matter developed by the other Party” that was
previously published or included in a published patent application by the other Party. The other Party will provide reasonable cooperation to such Party in connection with such Party’s efforts to invoke and rely on the CREATE Act. 

ARTICLE VIII 

CONFIDENTIALITY AND PUBLICATION 

8.1 Confidentiality Obligations. Each Party shall (a) maintain in confidence the Confidential Information of the other Party to the
same extent such Party maintains its own confidential information, (b) not disclose such Confidential Information to any Third Party without the prior written consent of the other Party, and (c) not use such Confidential Information for
any purpose except those permitted by this Agreement. Such obligations shall survive for a period of [***] ([***]) years after termination or expiration of this Agreement, except that such obligations shall survive with respect to any Confidential
Information identified by the disclosing Party as a trade secret for so long as such Confidential Information remains a trade secret. 
 8.2
Exceptions to Confidentiality. Notwithstanding the foregoing, the obligations of confidentiality set forth in Section 8.1 shall not apply to information that, in each case as demonstrated by competent written documentation: 

(a) is publicly disclosed or made generally available to the public by the disclosing Party, either before or after it becomes known to the
receiving Party; 
 (b) was known to the receiving Party, without any obligation to keep it confidential, prior to the date of first
disclosure by the disclosing Party to the receiving Party, as shown by the receiving Party’s files and records; 

  
 - 45 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 (c) is subsequently disclosed to the receiving Party by a Third Party lawfully in possession
thereof without obligation to keep it confidential and without a breach of such Third Party’s obligations of confidentiality; 
 (d)
has been publicly disclosed or made generally available to the public other than through any act or omission of the receiving Party or its Affiliates in breach of this Agreement; or 

(e) has been independently developed by the receiving Party without the aid, application or use of the disclosing Party’s Confidential
Information (the competent written proof of which must be contemporaneous with such independent development). 
 8.3 Authorized
Disclosure. Notwithstanding Section 8.1, a Party may disclose Confidential Information of the other Party to the extent such disclosure is reasonably necessary in the following instances: 

(a) Prosecuting and Maintaining Patent Rights in accordance with this Agreement; 

(b) making filings with Regulatory Authorities in accordance with this Agreement; 

(c) complying with applicable Laws or submitting information to tax or other Governmental Authorities; provided that if a Party is
required by Law to make any public disclosure of Confidential Information of the other Party, to the extent it may legally do so, it will give reasonable advance notice to the other Party of such disclosure and will use its reasonable efforts to
secure confidential treatment of such Confidential Information prior to its disclosure (whether through protective orders or otherwise); 

(d) to its Affiliates, and to prospective and actual acquirers, licensees, sublicensees, employees, consultants, agents, accountants, lawyers,
advisors, investors and underwriters, on a need to know basis, each of whom prior to disclosure must be bound by written or professional ethical obligations of confidentiality and non-use equivalent in scope
to those set forth in this ARTICLE VIII and that are of reasonable duration in view of the circumstances of the disclosure; or 
 (e) to the
extent mutually agreed to in writing by the Parties. 
 8.4 Scientific Publications. During the Research Term, neither Party shall
first publish or first present in a public forum the scientific or technical results of any activity performed pursuant to this Agreement without the opportunity for prior review and comment by and obtaining the permission of the other Party, except
that either Party may publish or first present in a public forum any information related to the Research Program and/or any pre-clinical or clinical results obtained by such Party pertaining to any New Capsid
Variants, without the need to obtain the other Party’s review or permission, provided that the publication or presentation does not disclose the sequence of any New Capsid Variant for which a Patent Right has not yet been filed under this
Agreement, and provided in the case of uniQure that the publication must 

  
 - 46 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 
only present data and information as to a Royalty-Bearing Construct or Royalty-Bearing Product for which uniQure at that time holds a commercialization license under this Agreement, not a New
Capsid Variant outside the context of a Royalty-Bearing Construct or Royalty-Bearing Product for which uniQure at that time holds a commercialization license under this Agreement. 

8.5 Press Releases and Other Permitted Disclosures. 

(a) 4DMT and uniQure each agree not to disclose any of the terms and conditions of this Agreement to any Third Party, except as described
below in this Section 8.5. The Parties will cooperate in the release of a mutually agreed upon press release announcing the collaboration contemplated by this Agreement as soon as practicable after the Effective Date. Subject to the other
provisions of this Agreement, no other press release, public statement or public disclosure concerning the existence or terms of this Agreement shall be made, either directly or indirectly, by either Party, without first obtaining the written
approval of the other Party, which such approval shall not be unreasonably withheld or delayed beyond [***] ([***]) Business Days (or [***] ([***]) Business Days if the Party wishing to make such disclosure or any of its controlling Affiliates is
then a public company) following submission to the approving Party of a draft of the respective press release, public statement or public disclosure. In no event shall any such subsequent press release, public statement or public disclosure by 4DMT
disclose, if previously undisclosed, the identity of any Construct or Product or the stage of development of any Construct or Product that uniQure is researching, Developing, manufacturing, or Commercializing; provided that for clarity,
uniQure may disclose, without the written approval of 4DMT, the identity of any Construct or Product or the stage of development of any Construct or Product that uniQure is researching, Developing, manufacturing, or Commercializing. In no event
shall any such subsequent press release, public statement or public disclosure by a Party disclose, if previously undisclosed, the financial terms of this Agreement; provided that 4DMT may disclose the receipt of, and uniQure may disclose the
payment of, any payment but not the amount of such payment; provided, further, however, that if disclosure of the amount of a payment is required by applicable Law, by applicable stock exchange regulation, or by order or other
ruling of a competent court, as set forth in Section 8.5(c), then 4DMT or uniQure, as the case may be, may also disclose such amount in a public statement or disclosure. Once any public statement or public disclosure has been approved in
accordance with this Section 8.5, then either Party may appropriately communicate information contained in such permitted statement or disclosure. 

(b) Either Party may disclose the existence and terms of this Agreement in confidence to its attorneys, to UC, and to each of the following,
under an agreement with terms of confidentiality and non-use no less rigorous than the terms contained in this Agreement and, as applicable, to use such information solely for the purpose permitted pursuant to
the applicable subsection of this Section 8.5(b): 
 (i) professional accountants, consultants, or auditors; 

(ii) bankers or other financial advisors, in connection with an initial public offering, private financing or other strategic transaction, or
corporate valuation for internal purposes; 

  
 - 47 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 (iii) potential acquirers (and their respective attorneys and professional advisors), in
connection with a potential merger, acquisition or reorganization; provided that the Party making the disclosure has a bona fide offer (e.g., a signed term sheet or letter of intent, even if
non-binding) from such Third Party for such a transaction; 
 (iv) to actual or potential
investors, lenders or permitted assignees of such Party (and their respective attorneys and professional advisors); or 
 (v) to actual or
potential licensees or sublicensees of such Party (and their respective attorneys and professional advisors); provided that such disclosure in the case of 4DMT shall not include any financial terms, the Delivery Success Criteria, nor any
other contents of the Research Plan for Liver nor the Research Plan for CNS. 
 (c) Notwithstanding the foregoing provisions of this ARTICLE
VIII, a Party may disclose the existence and terms of this Agreement, however excluding, as far as legally possible, Schedule 2, or the Parties’ activities under this Agreement, where required, as reasonably determined by the legal
counsel of the disclosing Party, by applicable Law, by applicable stock exchange regulation or by order or other ruling of a competent court, although, to the extent practicable, the other Party shall be given [***] ([***]) Business Days advance
notice of any such legally required disclosure to comment and reasonably consider such comments provided by such other Party on the proposed disclosure. In case either Party is obliged to publish this Agreement as a “material agreement” in
accordance with the U.S. stock exchange regulations (“SEC Filing”), this Agreement shall be redacted by the filing Party as far as legally possible, and the filing Party shall cooperate with the other Party reasonably in advance to
such SEC Filing to enable the other Party to review and comment on the scope of such redaction. 
 ARTICLE IX 

REPRESENTATIONS AND WARRANTIES; INDEMNIFICATION 

9.1 Representations and Warranties of the Parties. uniQure and 4DMT each represent, warrant and covenant to the other that: 

(a) as of the Effective Date, it has the authority and right to enter into and perform this Agreement and grant the rights embodied herein,
and it is not aware of any legal impediment that could inhibit its ability to perform its obligations under this Agreement; 
 (b) as of the
Effective Date, its execution, delivery and performance of this Agreement does not conflict with, or constitute a breach of, any order, judgment, agreement or instrument to which it is a party or is otherwise bound; 

(c) it shall comply in all material respects with all Laws applicable to its actions under this Agreement; and 

(d) as of the Effective Date, no consent of any Third Party is required for such Party to grant the licenses and rights granted to the other
Party under this Agreement or to perform its obligations hereunder. 

  
 - 48 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 9.2 Representations and Warranties of 4DMT. 4DMT represents, warrants and covenants to
uniQure that: 
 (a) [Intentionally omitted.] 

(b) as of the Effective Date, 4DMT has not previously assigned, transferred, conveyed or otherwise encumbered its right, title and interest in
4DMT Intellectual Property in a manner inconsistent with the terms hereof; 
 (c) as of the Effective Date, 4DMT has valid and existing
licenses, free and clear of all liens, charges and encumbrances, to the 4DMT Patent Rights not owned by 4DMT; 
 (d) as of the Effective
Date, to 4DMT’s knowledge, the conception, development and reduction to practice of the 4DMT Intellectual Property has not constituted or involved the misappropriation of trade secrets of any Third Party or the infringement of issued
Patent Rights of any Third Party; 
 (e) as of the Effective Date, 4DMT has not received any written notice of any unauthorized use,
infringement, or misappropriation by any person or entity, including any current or former employee or consultant of 4DMT, of any 4DMT Intellectual Property; 

(f) as of the Effective Date, to 4DMT’s knowledge, there are no claims, judgments, settlements pending or any action with respect to the
4DMT Intellectual Property; 
 (g) as of the Effective Date, to 4DMT’s knowledge, uniQure’s use of the 4DMT Intellectual Property,
as reasonably anticipated to be used in the conduct of the Research Program, will not infringe any valid Patent Right existing as of the Effective Date and owned by any Third Party; 

(h) all of 4DMT’s personnel and employees, and Third Parties, including agents and consultants, hired by 4DMT and involved in the
Research Program are, or when hired will be, under a written obligation to assign to 4DMT any right they may have in any Invention first invented, discovered, made, conceived or reduced to practice in the conduct of activities pursuant to the
Research Program, and all intellectual property rights therein; 
 (i) it will not, after the Effective Date, enter into any written or oral
contractual obligation with any Third Party that would be inconsistent with the obligations that arise on its part out of this Agreement or that would deprive uniQure of the benefits of or rights granted under this Agreement; 

(j) as of the Effective Date, each of the UCB Agreements is in full force and effect, and 4DMT will not, after the Effective Date, terminate,
amend or otherwise modify any of the terms thereof without prior written consent from uniQure, or take any action or refrain from taking any action that would permit UC to terminate any UCB Agreement (it being recognized that if the New Capsid
Variants are not UC AAV Capsid Variants, and UC terminates any UCB Agreement, 4DMT shall not be deemed to be in breach of the foregoing), and 4DMT shall promptly provide uniQure with a copy of each notice it receives from UC under any UCB Agreement;
and 

  
 - 49 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 (k) if, during the Term, 4DMT has reason to believe that it or any of its employees,
officers, subcontractors, or consultants rendering services hereunder (i) is or shall be debarred or convicted of a crime under 21 U.S.C. Section 335a, or (ii) is or shall be under indictment under said Section 335a, then 4DMT
shall immediately notify uniQure in writing. 
 For purposes of this Section 9.2, “knowledge” shall mean the actual knowledge of 4DMT,
including [***]. 
 9.3 Representations and Warranties of uniQure. uniQure represents, warrants and covenants to 4DMT that: 

(a) all of uniQure’s personnel and employees, and Third Parties, including agents and consultants, hired by uniQure and involved in the
Research Program are, or when hired will be, under a written obligation to assign to uniQure any right they may have in any Invention first invented, discovered, made, conceived or reduced to practice in the conduct of activities pursuant to the
Research Program, and all intellectual property rights therein; 
 (b) it will not, after the Effective Date, enter into any written or oral
contractual obligation with any Third Party that would be inconsistent with the obligations that arise on its part out of this Agreement or that would deprive 4DMT of the benefits of or rights granted under this Agreement; 

(c) if, during the Term, uniQure has reason to believe that it or any of its employees, officers, subcontractors, or consultants rendering
services hereunder (i) is or shall be debarred or convicted of a crime under 21 U.S.C. Section 335a, or (ii) is or shall be under indictment under said Section 335a, then uniQure shall immediately notify 4DMT in writing. 

9.4 No Other Warranties. 

(a) EXCEPT AS OTHERWISE EXPRESSLY SET FORTH HEREIN, THE PARTIES MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTIES OF ANY KIND, EITHER EXPRESS
OR IMPLIED, AND PARTICULARLY THAT PRODUCT(S) WILL BE SUCCESSFULLY DEVELOPED HEREUNDER, AND IF PRODUCT(S) ARE DEVELOPED, WITH RESPECT TO SUCH PRODUCT(S), THE PARTIES DISCLAIM ALL IMPLIED WARRANTIES OF TITLE,
NON-INFRINGEMENT, MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. 
 (b) uniQure acknowledges
that UC has not warranted to 4DMT under the UCB Agreements as to the validity of any Patent Rights or that practice under such Patent Rights shall be free of infringement. UNIQURE, ITS AFFILIATES AND ITS SUBLICENSEE(S) AGREE THAT (I) THE
LICENSES GRANTED PURSUANT TO THE UCB AGREEMENTS, THE UC AAV CAPSID VARIANTS, AND THE ASSOCIATED INVENTIONS ARE PROVIDED WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER WARRANTY, EXPRESSED OR IMPLIED; (II)

  
 - 50 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 
UC MAKES NO REPRESENTATION OR WARRANTY THAT ANY INVENTION CLAIMED BY THE UC PATENT RIGHTS, THE UC AAV CAPSID VARIANTS, THE UC PATENT RIGHTS, OR THE UC PRODUCTS WILL NOT INFRINGE ANY PATENT OR
OTHER PROPRIETARY RIGHT; AND (III) IN NO EVENT WILL UC BE LIABLE FOR ANY INCIDENTAL, SPECIAL OR CONSEQUENTIAL DAMAGES RESULTING FROM EXERCISE OF THE LICENSES GRANTED PURSUANT TO THE UCB AGREEMENTS OR THE USE OF ANY INVENTION CLAIMED BY THE UC
PATENT RIGHTS, THE UC AAV CAPSID VARIANTS, THE UC PATENT RIGHTS, OR THE UC PRODUCTS. 
 9.5 Indemnification by uniQure. uniQure shall
indemnify, hold harmless and defend 4DMT, its Affiliates and all of their respective officers, directors, employees, agents and shareholders (collectively, the “4DMT Indemnitees”) from and against any and all losses, damages,
liabilities, judgments, fines, amounts paid in settlement, expenses and costs of defense (including reasonable attorneys’ fees and witness fees) (collectively, “Damages”) resulting from any demand, claim, action or proceeding
brought or initiated by a Third Party (each a “Third Party Claim”) against any 4DMT Indemnitee to the extent arising out of: (a) a Default by uniQure; (b) the negligence or willful misconduct of a uniQure Indemnitee; or
(c) the use, Development, Commercialization, storage or other exploitation of any Construct or Product by uniQure, its Affiliates, Sublicensees, Third Party Distributors, or Third Party independent contractors; provided that (i) the
4DMT Indemnitees shall comply with the procedures set forth in Section 9.7(a); and (ii) such indemnity shall not apply to the extent such Third Party Claim is subject to indemnification by 4DMT under Section 9.6. 

9.6 Indemnification by 4DMT. 4DMT shall indemnify, hold harmless and defend uniQure, its Affiliates and all of their respective
officers, directors, employees, agents, and shareholders (collectively, the “uniQure Indemnitees”) from and against any and all Damages resulting from any Third Party Claim against any uniQure Indemnitee to the extent arising out
of: (a) a Default by 4DMT; (b) the negligence or willful misconduct of a 4DMT Indemnitee; or (c) the use, Development, Commercialization, storage or other exploitation of any 4DMT AAV Capsid Variant, Construct or Product (other than a
uniQure Product Developed, or Commercialized by uniQure, its Affiliate, or Sublicensee) by 4DMT, its Affiliates, Sublicensees or Third Party independent contractors; provided that (i) the uniQure Indemnitees shall comply with the
procedures set forth in Section 9.7(b); and (ii) such indemnity shall not apply to the extent such Third Party Claim is subject to indemnification by uniQure under Section 9.5. 

9.7 Procedure. 
 (a) To be
eligible for the 4DMT Indemnitees to be indemnified hereunder, 4DMT shall provide uniQure with prompt notice of the Third Party Claim giving rise to the indemnification obligation under Section 9.5 and the exclusive ability to defend or settle
any such claim; provided however that uniQure shall not enter into any settlement for damages, or that imposes upon 4DMT any obligation or liability, without 4DMT’s prior written consent, such consent not to be unreasonably
withheld, delayed or conditioned. 4DMT shall have the right to participate, at its own expense and with counsel of its choice, in the defense of any claim or suit that has been assumed by uniQure. 

  
 - 51 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 (b) To be eligible for the uniQure Indemnitees to be indemnified hereunder, uniQure shall
provide 4DMT with prompt notice of the Third Party Claim giving rise to the indemnification obligation under Section 9.6 and the exclusive ability to defend or settle any such claim; provided however that 4DMT shall not enter into
any settlement for damages, or that imposes upon uniQure any obligation or liability, without uniQure’s prior written consent, such consent not to be unreasonably withheld, delayed or conditioned. uniQure shall have the right to participate, at
its own expense and with counsel of its choice, in the defense of any claim or suit that has been assumed by 4DMT. 
 9.8 uniQure
Indemnity to UC. uniQure shall, and shall require its Sublicensees to, indemnify, defend, and hold harmless UC and IGT, and their officers, employees, and agents; sponsor(s) of the research that led to the inventions disclosed in the UC Patent
Rights and the UC AAV Capsid Variants; and the inventors of any UC Patent Rights and their employers against any and all losses, damages, costs, fees, and expenses resulting from Third Party claims and suits arising out of uniQure’s activities
under this Agreement or of any Sublicensee activities under any sublicense agreement granting rights under the UC Patent Rights or the UC AAV Capsid Variants, or any use or possession of the UC AAV Capsid Variants resulting from uniQure’s
exploitation of its rights thereto. This indemnification will include any product liability claims. uniQure will keep UC informed of its defense of any claims pursuant to this Section 9.8, and UC will cooperate reasonably in any such suit. If
UC invokes the provisions of this Section 9.8, UC will not make any admissions or take any actions in such claim or suit that may prejudice or impair uniQure’s ability to defend such claim or suit without uniQure’s prior written
consent, and uniQure will not admit liability or wrongdoing on behalf of UC without UC’s prior written consent. 
 9.9 Insurance.
Each Party shall procure and maintain insurance or self-insurance, including general liability insurance and product liability insurance, adequate to cover its obligations hereunder and that are consistent with normal business practices of prudent
companies similarly situated, at all times during which any Research Construct, Royalty Bearing Construct, or Royalty Bearing Product is being Developed, clinically tested in human subjects or Commercialized by or on behalf of such Party, its
Affiliates or sublicensees, including, in the case of uniQure, its Sublicensees. It is understood that any such insurance or self-insurance shall not be construed to create a limit of a Party’s liability with respect to its indemnification
obligations under this ARTICLE IX. Each Party shall provide the other Party with written evidence of such insurance or self-insurance upon request. Each Party shall provide the other Party with written notice at least [***] ([***]) days prior to the
cancellation, non-renewal or material change in such insurance or self-insurance which could adversely affect rights hereunder. Without limiting the generality of the foregoing: 

(a) uniQure, at its sole cost and expense, will ensure that the applicable entity performing activities in connection with any work performed
hereunder, whether uniQure, an Affiliate, or a Sublicensee, will obtain, keep in force, and maintain the following insurance: 
 (i) prior
to the start of Clinical Trials of a UC Product, commercial form general liability insurance (contractual liability included) with limits as follows: 

  
 - 52 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

			
	Each Occurrence	  	$[***]
	Products/Completed Operations Aggregate	  	$[***]
	Personal and Advertising Injury	  	$[***]
	General Aggregate	  	$[***]

 (ii) Upon the start of any Clinical Trials of a UC Product, commercial form general liability insurance
(contractual liability included), and product liability insurance if not otherwise included, with limits as follows: 
  

			
	Each Occurrence	  	$[***]
	Products/Completed Operations Aggregate	  	$[***]
	Personal and Advertising Injury	  	$[***]
	General Aggregate	  	$[***]

 (iii) Upon the First Commercial Sale of a UC Product, commercial form general liability insurance
(contractual liability included), and product liability insurance if not otherwise included, with limits as follows: 
  

			
	Each Occurrence	  	$[***]
	Products/Completed Operations Aggregate	  	$[***]
	Personal and Advertising Injury	  	$[***]
	General Aggregate	  	$[***]

 If the above insurance is written on a claims-made form, it shall continue for [***] ([***]) years following
termination or expiration of this Agreement. 
 (iv) worker’s compensation as legally required in the jurisdiction in which uniQure, an
Affiliate, or a Sublicensee, as applicable, is doing business. 
 uniQure will promptly notify UC of any material reduction in the insurance coverages below
the amounts required hereunder. 
 (b) Within [***] ([***]) days after the Effective Date, uniQure will furnish 4DMT with certificates of
insurance evidencing compliance with all requirements. Such certificates will: 
 (i) where possible, provide for [***] ([***])
days’ ([***] ([***]) days for non-payment of premium) advance written notice to 4DMT and UC of any cancellation of insurance coverages described above in Section 9.9(a); 

(ii) indicate that 4DMT and UC have been endorsed as additional insureds under the coverage described above in Section 9.9(a); and 

  
 - 53 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 (iii) include a provision that the coverages described above in Section 9.9(a) will be
primary and will not participate with, nor will be excess over, any valid and collectable insurance or program of self-insurance maintained by 4DMT or UC. 

9.10 No Consequential or Punitive Damages. EXCEPT WITH RESPECT TO (a) THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER PARTY
UNDER THIS AGREEMENT WITH RESPECT TO THIRD PARTY CLAIMS, (b) A BREACH OF THE CONFIDENTIALITY OBLIGATIONS OF ARTICLE VIII, (c) A BREACH OF SECTION 5.6, OR (d) A PARTY’S WILLFUL MISCONDUCT, NEITHER PARTY HERETO WILL BE LIABLE FOR
INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, EXEMPLARY OR PUNITIVE DAMAGES, INCLUDING LOST PROFITS, ARISING FROM OR RELATING TO THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF SUCH DAMAGES. 

ARTICLE X 
 TERM AND
TERMINATION 
 10.1 Term and Expiration. This Agreement shall be effective as of the Effective Date and unless terminated
earlier pursuant to Section 10.2, this Agreement shall continue in effect until the expiration of all of uniQure’s and 4DMT’s payment obligations hereunder (the “Term”). Upon expiration, all licenses granted hereunder
shall be fully paid-up, perpetual and irrevocable. 
 10.2 Termination. 

(a) Termination of Agreement for Cause. 

(i) This Agreement may be terminated at any time during the Term upon written notice by either Party (the “Non-Defaulting Party”) upon Default of the other Party (the “Defaulting Party”), which Default remains uncured for ninety (90) days after written notice requesting cure of such
Default. The Non-Defaulting Party shall provide written notice to the Defaulting Party, which notice shall identify the Default, the intent to so terminate and the actions or conduct that it considers would be
an acceptable cure of such Default. If the Defaulting Party disputes the Default under this Section 10.2(a), then the issue of whether the Non-Defaulting Party may properly terminate this Agreement on
expiration of the applicable cure period shall be resolved in accordance with ARTICLE XI. If, as a result of such dispute resolution process, it is determined that the alleged Defaulting Party committed a Default and the Defaulting Party does not
cure such Default within sixty (60) days after the date of such dispute resolution award (the “Additional Cure Period”), then such termination shall be effective as of the expiration of the Additional Cure Period. If the
Parties dispute whether such Default was so cured, either Party alone may request the same tribunal to determine whether it was so cured, and the Parties shall cooperate to allow such determination to be made within thirty (30) days after such
request by either Party. Any such dispute resolution proceeding does not suspend any obligation of either Party hereunder, and each Party shall use reasonable efforts to mitigate any damage. If, as a result of any such dispute resolution proceeding,
it is determined that the alleged Defaulting Party did not commit such Default (or such Default was cured in accordance with this Section 10.2(a)), then no termination shall be effective, and this Agreement shall continue in full force and
effect. 

  
 - 54 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 
Notwithstanding the foregoing, if the claimed Default relates to one or more Royalty-Bearing Constructs or Royalty-Bearing Products, and not this entire Agreement, then this Agreement shall be
terminated only with respect to the Indication for which such Royalty-Bearing Construct(s) or Royalty-Bearing Product(s) were intended to treat and if uniQure was the Defaulting Party then additionally such Indication shall be removed from the
Field.  
 (b) Termination for Bankruptcy. To the extent allowed under applicable Law, either Party shall have the right to
terminate this Agreement in the event of the commencement of any proceeding in or for bankruptcy, insolvency, dissolution or winding up by or against the other Party (other than pursuant to a corporate restructuring) that is not dismissed or
otherwise disposed of within sixty (60) days thereafter. 
 (c) Termination for Futility. uniQure shall have the right terminate
this Agreement immediately upon written notice to 4DMT summarizing the basis for such termination if, at any point prior to the first (1st) anniversary of the Effective Date, the JRSC determines
that (i) it would be futile to continue the Research Program, including if the JRSC determines that any Delivery Success Criteria cannot be met through use of the 4DMT Intellectual Property following the reasonable efforts of 4DMT to achieve
such Delivery Success Criteria or (ii) 4DMT is not making bona fide efforts to achieve the timelines set forth in the Research Plan. 

(d) Termination for Convenience. uniQure shall have the right terminate this Agreement at any time after the Research Term, for any
reason or for no reason, by giving 4DMT ninety (90) days’ prior written notice thereof. 
 10.3 Effect of Termination 

(a) If uniQure terminates this Agreement under Section 10.2(a) or Section 10.2(b): 

(i) uniQure’s licenses pursuant to this Agreement shall continue; provided however that uniQure shall continue to fulfill
uniQure’s payment obligations with respect to royalties and Sublicense Consideration under ARTICLE VI; and provided further that uniQure may reduce such payment obligations by the amount of monetary damage suffered by uniQure as a
direct result of 4DMT’s Default, as determined (A) in a final decision of the arbitrators in accordance with Section 11.2 or, with respect to an Excluded Claim, a court of competent jurisdiction, which decision is not appealable or
has not been appealed within the time allowed for appeal, or (B) by the Parties in a settlement agreement; 
 (ii) 4DMT shall, within
[***] ([***]) days after the effective date of such termination, return or cause to be returned to uniQure, copies of all uniQure’s Confidential Information and uniQure Intellectual Property and all Materials provided by uniQure, except that
4DMT may retain one copy of uniQure’s Confidential Information solely for legal archive purposes and to exercise the licenses granted to 4DMT which survive termination of this Agreement; 

  
 - 55 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 (iii) For clarity, uniQure shall be released of its ongoing diligence obligations under
Section 4.4 (if any) and uniQure and 4DMT shall be released of their disclosure and information exchange obligations under ARTICLE III and ARTICLE IV; 

(iv) For clarity, the JRSC and its subcommittees shall not meet anymore; and 

Notwithstanding the foregoing, if such termination is under Section 10.2(a) solely with respect to one or more given Indication(s), then
uniQure’s licenses pursuant to Section 5.1 will not terminate but the Field is automatically narrowed to exclude the relevant Indication(s); the license granted to 4DMT under Section 5.2(b) shall be automatically adjusted to include
the relevant Indication(s) rather than all fields of use; and uniQure’s obligations under subsection (ii) shall be limited to copies of 4DMT’s Confidential Information and 4DMT Intellectual Property and Materials that relate solely to
the relevant Indication(s). 
 (b) Upon termination of this Agreement by uniQure under Section 10.2(c) or Section 10.2(d), or by
4DMT under Section 10.2(a) or Section 10.2(b): 
 (i) For clarity, uniQure’s licenses pursuant to Section 5.1 and Step-In Rights under Section 4.4 shall terminate as of the effective date of such termination; 

(ii) Effective as of the effective date of such termination, the license granted to 4DMT under Section 5.2(b) shall be automatically
expanded to include the New Capsid Variants and all fields of use; 
 (iii) uniQure shall, within [***] ([***]) days after the effective
date of such termination, return or cause to be returned to 4DMT, copies of all 4DMT’s Confidential Information and 4DMT Intellectual Property and all Materials provided by 4DMT; except that uniQure may retain one copy of the 4DMT Confidential
Information solely for legal archive purposes; 
 (iv) 4DMT shall, within [***] ([***]) days after the effective date of such termination,
return or cause to be returned to uniQure, copies of all uniQure’s Confidential Information and uniQure Intellectual Property and all Materials provided by uniQure, except that 4DMT may retain one copy of uniQure’s Confidential Information
solely for legal archive purposes and to exercise the licenses granted to 4DMT which survive termination or are granted upon termination of this Agreement; and 

(v) For a period of [***] ([***]) months, if termination occurs after Regulatory Approval of Royalty Bearing Products, uniQure and its
Affiliates shall be entitled to finish work in progress and to sell any of the Royalty Bearing Products remaining in inventory in accordance with the terms of this Agreement to the extent such Royalty Bearing Products were being sold in the
Territory at the time of termination, provided that such sales shall be subject to the royalty provisions of this Agreement. 

  
 - 56 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 10.4 Effect of Expiration or Termination; Survival. 

(a) Expiration or termination of this Agreement shall not relieve the Parties of any obligation accruing prior to such expiration or
termination. Any expiration or termination of this Agreement shall be without prejudice to the rights of either Party against the other accrued or accruing under this Agreement prior to expiration or termination, including the obligation to pay
royalties for Royalty Bearing Product(s) sold prior to such expiration or termination. Termination of this Agreement shall be in addition to, and shall not prejudice, the Parties’ remedies at law or in equity, including the Parties’
ability to receive legal damages or equitable relief with respect to any breach of this Agreement, regardless of whether or not such breach was the reason for the termination. 

(b) The provisions of ARTICLE I, ARTICLE VII (but not Sections 7.4(c) nor 7.6-7.9), ARTICLE VIII,
ARTICLE XI, ARTICLE XII, and Sections 4.5, 5.2(b), 5.4, 5.5, 5.6, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 9.10, 10.3 and 10.4 shall survive any expiration or termination of this Agreement, and with respect to those Royalty Bearing Products in such countries
for which uniQure retains a Development and Commercialization license after the expiration or termination of this Agreement, the provisions of ARTICLE VI shall also survive as to uniQure Products in such countries. 

ARTICLE XI 
 DISPUTE
RESOLUTION 
 11.1 Seeking Consensus. If any dispute arises out of, in connection with or related to this Agreement, including
disputes over the interpretation, performance, enforcement or breach of this Agreement, including any dispute that is not within the jurisdiction of the JRSC, (a “Dispute”), excluding any dispute resolved in accordance with
Section 2.3(c) (subject to Section 2.3(d)), then upon the written request of either Party, the matter shall be referred to the Executives, who shall meet in a good faith effort to resolve the dispute within [***] ([***]) days. If the
Parties’ Executives cannot agree on a resolution of the Dispute within such [***] ([***]) day period, then it shall be resolved pursuant to the remaining provisions of this ARTICLE XI. 

11.2 Arbitration. If the Parties do not fully settle a Dispute pursuant to Section 2.3 (only as to those matters that may be
referred to arbitration) or 11.1, as applicable, and a Party wishes to pursue the matter, each such Dispute that is not an Excluded Claim (as defined below) shall be finally resolved by binding arbitration in accordance with the Rules of Arbitration
of the ICC (International Chamber of Commerce) and judgment on the arbitration award may be entered in any court having jurisdiction thereof. 

(a) The arbitration shall be conducted by a panel of three (3) persons. Within [***] ([***]) days after initiation of arbitration, each
Party shall select one person to act as arbitrator and the two Party-selected arbitrators shall select a third arbitrator within [***] ([***]) days after their appointment. If the arbitrators selected by the Parties are unable or fail to agree upon
the third arbitrator, the third arbitrator shall be appointed by the ICC. The place of arbitration shall be New York City, New York, and all proceedings and communications shall be in English. 

  
 - 57 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 (b) Either Party may apply to the arbitrators for interim injunctive relief until the
arbitration award is rendered or the Dispute is otherwise resolved. Either Party also may, without waiving any remedy under this Agreement, seek from any court having jurisdiction any injunctive or provisional relief necessary to protect the rights
or property of that Party pending the arbitration award. The scope of the authority of the arbitrators shall be limited to the strict application of law. The arbitrators shall have no authority to award punitive or any other type of damages not
measured by a Party’s compensatory damages, except as permitted by Section 9.10. Each Party participating in an arbitration pursuant to the terms of this Agreement shall, [***]. The arbitrators shall have the power to award recovery of all
costs (including reasonable attorney’s fees, administrative fees, arbitrators’ fees and court costs) to the prevailing Party. 

(c) Neither Party shall be required to give general discovery of documents, but may be required to produce documents or testimony that are
relevant or considered relevant by the arbitrators to the Dispute. It is the objective and intent of the Parties that any arbitration proceeding be conducted in such a manner that a decision will be rendered by the arbitrators within [***] ([***])
days after the third arbitrator is appointed to the panel, and the Parties and the panel selected in the manner provided above will adopt rules and procedures intended to implement such objective and intent. 

(d) Except to the extent necessary to confirm or vacate an award or as may be required by Law (including applicable securities laws or the
rules of any stock exchange on which a Party’s securities may then be listed), neither a Party nor an arbitrator may disclose the existence, content, or results of arbitration without the prior written consent of both Parties. In no event shall
arbitration be initiated after the date when commencement of a legal or equitable proceeding based on the dispute, controversy or claim would be barred by the applicable New York statute of limitations. 

(e) The Parties agree that any payment made pursuant to this Agreement pending resolution of the Dispute shall be refunded or credited if the
arbitrators or court determines that such payments are not due. 
 As used in this Section 11.2, the term “Excluded Claim” shall mean
a Dispute that concerns (a) the validity, enforceability, scope or infringement of a patent, trademark or copyright; or (b) any antitrust, anti-monopoly or competition law or regulation, whether or not statutory. 

ARTICLE XII 

MISCELLANEOUS 
 12.1
Governing Law. This Agreement shall be governed by and construed in accordance with the Laws of the State of New York, other than any principle of conflict or choice of laws that would cause the application of the Laws of any other
jurisdiction. 
 12.2 Waiver. Waiver by a Party of a breach hereunder by the other Party shall not be construed as a waiver of any
succeeding breach of the same or any other provision. No delay or omission by a Party to exercise or avail itself of any right, power or privilege that it has or may have hereunder shall operate as a waiver of any right, power or privilege by such
Party. No waiver shall be effective unless made in writing with specific reference to the relevant provision(s) of this Agreement and signed by a duly authorized representative of the Party granting the waiver. 

  
 - 58 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 12.3 Notices. All notices, instructions and other communications hereunder or in
connection herewith shall be in writing, shall be sent to the address specified in this Section 12.3 and shall be: (a) delivered personally; (b) transmitted by facsimile; (c) sent by registered or certified mail, return receipt
requested, postage prepaid; or (d) sent via a reputable international overnight delivery service. Any such notice, instruction or communication shall be deemed to have been delivered (i) upon receipt if delivered by hand, (ii) when
transmitted with electronic confirmation of receipt, if transmitted by facsimile (if such transmission is on a Business Day; otherwise, on the next Business Day following such transmission), provided that an original document is sent via an
internationally recognized overnight delivery service (receipt requested), (iii) three (3) Business Days after it is sent by registered or certified mail, return receipt requested, postage prepaid, or (iv) one (1) Business Day after it is
sent via a reputable international overnight delivery service. 
  

			
	 If to 4DMT, to:
	  	 4D Molecular Therapeutics, Inc. 
5858 Horton St

Emerystation North, Suite 460
 Emeryville, CA 94608

Attention: CEO 
Facsimile:

		
	 with a copy to:
	  	Latham & Watkins LLP 
140 Scott Drive 
Menlo Park, CA 94025 
Attention: [***] 
Facsimile: [***]
		
	 And a required email copy to:
	  	[***]
		
	 If to uniQure, to:
	  	uniQure biopharma B.V. 
P.O. Box 22506 
1100 DA Amsterdam 
The Netherlands 
Attention: CEO 
Facsimile: [***]
		
	 with a copy to:
	  	[***]

 or to such other address as the Party to whom notice is to be given may have furnished to the other Party in writing in
accordance herewith. 

  
 - 59 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 12.4 Entire Agreement; Amendment. This Agreement (including its Exhibits and
Schedules) contains the complete understanding of the Parties with respect to the subject matter hereof and supersedes all prior understandings and writings relating to such subject matter. In particular, it supersedes and replaces the Prior
Confidentiality Agreement and any and all term sheets relating to the transactions contemplated by this Agreement and exchanged between the Parties or their Affiliates prior to the Effective Date. No amendment, change or addition to this
Agreement will be effective or binding on either Party unless reduced to writing and duly executed on behalf of both Parties. 
 12.5
Headings. Headings in this Agreement are for convenience of reference only and shall not be considered in construing this Agreement. 

12.6 Severability. If any provision or portion thereof in this Agreement is for any reason held to be invalid, illegal or unenforceable,
the same shall not affect any other portion of this Agreement, as it is the intent of the Parties that this Agreement shall be construed in such fashion as to maintain its existence, validity and enforceability to the greatest extent possible. In
any such event, this Agreement shall be construed as if such clause of portion thereof had never been contained in this Agreement, and there shall be deemed substituted therefor such provision as will most nearly carry out the intent of the Parties
as expressed in this Agreement to the fullest extent permitted by applicable Law. 
 12.7 Assignment. Neither this Agreement nor any
right or obligation hereunder may be assigned or otherwise transferred by any Party without the consent of the other Party; provided, however, that any Party may, without such consent, assign this Agreement, in whole or in part:
(a) to any of its respective Affiliates; provided that the assigning Party shall remain jointly and severally liable with such Affiliate in respect of all obligations so assigned, or (b) to any successor in interest by way of
merger, acquisition or sale of all or substantially all of its assets to which this Agreement relates (an “M&A Event”). Any assignment not in accordance with this Section 12.7 shall be void. Each Party agrees that,
notwithstanding any provision of this Agreement to the contrary, neither the assignment of this Agreement by a Party in connection with an M&A Event, nor the occurrence of such M&A Event (whether or not a formal assignment of this Agreement
occurs), shall provide the non-assigning Party with rights or access to any intellectual property or technology of the acquirer of the assigning Party or its Affiliates that were not Affiliates of the
assigning Party prior to such M&A Event. If uniQure assigns its rights and obligations hereunder to an Affiliate or Third Party outside the United States or The Netherlands pursuant to this Section 12.7, and if such Affiliate or Third Party
shall be required by applicable Law to withhold additional taxes from or in respect of any amount payable under this Agreement as a result of such assignment, then any such amount payable under this Agreement shall be increased to take into account
the additional taxes withheld as may be necessary so that, after making all required withholdings, 4DMT receives an amount equal to the sum it would have received had no such assignment been made. 

12.8 Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original but all of
which together shall constitute one and the same instrument. Signatures provided by facsimile transmission or in Adobe Portable Document Format (PDF) sent by electronic mail shall be deemed to be original signatures. 

  
 - 60 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 12.9 Force Majeure. No Party shall be liable for failure of or delay in performing
obligations (other than payment obligations) set forth in this Agreement, and no Party shall be deemed in breach of its obligations, if such failure or delay is due to a natural disaster, explosion, fire, flood, tornado, thunderstorm, hurricane,
earthquake, war, terrorism, riot, embargo, loss or shortage of power, labor stoppage, substance or material shortage, events caused by reason of laws of any Governmental Authority, events caused by acts or omissions of a Third Party or any other
cause reasonably beyond the control of such Party, if the Party affected gives prompt notice of any such cause to the other Party. The Party giving such notice shall thereupon be excused from such of its obligations hereunder as it is thereby
disabled from performing for so long as it is so disabled, provided, however, that such affected Party commences and continues to use its Commercially Reasonable Efforts to cure such cause. 

12.10 Third Party Beneficiaries. None of the provisions of this Agreement shall be for the benefit of or enforceable by any Third Party,
other than a 4DMT Indemnitee under Section 9.5 or uniQure Indemnitee under Section 9.6. No such Third Party shall obtain any right under any provision of this Agreement or shall by reason of any such provision make any claim in respect of
any debt, liability or obligation (or otherwise) against either Party. 
 12.11 Relationship of the Parties. Each Party shall bear its
own costs incurred in the performance of its obligations hereunder without charge or expense to the other, except as expressly provided in this Agreement. Neither Party shall have any responsibility for the hiring, termination or compensation of the
other Party’s employees or for any employee compensation or benefits of the other Party’s employees. No employee or representative of a Party shall have any authority to bind or obligate the other Party for any sum or in any manner
whatsoever, or to create or impose any contractual or other liability on the other Party without said other Party’s approval. For all purposes, and notwithstanding any other provision of this Agreement to the contrary, the legal relationship
under this Agreement of each Party to the other Party shall be that of independent contractor. Nothing in this Agreement shall be construed to establish a relationship of partners or joint ventures between the Parties. 

12.12 Performance by Affiliates. To the extent that this Agreement imposes obligations on Affiliates of a Party or permits a Party to
exercise its rights or perform its obligations through its Affiliates, such Party agrees to cause its Affiliates to perform such obligations and shall guarantee performance of this Agreement by its Affiliates. If any disagreement arises out of the
performance of this Agreement by an Affiliate of a Party, or the alleged failure of an Affiliate to comply with the conditions and obligations of this Agreement, the Party seeking to resolve such dispute shall have the right do so directly with the
other Party, without any obligation to first pursue an action against, or recovery from, the Affiliate which is alleged to have caused a breach of this Agreement. 

12.13 Construction. Each Party acknowledges that it has been advised by counsel during the course of negotiation of this Agreement, and,
therefore, that this Agreement shall be interpreted without regard to any presumption or rule requiring construction against the Party causing this Agreement to be drafted. Any reference in this Agreement to an ARTICLE, Section, subsection,
paragraph, clause, or Schedule shall be deemed to be a reference to any article, section, subsection, paragraph, clause, schedule or exhibit, of or to, as the case may be, this 

  
 - 61 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 
Agreement. Except where the context otherwise requires, (a) wherever used, the use of any gender will be applicable to all genders; (b) the word “or” is used in the inclusive
sense (and/or); (c) any definition of or reference to any agreement, instrument or other document refers to such agreement, instrument other document as from time to time amended, supplemented or otherwise modified (subject to any restriction on
such amendments, supplements or modifications set forth herein or therein); (d) any reference to any Law refers to such Law as from time to time enacted, repealed or amended; (e) the words “herein”, “hereof” and
hereunder”, and words of similar import, refer to this Agreement in its entirety and not to any particular provision hereof; and (f) the words “include”, “includes” and “including” shall be deemed to be
followed by the phrase “but not limited to”, “without limitation” or words of similar import. 
 [Signature page
follows] 

  
 - 62 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 IN WITNESS WHEREOF, the Parties have executed this Collaboration and License Agreement as of the New
CLA Effective Date. 
  

									
	UNIQURE BIOPHARMA B.V.	 		 	4D MOLECULAR THERAPEUTICS, INC.
					
	BY:	 	 /s/ Lilly Burggraaf
	 		 	BY:	 	 /s/ David Kirn

	NAME: Lilly Burggraaf	 	        	 	NAME: David Kirn, MD
	TITLE: Vice President, Global Human Resources	 		 	TITLE: Chief Executive Officer

  

  
 - 63 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 SCHEDULE 1 

DRAFT INVOICE 
 Omitted
pursuant to Regulation S-K, Item 601(a)(5). 

  
 - 64 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 SCHEDULE 2 

RESEARCH PLAN 

Omitted pursuant to Regulation S-K, Item 601(a)(5). 

  
 - 65 - 

 [***] Certain information in this document has been excluded pursuant to
Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
  

 SCHEDULE 3 

SELECTED CAPSID VARIANTS 

Omitted pursuant to Regulation S-K, Item 601(a)(5). 

  
 - 66 -EX-10.8

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 Exhibit 10.8 
  

			
	 Agreement Control No. 2014-03-0089

 
 UNIVERSITY OF CALIFORNIA, BERKELEY

 
 OFFICE OF TECHNOLOGY LICENSING
	  	 

  
  

EXCLUSIVE LICENSE AND BAILMENT AGREEMENT 

BETWEEN 
 4D MOLECULAR
THERAPEUTICS, LLC 
 AND 

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 

FOR 
 [***] 

UC Case No.: B03-104 
  

 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 TABLE OF CONTENTS 

 

							
	1.	 	 Background
	  	 	3	 
			
	2.	 	 Definitions
	  	 	4	 
			
	3.	 	 Grant
	  	 	8	 
			
	4.	 	 Sublicenses
	  	 	9	 
			
	5.	 	 License Issue Fee
	  	 	12	 
			
	6.	 	 Royalties
	  	 	13	 
			
	7.	 	 Due Diligence
	  	 	16	 
			
	8.	 	 Progress and Royalty Reports
	  	 	18	 
			
	9.	 	 Books and Records
	  	 	19	 
			
	10.	 	 Life of the Agreement
	  	 	20	 
			
	11.	 	 Termination by Regents
	  	 	20	 
			
	12.	 	 Termination by Licensee
	  	 	21	 
			
	13.	 	 Disposition of Licensed Products upon Termination
	  	 	21	 
			
	14.	 	 Patent Prosecution and Maintenance
	  	 	21	 
			
	15.	 	 Marking
	  	 	23	 
			
	16.	 	 Use of Names and Trademarks
	  	 	23	 
			
	17.	 	 Limited Warranties and Covenants
	  	 	23	 
			
	18.	 	 Patent Infringement
	  	 	25	 
			
	19.	 	 Indemnification and Insurance
	  	 	26	 
			
	20.	 	 Compliance with Laws
	  	 	28	 
			
	21.	 	 Government Approval or Registration
	  	 	28	 
			
	22.	 	 Assignment
	  	 	29	 
			
	23.	 	 Notices
	  	 	29	 
			
	24.	 	 Late Payments
	  	 	29	 

  
 i 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

							
			
	25.	 	 Waiver
	  	 	29	 
			
	26.	 	 Confidentiality
	  	 	30	 
			
	27.	 	 Force Majeure
	  	 	31	 
			
	28.	 	 Severability
	  	 	31	 
			
	29.	 	 Applicable Law; Venue; Attorneys’ Fees
	  	 	31	 
			
	30.	 	 Electronic Copy; Counterparts
	  	 	32	 
			
	31.	 	 Scope of Agreement; Amendment; Waiver
	  	 	32	 

  
 ii 

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

			
	 UNIVERSITY OF CALIFORNIA, BERKELEY
  

OFFICE OF TECHNOLOGY LICENSING
	  	

  
  

EXCLUSIVE LICENSE AND BAILMENT AGREEMENT 

FOR 
 [***] 

UC Case No.: B03-104 
  

 
 This exclusive license agreement
(“Agreement”) is effective December 19, 2013 (“Effective Date”), by and between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, a California corporation, whose legal address is 1111 Franklin Street, 12th Floor, Oakland,
California 94607-5200, acting through its Office of Technology Licensing, at the University of California, Berkeley, 2150 Shattuck Avenue, Suite 510, Berkeley, CA 94704-1347 (“REGENTS”) and 4D MOLECULAR THERAPEUTICS LLC, a Delaware limited
liability company having a principal place of business at 19 Rima Court, Danville, CA 94526 (“LICENSEE”). The parties agree as follows: 
  

	1.	 BACKGROUND 

  

	 	1.1	 An invention, generally described as “[***]” and disclosed in REGENTS’ Case No. B03-104 (the
“INVENTION”), was jointly made in the course of research at the University of California, Berkeley by [***], employed by REGENTS, and at Integrative Gene Therapeutics, San Diego, California (“IGT”) by [***], employed by
Integrative Gene Therapeutics. 

  

	 	1.2	 REGENTS’ employees [***] have assigned to REGENTS their undivided interest in PATENT RIGHTS (as defined
below). 

  

	 	1.3	 IGT’s employee [***] has assigned his undivided interest to IGT in PATENT RIGHTS. 

 

	 	1.4	 REGENTS and IGT entered into an Interinstitutional Agreement (the “IIA”) on August 28, 2003,
Agreement Control No.: 2004-18-0020, that is attached to this Agreement as Exhibit A, under which IGT agrees not to license its undivided interest in PATENT
RIGHTS during the term of the IIA. 

  

	 	1.5	 LICENSEE entered into a letter agreement with REGENTS effective March 5, 2013, terminating on
December 5, 2013, for the purpose of evaluating the INVENTION and granting LICENSEE an exclusive right to negotiate an exclusive license in PATENT RIGHTS to the INVENTION, which letter agreement covers LICENSEE’s commitment to reimburse
REGENTS’ patent costs during such period. 

  
 Page 3 of 35 

 

			
	4D Molecular Therapeutics LLC	  	Exclusive License
	UC Case No.: B03-104	  	Confidential

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

	 	1.6	 LICENSEE has provided REGENTS with a commercialization plan for the INVENTION and business strategy in order to
evaluate its capabilities as a LICENSEE. 

  

	 	1.7	 REGENTS, IGT and LICENSEE wish to have the INVENTION perfected and marketed as soon as reasonably practicable
so that products resulting therefrom may be available for public use and benefit. 

  

	 	1.8	 LICENSEE wishes to acquire, and REGENTS wishes to grant to LICENSEE, an exclusive license under PATENT RIGHTS
and an exclusive bailment of the BIOLOGICAL MATERIAL included in the REGENTS’ PROPERTY RIGHTS for the purpose of undertaking development and to make, have made, use, sell, offer for sale, import, and export LICENSED PRODUCTS as defined below.

  

	 	1.9	 REGENTS and LICENSEE are simultaneously entering into a license agreement covering the inventions under
REGENTS’ Case No. B13-135 (the “OTHER LICENSE AGREEMENT”). 

  

	2.	 DEFINITIONS 

  

	 	2.1	 “PATENT RIGHTS” means the intellectual property rights in the following patents and patent
applications: 

  

	 	2.1.1	 [***]; 

  

	 	2.1.2	 [***]; 

  

	 	2.1.3	 [***]; 

  

	 	2.1.4	 [***]; 

  

	 	2.1.5	 [***]; 

  

	 	2.1.6	 [***]; 

  

	 	2.1.7	 [***]; 

  

	 	2.1.8	 [***]; 

  

	 	2.1.9	 [***]; 

  

	 	2.1.10	 [***]; and 

  

	 	2.1.11	 All continuing applications of the foregoing, including divisionals, substitutions, extensions and continuation-in-part applications (only to the 

  
 Page 4 of 35 

 

			
	4D Molecular Therapeutics LLC	  	Exclusive License
	UC Case No.: B03-104	  	Confidential

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

	 	
extent, however, that claims in the continuation-in-part applications are entitled to the priority filing date of
the parent patent application); any patents issuing on said application or continuing applications, including all reexaminations, reissues, and extensions thereof; and any corresponding foreign patents or applications. 

 

	 	2.2	 “LICENSED PRODUCTS” means all kits, compositions of matter, articles of manufacture, materials, and
products, the manufacture, use, SALE, offer for SALE, or import of which: (a) would require the performance of the LICENSED METHOD; or (b) but for the license granted pursuant to this Agreement, would infringe, or contribute to or induce
the infringement of, a VALID CLAIM of any issued, unexpired patent under PATENT RIGHTS or a VALID CLAIM being prosecuted in a pending patent application under PATENT RIGHTS. 

 

	 	2.3	 “LICENSED METHOD” means any process or method, the use or practice of which, but for the license
pursuant to this Agreement, would infringe, or contribute to or induce the infringement of, a VALID CLAIM of any issued patent or pending patent application under PATENT RIGHTS in that country in which the LICENSED METHOD is used or practiced.

  

	 	2.4	 “VALID CLAIM” means (i) a claim in an issued and unexpired patent included in the PATENT RIGHTS
that has not been disclaimed, abandoned or withdrawn and has not been held unenforceable or invalid by a final judgment of a court or other governmental agency of competent jurisdiction from which no appeal can be or is taken, and has not been
admitted to be invalid or unenforceable through reissue or disclaimer or otherwise, or (ii) a claim in a pending patent application included within the PATENT RIGHTS that has been filed in good faith and has not been abandoned or finally
disallowed without the possibility of appeal or refiling, which application has not been pending for more than [***] ([***]) years after its priority date, provided that for clarity, any claim of a pending patent application that is pending for more
than [***] ([***]) years after its priority date shall be eligible to become a VALID CLAIM if it later issues and otherwise falls within subsection (i). 

  

	 	2.5	 “LICENSED FIELD OF USE” means all fields of use, except the ophthalmic field of use.

  

	 	2.6	 “NET SALES” means the gross invoice price charged by, and the fair market value of non-cash consideration paid to, LICENSEE for SALES of LICENSED PRODUCTS, LICENSED SERVICES, and LICENSED METHODS, less the sum of the following actual and customary deductions where applicable: (i) the actual
amount of write-offs for bad debts (in accordance with generally accepted accounting principles and that would reasonably be taken by a similarly situated company) related to such SALES; (ii) cash, prompt pay, trade or quantity discounts;
(iii) sales tax, use tax, consumption tax, Deductible Value Added Tax, tariffs, import/export duties or other excise taxes when included in gross sales, but not income taxes derived from such sales; (iv) transportation charges; and

  
 Page 5 of 35 

 

			
	4D Molecular Therapeutics LLC	  	Exclusive License
	UC Case No.: B03-104	  	Confidential

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

	 	
(v) allowances or credits to customers because of rejections or returns. For purposes of calculating NET SALES, NET SALES shall not include any SALE of LICENSED PRODUCTS, LICENSED SERVICES,
or LICENSED METHODS used for development purposes (including, without limitation for clinical studies) or provided as samples or free goods (including, without limitation, product transferred in connection with patient assistance programs or other
charitable purposes); and a SALE to a sublicensee that is not intended for end use shall not be included in NET SALES. “Deductible Value Added Tax” is value added tax to the extent that is not subject to a tax credit, refund or deduction
by a taxing authority. 

 In the event that LICENSED PRODUCTS, LICENSED SERVICES or LICENSED METHODS are COMBINATION PRODUCTS,
the NET SALES of such COMBINATION PRODUCT, for the purposes of determining royalty payments pursuant to this Agreement, shall be determined by multiplying the NET SALES of the COMBINATION PRODUCT (as defined below) during the applicable royalty
reporting period, by the fraction A/(A+B), where A is the fair market value of the LICENSED PRODUCTS, LICENSED SERVICES or LICENSED METHODS, and B is the fair market value of all OTHER COMPONENTS included in the COMBINATION PRODUCT. If a COMBINATION
PRODUCT is sold, whether or not the OTHER COMPONENTS are also sold separately, LICENSEE shall make a good faith determination of the respective fair market values of the LICENSED PRODUCT, LICENSED SERVICES or LICENSED METHODS and all OTHER
COMPONENTS included in the COMBINATION PRODUCT, and shall notify REGENTS of such determination and provide REGENTS with data to support such determination. 
  

	 	2.7	 “COMBINATION PRODUCT” means a LICENSED PRODUCT, LICENSED SERVICE or LICENSED METHOD that incorporates
at least one OTHER COMPONENT. For clarity, all references to “LICENSED PRODUCTS, LICENSED SERVICES or LICENSED METHODS” in this Agreement shall be deemed to include COMBINATION PRODUCTS. 

 

	 	2.8	 “OTHER COMPONENT” means a proprietary active therapeutic ingredient or a delivery device, in each
case that is not itself a LICENSED PRODUCT, LICENSED SERVICE or LICENSED METHOD. 

  

	 	2.9	 “AFFILIATE” of LICENSEE means any entity that, directly or indirectly, Controls LICENSEE, is
Controlled by LICENSEE, or is under common Control with LICENSEE. “Control” means (i) having the actual, present capacity to elect a majority of the directors of such affiliate, (ii) having the power to direct at least fifty
percent (50%) of the voting rights entitled to elect directors, or (iii) in any country where the local law will not permit foreign equity participation of a majority, ownership or control, directly or indirectly, of the maximum percentage of
such outstanding stock or voting rights permitted by local law. 

  
 Page 6 of 35 

 

			
	4D Molecular Therapeutics LLC	  	Exclusive License
	UC Case No.: B03-104	  	Confidential

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

	 	2.10	 “LICENSED TERRITORY” means United States of America, its territories and possessions, and subject to
Paragraph 14.4, any foreign countries where PATENT RIGHTS exist. 

  

	 	2.11	 “SALE” means, for LICENSED PRODUCTS and LICENSED SERVICES, the act of selling, leasing or otherwise
transferring, providing, or furnishing such product or service, and for LICENSED METHODS, the act of performing such method for any consideration. Correspondingly, “SELL” means to make or cause to be made a SALE, and “SOLD” means
to have made or caused to be made a SALE. 

  

	 	2.12	 “LICENSED SERVICE” means a service provided using LICENSED PRODUCTS or LICENSED METHODS.

  

	 	2.13	 “NON-ROYALTY SUBLICENSE REVENUE” means any cash
consideration, and subject to Paragraph 4.3(b), the cash equivalent of all other consideration, received by LICENSEE under each sublicense for the grant of rights under the PATENT RIGHTS, but excluding: (a) any royalty payments on sales of
LICENSED PRODUCTS, LICENSED SERVICES and LICENSED METHODS by a sublicensee (which shall be included as EARNED ROYALTY SUBLICENSE REVENUE); (b) any amounts paid by a sublicensee as bona fide reimbursement for research and development costs at fair
market value for materials and full time equivalents; (c) bona fide loans or any payments in consideration for a grant of equity of the LICENSEE at fair market value; (d) amounts paid for supplies of product or other tangible materials;
(e) amounts paid as reimbursement for expenses directly related to the pursuit, maintenance, and/or defense of PATENT RIGHTS; (f) milestone payments by a sublicensee for a product, service, or method that is not a LICENSED PRODUCT,
LICENSED SERVICE, or LICENSED METHOD; (g) payments by a sublicensee for use of the BIOLOGICAL MATERIALS to identity or optimize products, services, or methods that are not LICENSED PRODUCTS, LICENSED SERVICES, or LICENSED METHODS;
(h) withholding taxes and any other amounts by a sublicensee from amounts otherwise payable to LICENSEE under such sublicense agreement other than past due payments; and (i) payments for the supply of LICENSED PRODUCTS or materials used in
the performance of LICENSED SERVICES or LICENSED METHODS. Without limiting the foregoing, the parties agree that NON-ROYALTY SUBLICENSE REVENUE shall not include consideration received by LICENSEE from a
sublicensee that is not received in consideration for the grant of rights under the PATENT RIGHTS to make, use, offer for SALE, import, and SELL LICENSED PRODUCTS and LICENSED SERVICES, and to practice LICENSED METHODS. 

 

	 	2.14	 “EARNED ROYALTY SUBLICENSE REVENUE” means any royalty payments received by LICENSEE pursuant to an
agreement between LICENSEE and a sublicensee pursuant to which such sublicensee receives a sublicense under the PATENT RIGHTS, on SALES of LICENSED PRODUCTS, LICENSED 

  
 Page 7 of 35 

 

			
	4D Molecular Therapeutics LLC	  	Exclusive License
	UC Case No.: B03-104	  	Confidential

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

	 	
SERVICES and LICENSED METHODS by such sublicensee (which sales shall not be included as NET SALES). 

  

	 	2.15	 “FIRST QUALIFIED ROUND” occurs on the first date on which the LICENSEE has received, in aggregate in
excess of [***] US Dollars ($[***]) from any one of or combination of equity financing, convertible debt financing, unrestricted grants, or the acquisition of all or substantially all of LICENSEE’s limited liability company interests, assets or
business; provided, however, that [***]. 

  

	 	2.16	 “FOUNDERS” means [***] and [***]. 

 

	 	2.17	 “PHASE I CLINICAL TRIAL” means a human clinical trial in any country that would satisfy the
requirements of 21 CFR 312.21(a). 

  

	 	2.18	 “PHASE IIB CLINICAL TRIAL” means a human clinical trial in any country that would satisfy the
requirements of 21 CFR 312.21(b) and that is designed to support and immediately precede the initiation of a Phase III Clinical Trial without any further phase II trials by evaluating the dose-dependent effectiveness of a pharmaceutical product for
a particular indication or indications in patients with the disease or condition under study and to determine the common side effects and risks associated with the pharmaceutical product. 

 

	 	2.19	 “PHASE III CLINICAL TRIAL” means a human clinical trial in any country that would satisfy the
requirements of 21 CFR 312.21(c). 

  

	 	2.20	 “REGENTS’ PROPERTY RIGHTS” means all of REGENTS’ personal property rights in the tangible
property in the INVENTION licensed hereunder and to the BIOLOGICAL MATERIALS. REGENTS’ PROPERTY RIGHTS do not include PATENT RIGHTS. 

  

	 	2.21	 “BIOLOGICAL MATERIALS” shall have the meaning set forth in Article 1 of the Letter Agreement between
REGENTS and LICENSEE, dated as of even date herewith (the “MTA”). 

  

	3.	 GRANT 

  

	 	3.1        (a)	 Subject to the limitations set forth in this Agreement, and the rights reserved in Paragraph 3.3, REGENTS
hereby grants and LICENSEE hereby accepts an exclusive license under PATENT RIGHTS to make, use, offer for SALE, import, and SELL LICENSED PRODUCTS and LICENSED SERVICES, and to practice LICENSED METHODS, in the LICENSED FIELD OF USE in the LICENSED
TERRITORY. 

  

	 	(b)	 Subject to the limitations set forth in this Agreement, REGENTS hereby grants and LICENSEE hereby accepts an
exclusive bailment and license under REGENTS’ PROPERTY RIGHTS to possess, make and use the BIOLOGICAL MATERIAL. LICENSEE acknowledges that the 

  
 Page 8 of 35 

 

			
	4D Molecular Therapeutics LLC	  	Exclusive License
	UC Case No.: B03-104	  	Confidential

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

	 	
REGENTS is and will remain the sole owner of the BIOLOGICAL MATERIAL and the title of the material is not transferred to LICENSEE under this Agreement. 

 

	 	(c)	 REGENTS have provided the LICENSEE with BIOLOGICAL MATERIAL in quantities as set forth in the MTA. No
additional obligation is required of REGENTS’ with respect to bailment of the BIOLOGICAL MATERIAL. 

 This Agreement
is subject to IGT’s rights under the IIA. 
  

	 	3.2	 The licenses under Paragraph 3.1 will be exclusive for a term commencing on the Effective Date and ending on
the date of the last-to-expire VALID CLAIM under PATENT RIGHTS. 

  

	 	3.3	 Nothing in this Agreement will be deemed to limit the right of REGENTS and IGT to publish any and all technical
data resulting from any research performed by REGENTS and IGT relating to the INVENTION and the BIOLOGICAL MATERIAL REGENTS and IGT expressly reserve the right to use the INVENTION, the BIOLOGICAL MATERIAL and related technology for its educational
and research purposes; to disseminate the BIOLOGICAL MATERIAL and other tangible materials associated with, or required to practice the INVENTION and/or the PATENT RIGHTS to researchers at nonprofit institutions for their educational and research
purposes and to permit other nonprofit institutions to use such BIOLOGICAL MATERIAL to practice the PATENT RIGHTS for education and research purposes. 

  

	 	3.4	 This Agreement will terminate immediately if LICENSEE files a claim asserting that any portion of the PATENT
RIGHTS is invalid or unenforceable where the filing is by the LICENSEE, a third party on behalf of the LICENSEE, or a third party at the written urging of the LICENSEE. 

 

	 	3.5	 LICENSEE will have a continuing responsibility to keep REGENTS informed of the large/small entity status, as
defined in 15 U.S.C. 632, of itself and its sublicensees. 

  

	4.	 SUBLICENSES 

  

	 	4.1	 REGENTS also grants to LICENSEE the right to sublicense to AFFILIATES and third parties the right to make, use,
offer for SALE, import, and SELL LICENSED PRODUCTS and LICENSED SERVICES, and to practice LICENSED METHODS, provided that LICENSEE has exclusive rights under this Agreement at the time of sublicensing. LICENSEE will notify REGENTS of each sublicense
granted hereunder and furnish to REGENTS a copy of each such sublicense agreement, which shall be treated as confidential information of LICENSEE. Every such sublicense will include: 

  
 Page 9 of 35 

 

			
	4D Molecular Therapeutics LLC	  	Exclusive License
	UC Case No.: B03-104	  	Confidential

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

	 	(a)	 a statement setting forth the term after which LICENSEE’s exclusive rights, privileges, and license
hereunder will expire; 

  

	 	(b)	 as applicable, all the rights of, and require the performance of all the obligations due to, REGENTS under this
Agreement, other than those rights and obligations specified in Article 5 (License Issue Fee) and Article 6 (Royalties), for which LICENSEE shall remain responsible; and 

 

	 	(c)	 the same provision for indemnification of REGENTS as has been provided for in this Agreement.

  

	 	4.2	 To the extent permitted under the sublicense agreement, a sublicensee shall have the right to grant further
sublicenses to its AFFILIATE and third parties to the extent such sublicensee deems such further sublicense to be commercially reasonable, useful or necessary for the development and/or commercialization of LICENSED PRODUCT(S) or LICENSED METHOD(S)
in accordance with this Agreement; provided that (i) such further sublicense is subject to a written sublicense agreement and is bound by all of the applicable terms, conditions, obligations, restrictions and other covenants of this Agreement
that protect or benefit the REGENTS’ rights and interests under this Agreement, and (ii) the sublicensee shall, within [***] ([***]) days after issuing any further sublicense, furnish to LICENSEE for delivery to REGENTS, subject to any
confidentiality provisions with third parties, all material terms of any such sublicenses, pertaining to the REGENTS’ interests, including the sublicensee’s name and address, and indemnification of REGENTS as provided in this Agreement.

  

	 	4.3	 LICENSEE will pay to REGENTS (i) [***] percent ([***]%) of NON-ROYALTY
SUBLICENSE REVENUE and (ii) [***] percent ([***]%) of EARNED ROYALTY SUBLICENSE REVENUE, provided that in no event will the EARNED ROYALTY SUBLICENSE REVENUE due to REGENTS on sales of LICENSED PRODUCTS, LICENSED SERVICES and LICENSED METHODS by a
sublicensee be less than [***] percent ([***]%) of net sales of such sublicensee (which for purposes of this Paragraph 4.3 shall be calculated as though such sublicensee were LICENSEE under Paragraph 2.6. 

 

	 	(a)	 In the event LICENSEE sublicenses the PATENT RIGHTS along with its own patent rights or those of other third
parties, LICENSEE may reasonably determine in good faith the percentage of compensation received under such sublicense that represents consideration due for the grant of the rights under the PATENT RIGHTS, which percentage will be based upon the
value of the PATENT RIGHTS licensed to the sublicensee relative to the value of LICENSEE’s own patent rights or the other third party patent rights licensed to the sublicensee. When making payment under this Paragraph 4.3(a), LICENSEE shall
provide REGENTS with all supporting information and documentation used to determine any such percentage (or shall reference previously provided supporting information and documentation).

  
 Page 10 of 35 

 

			
	4D Molecular Therapeutics LLC	  	Exclusive License
	UC Case No.: B03-104	  	Confidential

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

	 	
Notwithstanding the foregoing, in no case will LICENSEE be permitted to reduce the compensation to REGENTS under this Paragraph 4.3(a) in connection with LICENSEE’s own patent rights or
those of third parties by more than [***] percent ([***]%). 

  

	 	(b)	 If the consideration received is equity and approval to accept equity is granted by REGENTS, then the LICENSEE
will transfer [***] percent ([***]%) of the equity LICENSEE receives to REGENTS or REGENTS’ nominee. REGENTS will promptly notify the LICENSEE upon REGENTS’ Office of the President’s approval for the equity. If equity is not accepted,
then the LICENSEE will pay REGENTS’ portion in cash once the equity is liquidated. 

  

	 	(c)	 LICENSEE shall not be required to pay REGENTS more than [***] percent ([***]%) of NON-ROYALTY SUBLICENSE REVENUE and [***] percent ([***]%) of EARNED ROYALTY SUBLICENSE REVENUE even if LICENSEE sublicenses the PATENT RIGHTS under this Agreement and the patent rights under the OTHER LICENSE
AGREEMENT. All amounts paid under this Paragraph 4.3 shall be credited against amounts due for the same LICENSED PRODUCT, LICENSED METHOD or LICENSED SERVICE under Paragraph 4.3 of the OTHER LICENSE AGREEMENT. 

 

	 	4.4	 AFFILIATES will have no licenses under PATENT RIGHTS except as granted by sublicense pursuant to this
Agreement. 

  

	 	4.5	 For the purposes of this Agreement, the activities of all sublicensees pursuant to any sublicense shall be
deemed to be the activities of LICENSEE, for which LICENSEE shall be responsible. 

  

	 	4.6	 LICENSEE will collect payment of all monies and other consideration due REGENTS from sublicensees, and deliver
all reports due REGENTS and received from sublicensees. 

  

	 	4.7	 Upon termination of this Agreement for any reason, all sublicenses that are granted by LICENSEE pursuant to
this Agreement, where the sublicensee is in compliance with its sublicense agreement as of the date of such termination, will remain in effect and will be assigned to REGENTS, except that REGENTS will not be bound to perform any duties or
obligations set forth in any sublicenses that extend beyond the duties and obligations of REGENTS set forth in this Agreement. 

  

	 	4.8	 If REGENTS (to the extent of the actual knowledge of the licensing professional responsible for administration
of this case) discovers, or a third party discovers and notifies that licensing professional, that the INVENTION is [***] for an application covered by the LICENSED FIELD OF USE, but for which LICENSED PRODUCTS have not been developed or are not
currently under development by LICENSEE, then REGENTS, as represented by the Office of Technology 

  
 Page 11 of 35 

 

			
	4D Molecular Therapeutics LLC	  	Exclusive License
	UC Case No.: B03-104	  	Confidential

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

	 	
Licensing, shall give written notice to LICENSEE, except for: (1) information that is subject to restrictions of confidentiality with third parties, and (2) information which originates
with REGENTS’ personnel who do not assent to its disclosure to LICENSEE. REGENTS shall endeavor to provide to LICENSEE, at a minimum, a description of the nature and scope of the proposed sublicense sufficient for LICENSEE to evaluate its
desire to develop and commercialize products for the relevant application as provided in this Paragraph 4.8. 

 LICENSEE shall
have [***] ([***]) days to give REGENTS written notice stating whether LICENSEE elects to develop LICENSED PRODUCTS for such application. 

If LICENSEE elects to develop and commercialize the proposed LICENSED PRODUCTS for such application, LICENSEE shall submit progress reports
with respect thereto to REGENTS pursuant to Article 8. 
 If LICENSEE elects not to develop and commercialize the proposed LICENSED PRODUCTS
for such application, REGENTS may seek a third party(ies) to develop and commercialize the proposed LICENSED PRODUCTS for such application. If REGENTS is successful in finding a third party, it shall refer such third party to LICENSEE. If the third
party requests a sublicense under this Agreement for such application, then LICENSEE shall report the request to REGENTS within [***] ([***]) days from the date of such written request. If the request results in a sublicense, then LICENSEE shall
notify REGENTS pursuant to Paragraph 4.1. 
 If LICENSEE refuses to grant a sublicense to such third party, then within [***] ([***]) days
after such refusal, LICENSEE shall submit to REGENTS a report specifying the license terms proposed by the third party and a written justification for LICENSEE’s refusal to grant the proposed sublicense. If REGENTS, [***], determines that
[***], then REGENTS shall [***], provided that [***]. 
  

	5.	 LICENSE ISSUE FEE 

 

	 	5.1	 LICENSEE will pay to REGENTS a non-creditable, non-refundable license issue fee as follows: 

  

	 	(a)	 Five Thousand U.S. Dollars ($5,000) within [***] ([***]) days following the Effective Date of this Agreement;

  

	 	(b)	 If approval to accept equity in LICENSEE is granted by REGENTS in accordance with this Agreement, then within
[***] ([***]) days following the date on which the ACCEPTANCE NOTICE (as defined below) is received by the LICENSEE, LICENSEE shall issue to REGENTS’ nominee (under the terms of a mutually agreed upon unit purchase agreement to be executed by
the parties), an interest in LICENSEE (a “MEMBERSHIP INTEREST”) which shall be non-voting, with an allocation percentage with 

  
 Page 12 of 35 

 

			
	4D Molecular Therapeutics LLC	  	Exclusive License
	UC Case No.: B03-104	  	Confidential

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

	 	
respect to profits and losses equal to three percent (3%) as of close of the FIRST QUALIFIED ROUND; if all or a portion of the FIRST QUALIFIED ROUND involves convertible securities which will not
convert into MEMBERSHIP INTERESTS until a subsequent financing event, then at the time of the conversion of those securities into MEMBERSHIP INTERESTS, the LICENSEE shall issue additional MEMBERSHIP INTERESTS to REGENTS such that REGENTS’
allocation percentage with respect to profits and losses continues to equal three percent (3%) as of the FIRST QUALIFIED ROUND (following the conversion of any convertible securities such as convertible debt issued at the FIRST QUALIFIED ROUND).
LICENSEE further agrees that as holders of MEMBERSHIP INTERESTS REGENTS shall receive the same anti-dilution treatment as any other MEMBERSHIP INTERESTS held by either of the FOUNDERS as of the date of this
Agreement. REGENTS may transfer or direct LICENSEE to transfer an inventor share portion of the MEMBERSHIP INTERESTS to be issued pursuant to this Section 5.1(b) under REGENTS’ patent policy of the shares otherwise due to REGENTS to the
REGENTS’ inventors of PATENT RIGHTS notwithstanding the provisions of other contracts associated with the transfer of the shares. 

LICENSEE will promptly notify REGENTS following the close of the FIRST QUALIFIED ROUND. Following receipt of notice of the closing of the
FIRST QUALIFIED ROUND, REGENTS will promptly notify the LICENSEE upon REGENTS’ Office of the President’s approval for the equity (the “ACCEPTANCE NOTICE”). If REGENTS’ Office of the President does not provide an ACCEPTANCE
NOTICE to LICENSEE within [***] ([***]) days following the close of the FIRST QUALIFIED ROUND, then Fifty Thousand U.S. Dollars ($50,000) shall be due [***] in lieu of the MEMBERSHIP INTERESTS to be issued under this Section 5.1(b). 

 

	 	5.2	 LICENSEE will also pay to REGENTS a license maintenance fee of Five Thousand U.S. Dollars ($5,000) on the one
(1) year anniversary date of the Effective Date and on each anniversary of the Effective Date thereafter. Notwithstanding the foregoing, the license maintenance fee will not be due and payable on any anniversary of the Effective Date, if on
such date the LICENSEE or a sublicensee is selling or otherwise exploiting LICENSED PRODUCTS or LICENSED METHODS, and LICENSEE pays an earned royalty to REGENTS on the NET SALES of such LICENSED PRODUCTS or LICENSED METHODS or a payment on EARNED
ROYALTY SUBLICENSE REVENUE. 

  

	6.	 ROYALTIES 

  

	 	6.1	 LICENSEE will pay to REGENTS earned royalties at the rate of [***] percent ([***]%) of NET SALES of LICENSEE,
subject to the following: 

  
 Page 13 of 35 

 

			
	4D Molecular Therapeutics LLC	  	Exclusive License
	UC Case No.: B03-104	  	Confidential

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

	 	(a)	 If LICENSEE is required to make any payment (including royalties or other license fees) to a third party to
obtain any intellectual property rights in the absence of which LICENSEE could not practice PATENT RIGHTS, such third party payments will be credited against royalties owed hereunder by LICENSEE to REGENTS, provided that in no one [***] will the
total of such credits reduce earned royalties owed by LICENSEE to REGENTS by more than [***] percent ([***]%). 

  

	 	(b)	 In the event a LICENSED PRODUCT, LICENSED SERVICE or LICENSED METHOD are SOLD to end users, and the total
combined royalty burden to LICENSEE on NET SALES (including royalties due to REGENTS under this Agreement and royalties due to third parties on such NET SALES) exceeds [***] percent ([***]%), the earned royalty due to REGENTS will be adjusted,
according to the following formula, [***]: 

 Adjusted royalty = [***] 

For example, [***]. 
  

	 	(c)	 Only one royalty will be due to REGENTS on any given LICENSED PRODUCT, LICENSED METHOD and LICENSED SERVICE.
All amounts paid under this Paragraph 6.1 shall be credited against amounts due for the same LICENSED PRODUCT, LICENSED METHOD or LICENSED SERVICE under Paragraph 6.1 of the OTHER LICENSE AGREEMENT. 

 

	 	6.2	 Royalties accruing to REGENTS will be paid to REGENTS [***] within [***] ([***]) days after the end of
each [***]. 

  

	 	6.3	 Royalties will be payable on NET SALES of LICENSED PRODUCTS, LICENSED METHODS and LICENSED SERVICES covered by
VALID CLAIMS of both pending patent applications and issued patents. 

  

	 	6.4	 LICENSEE will pay to REGENTS milestone payments as follows, provided that all amounts paid under this Paragraph
6.4 shall be credited against amounts due with respect to NON-ROYALTY SUBLICENSE REVENUE pursuant to Paragraph 4.3: 

  

	 	(a)	 LICENSEE shall pay to REGENTS a milestone payment of [***] U.S. Dollars ($[***]) within [***] ([***]) days of
[***] for the first LICENSED PRODUCT or LICENSED METHOD and; 

  

	 	(b)	 LICENSEE shall pay to REGENTS a milestone payment of [***] U.S. Dollars ($[***]) within [***] ([***]) days of
[***] for the first LICENSED PRODUCT or LICENSED METHOD; 

  
 Page 14 of 35 

 

			
	4D Molecular Therapeutics LLC	  	Exclusive License
	UC Case No.: B03-104	  	Confidential

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

	 	(c)	 LICENSEE will pay to REGENTS a milestone payment of [***] U.S. Dollars ($[***]) within [***] ([***]) days of
[***] for the first LICENSED PRODUCT or LICENSED METHOD; 

  

	 	(d)	 LICENSEE will pay to REGENTS a milestone payment of [***] U.S. Dollars ($[***]) within [***] ([***]) days of
[***] for the first LICENSED PRODUCT or LICENSED METHOD; 

  

	 	(e)	 LICENSEE will pay to REGENTS a milestone payment of [***] U.S. Dollars ($[***]) within [***] ([***]) days of
[***] for the first LICENSED PRODUCT or LICENSED METHOD; and 

  

	 	(f)	 LICENSEE will pay to REGENTS a milestone payment of [***] U.S. Dollars ($[***]) within [***] ([***]) days of
[***] for the first LICENSED PRODUCT or LICENSED METHOD, [***]. 

 Only the milestones listed in this Paragraph 6.4 will be
due on any given LICENSED PRODUCT or LICENSED METHOD, even if such milestone is payable under this Agreement and under the OTHER LICENSE AGREEMENT. All amounts paid under this Paragraph 6.4 shall be credited against amounts due for the same LICENSED
PRODUCT or LICENSED METHOD under Paragraph 6.4 of the OTHER LICENSE AGREEMENT. 
  

	 	6.5	 Beginning in the first calendar year after the year in which the first occurrence of NET SALES takes place, and
each succeeding calendar year thereafter, LICENSEE will pay to the REGENTS a minimum annual royalty of [***] U.S. Dollars ($[***]), increasing by [***] Dollars ($[***]) every year thereafter but capped at a total of One Hundred Thousand Dollars
($100,000) per year in minimum royalties for the remainder of the term of this Agreement. This minimum annual royalty will be paid to REGENTS by [***] of the year following each applicable calendar year and will be credited against by the earned
royalties (including royalty payments based on NET SALES and payments based on EARNED ROYALTY SUBLICENSE REVENUE due pursuant to Sections 6.1 and 4.3, respectively) paid for the [***] calendar year for which the minimum payment is made, whether
under this Agreement or the OTHER LICENSE AGREEMENT. 

 Only one minimum annual royalty will be due under this Agreement
and under the OTHER LICENSE AGREEMENT. All amounts paid under this Paragraph 6.5 shall be credited against amounts due under Paragraph 6.5 of the OTHER LICENSE AGREEMENT. 
  

	 	6.6	 All payments due REGENTS will be payable in United States dollars. When LICENSED PRODUCTS, LICENSED SERVICES,
or LICENSED METHODS are SOLD for monies other than United States dollars, earned royalties will first be determined in the foreign currency of the country in which the SALE was made and then converted into equivalent United States dollars. The
exchange rate will be that rate quoted in the Wall Street Journal on the last business day of the reporting period. 

  
 Page 15 of 35 

 

			
	4D Molecular Therapeutics LLC	  	Exclusive License
	UC Case No.: B03-104	  	Confidential

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

	 	6.7	 In the event that any royalties or other payments due to REGENTS are subject to withholding tax required by
applicable law to be paid by LICENSEE to the taxing authority of any foreign country on REGENTS’ behalf, LICENSEE may deduct the amount of such tax from the applicable royalties or other payment otherwise payable to REGENTS. In such event,
LICENSEE shall pay the taxes to the proper taxing authority and shall send evidence of the obligation together with proof of payment to REGENTS following such payment and shall reasonably cooperate with REGENTS in its efforts to avoid or minimize
such withholding obligations and/or to obtain credit for payment thereof. To the extent that such amounts are so withheld and remitted to the proper taxing authority by LICENSEE, such withheld amounts shall be treated for all purposes of this
Agreement as having been paid to the party in respect of whom such deduction and withholding was made. LICENSEE will be responsible for all bank transfer charges. 

 

	 	6.8	 LICENSEE will make all payments under this Agreement by check payable to “The Regents of the University of
California” and sent to REGENTS at the address shown in Article 23 (Notices). 

  

	 	6.9	 For the avoidance of doubt, if any patent or patent application, or any claim thereof, included within PATENT
RIGHTS expires or is held invalid in a final decision by a court of competent jurisdiction and last resort and from which no appeal has been or can be taken, all obligation to pay royalties based on such patent, patent application or claim, or any
claims patentably indistinct therefrom will cease as of the date of such expiration or final decision. LICENSEE will not, however, be relieved from paying any royalties that accrued before such expiration or decision or that are based on another
valid patent or claim not expired or involved in such decision. 

  

	 	6.10	 No royalties will be collected or paid hereunder on LICENSED PRODUCTS, LICENSED SERVICES, and LICENSED METHODS
distributed to or used by the United States Government. LICENSEE agrees to reduce the amount charged for LICENSED PRODUCTS, LICENSED SERVICES, and LICENSED METHODS distributed to the United States Government by an amount equal to the royalty for
such LICENSED PRODUCTS otherwise due REGENTS as provided herein. 

  

	7.	 DUE DILIGENCE 

 

	 	7.1	 LICENSEE, upon execution of this Agreement, will diligently proceed with the development, manufacture, and SALE
of LICENSED PRODUCTS, LICENSED SERVICES, and LICENSED METHODS, and will diligently market them in quantities sufficient to meet the market demand. 

  
 Page 16 of 35 

 

			
	4D Molecular Therapeutics LLC	  	Exclusive License
	UC Case No.: B03-104	  	Confidential

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

	 	7.2	 In addition to its obligations under Paragraph 7.1, LICENSEE will perform the following due diligence
activities under this Agreement, through itself and/or its sublicensees: 

  

	 	(a)	 [***] within [***] ([***]) months after the Effective Date. 

 

	 	(b)	 [***] within [***] ([***]) months of [***]. 

 

	 	(c)	 [***] within [***] ([***]) months after [***]. 

 

	 	(d)	 [***] within [***] ([***]) months of [***]. 

 

	 	(e)	 [***] within [***] ([***]) months after [***]. 

If LICENSEE has failed to meet any of its diligence obligations set forth in Paragraphs 7.1 and 7.2, through itself and/or its sublicensees, as
applicable, then REGENTS will so notify LICENSEE in writing of its failure to perform. 
  

	 	7.3	 LICENSEE will have the right and option to extend the target date of any such due diligence obligation (and
each subsequent milestone due thereafter) for a period of [***] ([***]) months upon the payment of [***] dollars ($[***]) within [***] ([***]) days after the date to be extended, for each such extension option exercised by LICENSEE. LICENSEE may
further extend the target date of any diligence obligation (and each subsequent milestone due thereafter) for an additional [***] ([***]) months upon payment of an additional [***] dollars ($[***]). These payments are in addition to the minimum
royalty payments specified in Paragraph 6.5. Additional extensions may be granted only by mutual written agreement of the parties to this Agreement. In the event that Licensee is unable to meet the timeframes in Paragraph 7.2, as extended by this
Paragraph 7.3, despite using diligent efforts to do so, taking into account delays which are due to factors (including technical or regulatory issues) which are outside of the reasonable control of LICENSEE, REGENTS and LICENSEE agree to discuss
extending such timeframes and target dates in good faith; provided, however, that in no case is REGENTS bound to agree to cumulative extensions longer than [***] ([***]) years unless REGENTS concludes in its sole discretion that such
an extension is appropriate. 

  

	 	7.4	 Should LICENSEE opt not to extend such timeframes or fail to use diligent efforts to meet a diligence
obligation by the extended target date, then subject to Paragraph 7.6, REGENTS will have the right and option either to terminate this Agreement or to reduce LICENSEE’s exclusive license to a
non-exclusive royalty-bearing license. This right, if exercised by REGENTS, supersedes the rights granted in Article 3. The right to terminate this Agreement or reduce
LICENSEE’s exclusive license granted hereunder to a non-exclusive license will be REGENTS’ sole remedy for breach of Paragraphs 7.1 or 7.2. 

  
 Page 17 of 35 

 

			
	4D Molecular Therapeutics LLC	  	Exclusive License
	UC Case No.: B03-104	  	Confidential

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

	 	7.5	 At the request of either party, any controversy or claim arising out of or relating to the diligence provisions
of Paragraphs 7.1 and 7.2 will be settled by arbitration conducted in San Francisco, California in accordance with the then current Commercial Arbitration Rules of the American Arbitration Association but such arbitration must be requested by a
party within the sixty (60) day cure period set forth in Paragraph 7.6, except as otherwise provided in Paragraph 7.6 or unless the parties mutually agree later to arbitration hereunder. Judgment upon the award rendered by the arbitrator(s)
will be binding on the parties and may be entered by either party in any court having jurisdiction. In determination of due diligence, the arbitrator may determine solely the issues of fact or law with respect to LICENSEE’s rights under this
Agreement but will not have the authority to award monetary damages or grant equitable relief. 

  

	 	7.6	 To exercise either the right to terminate this Agreement or to reduce the license to a non-exclusive license for lack of diligence under Paragraphs 7.1 or 7.2, REGENTS will give LICENSEE written notice of the deficiency. LICENSEE thereafter has sixty (60) days to cure the deficiency or to request
arbitration in accordance with Paragraph 7.5. If REGENTS has not received a written request for arbitration or satisfactory tangible evidence that the deficiency has been cured by the end of the sixty (60) day period, then REGENTS may, at its
option, either terminate this Agreement or reduce LICENSEE’s exclusive license to a non-exclusive license by giving further written notice to LICENSEE. These notices will be subject to Article 23
(Notices). Notwithstanding the foregoing, in the event that LICENSEE disputes in good faith whether the deficiency was timely cured, it may seek resolution of such dispute pursuant to Article 7.5, and in such event, no termination of this Agreement
pursuant to this Article 7.6 may occur unless and until completion of such dispute resolution results in a determination that such deficiency has not been timely cured. 

 

	8.	 PROGRESS AND ROYALTY REPORTS 

 

	 	8.1	 For each [***] period beginning July 1, 2014, LICENSEE will submit to REGENTS a [***] progress report
covering LICENSEE’s activities related to the development and testing of all LICENSED PRODUCTS, LICENSED SERVICES and LICENSED METHODS and the obtaining of necessary governmental approvals, if any, for marketing in the United States. These
progress reports will be made for all development activities until the first SALE occurs in the United States. 

  

	 	8.2	 Each progress report will be a sufficiently detailed summary of activities of LICENSEE and any sublicensees so
that REGENTS may evaluate and determine LICENSEE’s progress in development of LICENSED PRODUCTS, LICENSED SERVICES, and LICENSED METHODS, and in meeting its diligence obligations under Article 7, and will include (but not be limited to) the
following: summary of work completed and in progress; current schedule of anticipated events and milestones, including diligence milestones under Paragraph 7.2; anticipated market introduction dates for the LICENSED TERRITORY; and sublicensees’
activities during the reporting period. 

  
 Page 18 of 35 

 

			
	4D Molecular Therapeutics LLC	  	Exclusive License
	UC Case No.: B03-104	  	Confidential

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

	 	8.3	 LICENSEE also will report to REGENTS in its subsequent progress and royalty reports, the date of first SALE.

  

	 	8.4	 After the first SALE anywhere in the world, LICENSEE will make [***] royalty reports to REGENTS within [***]
([***]) days after [***]. Each such royalty report will include at least the following: 

  

	 	(a)	 The number of LICENSED PRODUCTS manufactured and the number SOLD; 

 

	 	(b)	 Gross revenue from SALE of LICENSED PRODUCTS, LICENSED SERVICES and LICENSED METHODS; 

 

	 	(c)	 NET SALES pursuant to Paragraph 2.6; 

 

	 	(d)	 Total royalties due REGENTS; and 

 

	 	(e)	 Names and addresses of any new sublicensees. 

 

	 	8.5	 If no SALES have occurred during the reporting period, a statement to this effect is required in the royalty
report for that period. 

  

	 	8.6	 All reports under this Article 8 shall be treated as confidential information of LICENSEE.

  

	9.	 BOOKS AND RECORDS 

 

	 	9.1	 LICENSEE will keep full, true, and accurate books and records containing all particulars that are necessary for
the purpose of showing the amount of royalties payable to REGENTS and LICENSEE’s compliance with other obligations under this Agreement. Said books and records will be kept at LICENSEE’s principal place of business or the principal place
of business of the appropriate division of LICENSEE to which this Agreement relates. Said books and records and the supporting data will be open at all reasonable times during normal business hours upon reasonable notice, for [***] ([***]) years
following the end of the calendar year to which they pertain, for the inspection and audit by a mutually acceptable independent auditor engaged by REGENTS for the purpose of verifying LICENSEE’s royalty statement or compliance in other respects
with this Agreement. Such auditor will be bound to hold all information in confidence except as necessary to communicate LICENSEE’s non-compliance with this Agreement to REGENTS. 

 

	 	9.2	 The fees and expenses of REGENTS’ mutually acceptable independent auditor performing such an examination
will be borne by REGENTS. However, if an error 

  
 Page 19 of 35 

 

			
	4D Molecular Therapeutics LLC	  	Exclusive License
	UC Case No.: B03-104	  	Confidential

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

	 	
in underpaid royalties to REGENTS of more than [***] percent ([***]%) of the total royalties due for any year is discovered, then the fees and expenses of such auditor will be borne by LICENSEE.

  

	10.	 LIFE OF THE AGREEMENT 

 

	 	10.1	 Unless otherwise terminated by the operation of law or by acts of the parties in accordance with the terms of
this Agreement, this Agreement will be in force from the Effective Date and will remain in effect until the expiration of the last VALID CLAIM under this Agreement. 

 

	 	10.2	 Any termination of this Agreement shall not affect the rights and obligations set forth in the following
articles or paragraphs: 

  

			
	Article 2	  	Definitions
		
	Article 4	  	Sublicenses (only as to Paragraphs 4.2 and 4.7)
		
	Article 9	  	Books and Records
		
	Article 10	  	Life of the Agreement (only as to Paragraphs 10.2 and 10.3)
		
	Article 13	  	Disposition of Licensed Products Upon Termination
		
	Article 16	  	Use of Names and Trademarks
		
	Article 17	  	Limited Warranties
		
	Article 19	  	Indemnification and Insurance
		
	Article 23	  	Notices
		
	Article 24	  	Late Payments (only as to outstanding payments)
		
	Article 26	  	Confidentiality
		
	Article 28	  	Severability
		
	Article 29	  	Applicable Law; Venue; Attorney’s Fees

  

	 	10.3	 Any termination of this Agreement will not relieve LICENSEE of its obligation to pay any monies due or owing at
the time of such termination and will not relieve any obligations, of either party to the other party, established prior to termination. 

  

	11.	 TERMINATION BY REGENTS 

 

	 	11.1	 Except for breach of diligence obligations, which is set forth in Article 7, if LICENSEE should violate or fail
to perform any term of this Agreement, then 

  
 Page 20 of 35 

 

			
	4D Molecular Therapeutics LLC	  	Exclusive License
	UC Case No.: B03-104	  	Confidential

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

	 	
REGENTS may give written notice of such default (“Notice of Default”) to LICENSEE. If LICENSEE should fail to repair such default within sixty (60) days of the effective date of
such notice, REGENTS will have the right to terminate this Agreement, and the licenses herein, by a second written notice (“Notice of Termination”) to LICENSEE. If a Notice of Termination is sent to LICENSEE, this Agreement will
automatically terminate on the effective date of such notice. Such termination will not relieve LICENSEE of its obligation to pay any royalty or license fees accrued at the time of such termination and will not impair any accrued rights of REGENTS.
These notices will be subject to Article 23 (Notices). 

  

	12.	 TERMINATION BY LICENSEE 

 

	 	12.1	 LICENSEE will have the right at any time to terminate this Agreement in whole or as to any portion of PATENT
RIGHTS by giving notice in writing to REGENTS. Such notice of termination will be subject to Article 23 (Notices) and termination of this Agreement will be effective ninety (90) days after the effective date of such notice.

  

	 	12.2	 Any termination pursuant to Paragraph 12.1 will not relieve LICENSEE of any obligation or liability accrued
hereunder prior to such termination or rescind anything done by LICENSEE or any payments made to REGENTS hereunder prior to the time such termination becomes effective, and such termination will not affect in any manner any rights of REGENTS arising
under this Agreement prior to such termination. 

  

	13.	 DISPOSITION OF LICENSED PRODUCTS UPON TERMINATION 

 

	 	13.1	 Upon termination of this Agreement by either party, for a period of [***] ([***]) days after the date of
termination, LICENSEE may complete and SELL any partially made LICENSED PRODUCTS and continue to render any previously commenced LICENSED SERVICES, and continue the practice of LICENSED METHODS; provided, however, that all such SALES will be subject
to the terms of this Agreement including, but not limited to, the payment of royalties at the rate and at the time provided herein and the rendering of reports thereon. 

 

	14.	 PATENT PROSECUTION AND MAINTENANCE 

 

	 	14.1	 REGENTS will diligently prosecute and maintain the United States and foreign patent applications and patents
under PATENT RIGHTS, subject to LICENSEE’S reimbursement of REGENTS’ out of pocket costs under Article 14.3 below. All patent applications and patents under PATENT RIGHTS will be held in the name of REGENTS and IGT. REGENTS will have sole
responsibility for retaining and instructing patent counsel, but continued use of such counsel at any point in the patent prosecution process, subsequent to the initial filing of a U.S. patent application covering the INVENTION, shall be subject to
the approval of LICENSEE. If LICENSEE rejects [***] of REGENTS’ choice of prosecution counsel, then REGENTS may select new prosecution counsel without 

  
 Page 21 of 35 

 

			
	4D Molecular Therapeutics LLC	  	Exclusive License
	UC Case No.: B03-104	  	Confidential

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

	 	
LICENSEE’s consent. REGENTS shall promptly provide LICENSEE with copies of all relevant documentation, including all responses at least [***] ([***]) days prior to the anticipated filing
deadline to the extent such advance notice is available, so that LICENSEE may be currently informed and apprised of the continuing prosecution of PATENT RIGHTS. LICENSEE agrees to keep this documentation confidential in accordance with Article 26.
LICENSEE may comment upon such documentation, and REGENTS will reasonably consider all such comments made by LICENSEE; provided, however, that if LICENSEE has not commented upon such documentation in reasonable time for REGENTS to sufficiently
consider LICENSEE’s comments prior to the deadline for filing a response with the relevant government patent office, REGENTS will be free to respond appropriately without consideration of LICENSEE’s comments. LICENSEE and LICENSEE’s
patent counsel will have the right to consult with patent counsel chosen by REGENTS. REGENTS will file foreign counterparts of the REGENTS’ PATENT RIGHTS in countries selected by LICENSEE, subject to Paragraph 14.4. 

 

	 	14.2	 REGENTS will use reasonable efforts to prepare or amend any patent application to include claims reasonably
requested by LICENSEE to protect the LICENSED PRODUCTS, LICENSED SERVICES and LICENSED METHODS contemplated to be SOLD or to be practiced under this Agreement. REGENTS will not abandon a patent application (unless filing a continuation or divisional
filing or an equivalent thereof) or fail to maintain a patent without LICENSEE’s prior written consent. 

  

	 	14.3	 Subject to Paragraph 14.4, one half (1/2) of the past, unreimbursed costs for preparing, filing, prosecuting,
and maintaining all United States and foreign patent applications and patents under PATENT RIGHTS will be paid by LICENSEE within [***] ([***]) days of the Effective Date of this Agreement. The remaining other one half (1/2) of the past,
unreimbursed costs for preparing, filing, prosecuting, and maintaining all United States and foreign patent applications and patents under PATENT RIGHTS will be paid by LICENSEE within [***] ([***]) days of [***]. If, however, REGENTS grants
additional exclusive license by [***], the second half installment of the past, unreimbursed patents costs will be not be due to REGENTS. To date, the remaining total past patent costs paid by REGENTS are about [***] U.S. Dollars ($[***]). Subject
to Paragraph 14.4, all future costs for preparing, filing, prosecuting, and maintaining all United States and foreign patent applications and patents under PATENT RIGHTS will be borne by LICENSEE. If, however, REGENTS grants additional exclusive
license, the costs of preparing, filing, prosecuting and maintaining such patent applications and patents will be divided equally among the exclusive licensees from the effective date of such subsequently granted license agreement. In addition, if,
REGENTS reduces the exclusive license granted herein to non-exclusive licenses pursuant to Paragraphs 7.3 7.4, 7.5 or 7.6, and REGENTS grants additional license(s), the costs of preparing, filing, prosecuting
and maintaining such patent applications and patents will be divided equally among the licensed parties from the effective date of each subsequently granted license agreement. Payments are due within [***] ([***]) days after receipt of invoice from
REGENTS. 

  
 Page 22 of 35 

 

			
	4D Molecular Therapeutics LLC	  	Exclusive License
	UC Case No.: B03-104	  	Confidential

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

	 	14.4	 LICENSEE’s obligation to underwrite and to pay all domestic and foreign patent filing, prosecution, and
maintenance costs will continue for so long as this Agreement remains in effect; provided, however, that LICENSEE may terminate its obligations with respect to any given patent application or patent in any or all designated countries upon [***]
([***]) months’ written notice to REGENTS. REGENTS will use its best efforts to curtail patent costs when such a notice is received from LICENSEE. REGENTS may continue prosecution and/or maintenance of such applications or patents at its sole
discretion and expense; provided, however, that LICENSEE will have no further right or licenses thereunder. 

  

	15.	 MARKING 

  

	 	15.1	 Prior to the issuance in the United States of patents under PATENT RIGHTS, LICENSEE agrees to mark LICENSED
PRODUCT(S) (or their containers or labels) SOLD by it in the United States under the license granted in this Agreement with the words “Patent Pending,” and following the issuance in the United States of one or more patents under PATENT
RIGHTS, with the patent numbers of the PATENT RIGHTS. All LICENSED PRODUCTS SOLD in other countries will be marked in such manner as to conform with the patent laws and practice of such countries. 

 

	16.	 USE OF NAMES AND TRADEMARKS 

 

	 	16.1	 Nothing contained in this Agreement will be construed as conferring any right to use in advertising, publicity
or other promotional activities any name, trademark, trade name, or other designation of either party hereto by the other (including any contraction, abbreviation, or simulation of any of the foregoing). Unless required by law, regulation, or rules
of a securities exchange, or consented to in writing by REGENTS, the use by LICENSEE of the name “The Regents of the University of California” or the name of any University of California campus in advertising, publicity or other
promotional activities is expressly prohibited. 

  

	17.	 LIMITED WARRANTIES AND COVENANTS 

 

	 	17.1	 REGENTS warrants to LICENSEE that (a) to the extent of the actual knowledge of the licensing professional
responsible for administration of this Agreement, it has the lawful right to grant the licenses granted to LICENSE pursuant to this Agreement, (b) to the extent of the actual knowledge of the licensing professional responsible for
administration of this Agreement, it has not previously granted to any third party any rights that conflict with the licenses granted to LICENSEE pursuant to this Agreement, and (c) to the extent of the actual knowledge of the licensing
professional responsible for administration of this Agreement and of REGENTS’ patent prosecution counsel, no third party who is not designated in filings with relevant patent authorities as an inventor of the PATENT RIGHTS is, or has claimed or
asserted in writing to REGENTS that it is, an inventor of the PATENT RIGHTS. 

  
 Page 23 of 35 

 

			
	4D Molecular Therapeutics LLC	  	Exclusive License
	UC Case No.: B03-104	  	Confidential

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

	 	17.2	 Except as expressly provided in this Agreement, the licenses granted pursuant to this Agreement, the BIOLOGICAL
MATERIAL, and the associated INVENTION are provided WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER WARRANTY, EXPRESSED OR IMPLIED. REGENTS MAKES NO REPRESENTATION OR WARRANTY THAT THE INVENTION, THE BIOLOGICAL
MATERIAL, PATENT RIGHTS, LICENSED PRODUCTS, LICENSED SERVICES OR LICENSED METHODS WILL NOT INFRINGE ANY PATENT OR OTHER PROPRIETARY RIGHT. 

  

	 	17.3	 EXCEPT FOR LICENSEE’S OBLIGATION TO INDEMNIFY AGAINST CLAIMS OF THIRD PARTIES UNDER ARTICLE 19
(INDEMNIFICATION AND INSURANCE), IN NO EVENT WILL EITHER PARTY BE LIABLE TO THE OTHER FOR ANY INCIDENTAL, SPECIAL OR CONSEQUENTIAL DAMAGES RESULTING FROM EXERCISE OF THE LICENSES GRANTED PURSUANT TO THIS AGREEMENT OR THE USE OF THE INVENTION, THE
BIOLOGICAL MATERIAL, PATENT RIGHTS, LICENSED METHODS, LICENSED SERVICES OR LICENSED PRODUCTS. THE REGENTS WILL NOT BE LIABLE FOR DIRECT DAMAGES TO THE OTHER PARTY CAUSED BY AN ASSIGNMENT BY THE REGENTS’ INVENTORS OF THE PATENT RIGHTS TO A THIRD
PARTY. 

  

	 	17.4	 Nothing in this Agreement is or will be construed as: 

 

	 	(a)	 A warranty or representation by REGENTS as to the validity, enforceability or scope of any PATENT RIGHTS; or

  

	 	(b)	 A warranty or representation that anything made, used, or SOLD under any license granted in this Agreement is
or will be free from infringement of patents of third parties; or 

  

	 	(c)	 An obligation to bring or prosecute actions or suits against third parties for patent infringement, except as
provided in Article 18; or 

  

	 	(d)	 Conferring by implication, estoppel, or otherwise any license or rights under any patents of REGENTS or IGT
other than PATENT RIGHTS as defined herein, regardless of whether such patents are dominant or subordinate to PATENT RIGHTS; or 

  

	 	(e)	 An obligation to furnish any know-how not provided in the patents and
patent applications under PATENT RIGHTS and REGENTS’ PROPERTY RIGHTS. 

  
 Page 24 of 35 

 

			
	4D Molecular Therapeutics LLC	  	Exclusive License
	UC Case No.: B03-104	  	Confidential

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

	 	17.5	 REGENTS shall promptly notify LICENSEE in the event (to the extent of the actual knowledge of the licensing
professional responsible for administration of this agreement) that IGT (a) files in any court or agency pursuant to any statute or regulation of any state or country, a petition in bankruptcy or insolvency, for reorganization, or for an
arrangement or appointment of a receiver or trustee of IGT or of its assets; (b) is served with an involuntary petition against it, filed in any insolvency proceeding; (c) proposes or is a party to any dissolution or liquidation; or
(d) makes an assignment for the benefit of its creditors. REGENTS shall promptly notify LICENSEE upon any termination of the IIA, or receipt of notice of termination thereof. 

 

	18.	 PATENT INFRINGEMENT 

 

	 	18.1	 In the event that either party (and in the case of REGENTS, to the extent of the actual knowledge of the
licensing professional responsible for administration of this Agreement) learns of the infringement of any PATENT RIGHTS under this Agreement, such party will promptly provide the other party with notice and reasonable evidence of such infringement
(“Infringement Notice”). During the period and in a jurisdiction where LICENSEE has exclusive rights under this Agreement, neither party will notify a third party, including the infringer, of the infringement without first obtaining
consent of the other party, which consent will not be unreasonably withheld; provided, however, that LICENSEE may notify any then-existing sublicensees under the relevant PATENT RIGHTS of such infringement without REGENTS’ prior consent if such
sublicensee is bound by obligations of confidentiality with respect to such information. Both parties will use diligent efforts, in cooperation with each other, to terminate such infringement without litigation. 

 

	 	18.2	 If the infringing activity of potential commercial significance has not been abated within [***] ([***]) days
following the effective date of the Infringement Notice, LICENSEE may institute suit for patent infringement against the infringer. In accordance with the terms of the IIA, REGENTS and/or IGT may voluntarily join such suit at its own expense, but
may not thereafter commence suit against the infringer for the acts of infringement that are the subject of LICENSEE’s suit or any judgment rendered in that suit. [***]. If, in a suit initiated by LICENSEE, REGENTS is involuntarily joined
[***]. 

 If, within [***] ([***]) days following the effective date of the Infringement Notice, the infringing activity of
potential commercial significance has not been abated and LICENSEE has not brought suit against the infringer, REGENTS or IGT may institute suit for patent infringement against the infringer. If REGENTS or IGT institutes such suit, LICENSEE may not
join such suit without REGENTS’ or IGT’s consent, as applicable, and may not thereafter commence suit against the infringer for the acts of infringement that are the subject of REGENTS’ or IGT’s suit or any judgment rendered in
that suit. 

  
 Page 25 of 35 

 

			
	4D Molecular Therapeutics LLC	  	Exclusive License
	UC Case No.: B03-104	  	Confidential

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 Notwithstanding the foregoing, the parties may by mutual agreement, at any time, bring and
control such suit jointly against an infringer of the PATENT RIGHTS, sharing costs in such manner as they may then agree. 
  

	 	18.3	 Such legal action as is decided upon will be at the expense of the party instituting the suit pursuant to
Paragraph 18.2, and all recoveries recovered thereby will [***], provided that legal action brought jointly by REGENTS and/or IGT and LICENSEE, and participated in by each, will be [***] and all recoveries will be allocated in the following order:
(a) to each party pro rata reimbursement of the attorney’s costs, fees, and other related expenses to the extent each party paid for such costs, fees, and expenses, until all such costs, fees, and expenses are reimbursed to each party; and
(b) [***]. 

  

	 	18.4	 Each party will cooperate with the other in litigation instituted hereunder but at the expense of the party
instituting the suit pursuant to Paragraph 18.2. Such litigation will be controlled by the party instituting such suit, but the other party may be represented by counsel of its choice. In no event may either party admit liability or wrongdoing on
behalf of the other party without the other party’s prior written consent. 

  

	 	18.5	 Any agreement made by LICENSEE for the purposes of settling litigation or other dispute shall comply with the
requirements of Article 4 (Sublicenses) of this Agreement. 

  

	19.	 INDEMNIFICATION AND INSURANCE 

 

	 	19.1	 LICENSEE will, and will require its sublicensees to, indemnify, hold harmless, and defend REGENTS and IGT and
their officers, employees, and agents; sponsor(s) of the research that led to the INVENTION and BIOLOGICAL MATERIAL included in PROPERTY RIGHTS; and the inventors of any patents and patent applications under PATENT RIGHTS and their employers against
any and all losses, damages, costs, fees, and expenses resulting from third party claims and suits arising out of exercise of this license or any sublicense or any use or possession of the BIOLOGICAL MATERIAL. This indemnification will include, but
not be limited to, any product liability claims. 

  

	 	19.2	 LICENSEE, at its sole cost and expense, will ensure that the applicable entity performing activities in
connection with any work performed hereunder, whether LICENSEE, an AFFILIATE, or a sublicensee, will obtain, keep in force, and maintain the following insurance: 

 

	 	(a)	 prior to the start of clinical trials of a LICENSED PRODUCT, Commercial Form General Liability Insurance
(contractual liability included) with limits as follows: 

  

					
	 Each Occurrence
	  	 	$[***]	 
	 Products/Completed Operations Aggregate
	  	 	$[***]	 
	 Personal and Advertising Injury
	  	 	$[***]	 
	 General Aggregate
	  	 	$[***]	 

  
 Page 26 of 35 

 

			
	4D Molecular Therapeutics LLC	  	Exclusive License
	UC Case No.: B03-104	  	Confidential

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

	 	(b)	 upon the start of any clinical trials of a LICENSED PRODUCT, Commercial Form General Liability Insurance
(contractual liability included), and product liability insurance if not otherwise included, with limits as follows: 

  

					
	 Each Occurrence
	  	 	$[***]	 
	 Products/Completed Operations Aggregate
	  	 	$[***]	 
	 Personal and Advertising Injury
	  	 	$[***]	 
	 General Aggregate
	  	 	$[***]	 

  

	 	(c)	 upon the first commercial sale of a LICENSED PRODUCT, LICENSED SERVICE or LICENSED METHOD, Commercial Form
General Liability Insurance (contractual liability included), and product liability insurance if not otherwise included, with limits as follows: 

  

					
	 Each Occurrence
	  	 	$[***]	 
	 Products/Completed Operations Aggregate
	  	 	$[***]	 
	 Personal and Advertising Injury
	  	 	$[***]	 
	 General Aggregate
	  	 	$[***]	 

 If the above insurance is written on a claims-made form, it shall continue for [***] ([***]) years following
termination or expiration of this Agreement. 
  

	 	(d)	 worker’s compensation as legally required in the jurisdiction in which LICENSEE, an AFFILIATE, or a
sublicensee, as applicable, is doing business. 

 LICENSEE will promptly notify REGENTS of any material reduction in the
insurance coverages below the amounts required hereunder. 
  

	 	19.3	 The coverage and limits referred to in Paragraph 19.2 above will not in any way limit the liability of LICENSEE
under Paragraph 19.1. Upon the execution of this Agreement, LICENSEE will furnish REGENTS with certificates of insurance evidencing compliance with all requirements. Such certificates will: 

  
 Page 27 of 35 

 

			
	4D Molecular Therapeutics LLC	  	Exclusive License
	UC Case No.: B03-104	  	Confidential

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

	 	(a)	 where possible, provide for [***] ([***]) days’ ([***] ([***]) days for
non-payment of premium) advance written notice to REGENTS of any cancellation of insurance coverages; 

  

	 	(b)	 indicate that REGENTS has been endorsed as an additional insured under the coverage described above in
Paragraph 19.2; and 

  

	 	(c)	 include a provision that the coverage will be primary and will not participate with, nor will be excess over,
any valid and collectable insurance or program of self-insurance maintained by REGENTS. 

  

	 	19.4	 REGENTS will promptly notify LICENSEE in writing of any claim or suit brought against REGENTS for which REGENTS
intends to invoke the provisions of Paragraph 19.1. LICENSEE will keep REGENTS informed of its defense of any claims pursuant to Paragraph 19.1, and REGENTS will cooperate reasonably in any such suit. If REGENTS invokes the provisions of Paragraph
19.1, REGENTS will not make any admissions or take any actions in such claim or suit that may prejudice or impair LICENSEE’s ability to defend such claim or suit without LICENSEE’s prior written consent, and LICENSEE will not admit
liability or wrongdoing on behalf of REGENTS without REGENTS’ prior written consent. 

  

	20.	 COMPLIANCE WITH LAWS 

 

	 	20.1	 LICENSEE will comply with all applicable international, national, state, regional, and local laws and
regulations in performing its obligations hereunder and in its use, manufacture, SALE or import of the LICENSED PRODUCTS, LICENSED SERVICES, or practice of the LICENSED METHODS. LICENSEE understands that REGENTS is subject to United States laws and
regulations (including the Arms Export Control Act, as amended, and the Export Administration Act of 1979), controlling the export of technical data, computer software, laboratory prototypes and other commodities, and REGENTS’ obligations under
this Agreement are contingent on compliance with such laws and regulations. The transfer of certain technical data and commodities may require a license from the cognizant agency of the United States Government and/or written assurances by LICENSEE
that LICENSEE will not export such technical data and/or commodities to certain foreign countries without prior approval of such agency. REGENTS neither represents that a license will not be required nor that, if required, it will be issued.

  

	21.	 GOVERNMENT APPROVAL OR REGISTRATION 

 

	 	21.1	 If this Agreement or any associated transaction is required by the law of any nation to be either approved or
registered with any governmental agency, LICENSEE will assume all legal obligations to do so. LICENSEE will notify REGENTS if it becomes aware that this Agreement is subject to a United States or foreign government reporting or approval requirement.
LICENSEE will make all necessary filings and pay all costs including fees, penalties, and all other out-of-pocket costs associated with such reporting or approval
process. 

  
 Page 28 of 35 

 

			
	4D Molecular Therapeutics LLC	  	Exclusive License
	UC Case No.: B03-104	  	Confidential

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

	22.	 ASSIGNMENT 

  

	 	22.1	 This Agreement is binding upon and shall inure to the benefit of REGENTS, and its successors and assigns. This
Agreement will be personal to LICENSEE and assignable by LICENSEE only with the written consent of REGENTS, except that LICENSEE may freely assign this Agreement to its AFFILIATE or to an acquirer of all or substantially all of LICENSEE’s
stock, assets or business to which this Agreement relates. If LICENSEE assigns this Agreement to a non-AFFILIATE third party, then upon execution of the assignment agreement, LICENSEE will (i) provide
REGENTS with the updated contact information, and (ii) [***]. 

  

	23.	 NOTICES 

  

	 	23.1	 All notices under this Agreement will be deemed to have been fully given and effective when done in writing and
delivered in person, or three (3) business days after mailed by registered or certified U.S. mail, or one (1) business day after deposited with an express carrier service requiring signature by recipient, and addressed as follows:

  

			
	To REGENTS:	  	Office of Technology Licensing
		  	2150 Shattuck Avenue, Suite 510
		  	Berkeley, CA 94704-1347
		  	Attn.: Director (UC Case No.: B03-104)
		
	To LICENSEE:	  	4D Molecular Therapeutics LLC
		  	444 Laverne Avenue
		  	Mill Valley, CA 94941
		  	Attn.: [***]

 Either party may change its address upon written notice to the other party. 

 

	24.	 LATE PAYMENTS 

 

	 	24.1	 If monies owed to REGENTS under this Agreement are not received by REGENTS when due, LICENSEE will pay to
REGENTS interest charges at a rate of [***] percent ([***]%) per annum, or less if required by applicable law. Such interest will be calculated from the date payment was due until actually received by REGENTS. Such accrual of interest will be in
addition to, and not in lieu of, enforcement of any other rights of REGENTS related to such late payment. Acceptance of any late payment will not constitute a waiver under Article 25 (Waiver) of this Agreement. 

 

	25.	 WAIVER 

  

	 	25.1	 The failure of either party to assert a right hereunder or to insist upon compliance with any term or condition
of this Agreement will not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition 

  
 Page 29 of 35 

 

			
	4D Molecular Therapeutics LLC	  	Exclusive License
	UC Case No.: B03-104	  	Confidential

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

	 	
by the other party. None of the terms and conditions of this Agreement can be waived except by the written consent of the party waiving compliance. 

 

	26.	 CONFIDENTIALITY 

 

	 	26.1	 Each party will hold the other party’s proprietary business and technical information, patent prosecution
material and other proprietary information, including the negotiated terms of this Agreement, in confidence and against disclosure to third parties (except to those employees or authorized representatives having a need to know such information and
who are bound by confidentiality obligations with respect thereto) with at least the same degree of care as it exercises to protect its own data and license agreements of a similar nature. Each party will only use such information of the other party
in accordance with the terms of this Agreement. These obligations will expire [***] ([***]) years after the termination or expiration of this Agreement. 

  

	 	26.2	 Nothing contained herein will in any way restrict or impair the right of LICENSEE or REGENTS to use, disclose,
or otherwise deal with any information or data which: 

  

	 	(a)	 at the time of disclosure to the receiving party is generally available to the public or thereafter becomes
generally available to the public by publication or otherwise, through no act or omission of the receiving party; 

  

	 	(b)	 the receiving party can show by its contemporaneous written records was in its possession, without
confidentiality restrictions, prior to the time of disclosure to it hereunder, and was not acquired directly or indirectly from the disclosing party; 

  

	 	(c)	 is independently made available to the receiving party, without confidentiality restrictions, as a matter of
right by a third party under no obligation of confidentiality to the disclosing party; 

  

	 	(d)	 is independently developed by the receiving party without any use of the information disclosed, as shown by the
receiving party’s contemporaneous written records; or 

  

	 	(e)	 is subject to disclosure under the California Public Records Act, court order, or other requirements of law,
regulation, or rules of a securities exchange, provided that the receiving party promptly informs the disclosing party of such request. 

  

	 	26.3	 Notwithstanding anything to the contrary in Paragraph 26.1, LICENSEE may disclose proprietary information it
receives pursuant to this Agreement, and the terms of this Agreement, to its actual or potential investors, acquirers, and sublicensees who are bound by obligations of confidentiality with respect thereto. Moreover, REGENTS has the right to share
such information with IGT under the 

  
 Page 30 of 35 

 

			
	4D Molecular Therapeutics LLC	  	Exclusive License
	UC Case No.: B03-104	  	Confidential

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

	 	
confidentiality terms in the IIA. REGENTS will be free to release to IGT, the inventors, and senior administrators employed by REGENTS the terms and conditions of this Agreement upon their
request. If such request is made, REGENTS will inform such employees of the confidentiality obligations set forth above and will request that they do not disclose such terms and conditions to others. Should a third party inquire whether a license to
PATENT RIGHTS is available, REGENTS may disclose the existence of this Agreement and the extent of the grant in Articles 3 and 4 to such third party, but will not disclose the name of LICENSEE unless LICENSEE has already made such disclosure
publicly, except where REGENTS is required to release information under either the California Public Records Act or other applicable law, provided REGENTS gives prior written notice to LICENSEE of such disclosure. 

 

	 	26.4	 LICENSEE and REGENTS agree to destroy or return to the disclosing party proprietary information received from
the other in its possession within [***] ([***]) days following the effective date of termination of this Agreement. However, each party may retain one copy of proprietary information of the other solely for archival purposes in non-working files for the sole purpose of verifying the ownership of the proprietary information, provided such proprietary information will be subject to the confidentiality provisions set forth in this Article 26.
LICENSEE and REGENTS agree to provide each other, within [***] ([***]) days following termination of this Agreement, with a written notice that such proprietary information has been returned or destroyed. 

 

	27.	 FORCE MAJEURE 

 

	 	27.1	 Except for LICENSEE’s obligation to make any payments to REGENTS hereunder, the parties to this Agreement
shall be excused from any performance required hereunder if such performance is rendered impossible or unfeasible due to any catastrophes or other major events beyond their reasonable control, including, without limitation, war, riot, and
insurrection; laws, proclamations, edicts, ordinances, or regulations; strikes, lockouts, or other serious labor disputes; and floods, fires, explosions, or other natural disasters. When such events have abated, the parties’ respective
obligations hereunder will resume. 

  

	28.	 SEVERABILITY 

  

	 	28.1	 The provisions of this Agreement are severable, and in the event that any provision of this Agreement will be
determined to be invalid or unenforceable under any controlling body of law, such invalidity or enforceability will not in any way affect the validity or enforceability of the remaining provisions hereof. 

 

	29.	 APPLICABLE LAW; VENUE; ATTORNEYS’ FEES 

 

	 	29.1	 THIS AGREEMENT WILL BE CONSTRUED, INTERPRETED, AND APPLIED IN ACCORDANCE WITH THE LAWS OF THE STATE OF
CALIFORNIA, excluding any choice of law rules that would direct the application of the laws of 

  
 Page 31 of 35 

 

			
	4D Molecular Therapeutics LLC	  	Exclusive License
	UC Case No.: B03-104	  	Confidential

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

	 	
another jurisdiction, but the scope and validity of any patent or patent application under PATENT RIGHTS will be determined by the applicable law of the country of such patent or patent
application. Any legal action brought by the parties relating to this Agreement will be conducted in San Francisco, California. The prevailing party in any legal action under this Agreement will be entitled to recover its reasonable attorneys’
fees in addition to its costs and necessary disbursements. 

  

	30.	 ELECTRONIC COPY; COUNTERPARTS 

 

	 	30.1	 The parties to this document agree that a copy of the original signature to this Agreement (including an
electronic copy) may be used for any and all purposes for which the original signature may have been used. The parties further waive any right to challenge the admissibility or authenticity of this document in a court of law based solely on the
absence of an original signature. 

  

	 	30.2	 This Agreement may be executed in two or more counterparts, including by facsimile or electronic exchange of
signed copies in PDF format, each of which shall be deemed an original document, and all of which, together with this writing, shall be deemed one instrument. 

 

	31.	 SCOPE OF AGREEMENT; AMENDMENT; WAIVER 

 

	 	31.1	 This Agreement, together with the OTHER LICENSE AGREEMENT and the MTA, incorporates the entire agreement
between the parties with respect to the subject matter hereof, and supersedes all prior agreements, discussions and writings in respect thereof, including without limitation the Letter Agreement dated May 8, 2013. 

 

	 	31.2	 This Agreement may be altered or modified only by written amendment duly executed by the parties hereto. A
waiver of any breach or default of this Agreement shall not constitute a waiver of any other right hereunder or any subsequent breach or default. 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement in duplicate originals by their duly authorized officers or representatives. 

 

									
	THE REGENTS OF THE UNIVERSITY, OF CALIFORNIA	  		 	4D MOLECULAR THERAPEUTICS LLC
					
	By	  	 /s/ Carol Mimura
	  		 	By	  	 /s/ David H. Kirn

									
		 	Carol Mimura, Ph.D.	 		 		 	
		 	Assistant Vice Chancellor	 		 	Printed Name	 	 David H. Kirn

		 	Office of Technology Licensing	 		 		 	

									
		 		 		 	Title	 	 Co-Founder, Executive
Chair

									
					
	Date	 	 Dec. 19, 2013
	 		 	Date	 	 December 19, 2013

  
 Page 32 of 35 

 

			
	4D Molecular Therapeutics LLC	  	Exclusive License
	UC Case No.: B03-104	  	Confidential

 [***] Certain information in this document has been excluded pursuant to Regulation S-K,
Item 601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly disclosed.

  

 Exhibit A 

Omitted pursuant to Regulation S-K, Item 601(a)(5). 

  
 1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00317-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00317-of-00352.parquet"}]]